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Abstract 
 
Vaccinia virus (VACV) expresses many proteins that subvert the host innate immune 
response and this thesis describes the characterisation of C4, a VACV protein 
unstudied hitherto, which was hypothesised to have such a role. 
 
C4 is conserved in six orthopoxvirus species and shares 43.7% amino acid identity to 
VACV protein C16, a known virulence factor. C4 is an intracellular protein that is 
expressed early during infection and localises to both the cytoplasm and nucleus. 
Functional screens revealed C4 is an inhibitor of IFN" promoter activation via the 
inhibition of NF-!B activation. Mechanistically, this inhibition is attributable to the 
prevention of I!B# phosphorylation. Consistent with this mode of action, C4 co-
precipitated with the canonical IKK proteins, IKK" and NEMO. Protein C16 and the 
icIL-1Ra were also found to inhibit NF-!B activation. Furthermore, C4 is an inhibitor 
of cytoplasmic DNA sensing in MEFs and interacts with Ku70 and Ku80 (Ku), two 
components of the DNA sensor, DNA-PK.  
 
Another novel discovery is that VACV infection leads to the stabilisation and 
translocation of HIF-1#. This process is largely dependent on C16, however C4 is 
also required for maximal HIF-1# stabilisation and transactivation. The role of HIF-
1# during infection and the mechanism used by C4 to contribute to its stabilisation 
process require further investigation. 
  
Whilst C4 is non-essential for virus replication and spread in cell culture, its deletion 
does result in reduced virus virulence in a murine intranasal model of infection. 
Finally, the deletion of both C16 and C4 lead to a synergistic attenuation of virus 
virulence in both the intranasal and intradermal models of infection.  
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Chapter One 
Introduction 
 
1.1. Introduction to poxviruses and vaccinia virus 
 
Vaccinia virus (VACV) is the prototypal member of the Orthopoxvirus (OPV) genus 
of the Poxviridae – a family of large viruses with linear double-stranded (ds)DNA 
genomes ranging in size from 130  to 300 kb. These viruses replicate in viral factories 
within the cytoplasm of host cells and thus need to encode most of the proteins 
required for virus transcription and DNA replication (Moss, 2007). The Poxviridae is 
divided into two subfamilies, the Entomopoxviridae and Chordopoxviridae, which 
infect insects and chordates, respectively. The Chordopoxviridae is further subdivided 
into eight genera: OPV, Avipoxvirus, Capripoxvirus, Leporipoxvirus, 
Molluscipoxvirus, Parapoxvirus, Suipoxvirus and Yatapoxvirus. The OPV genus is 
the most intensively studied and most notably includes Variola virus (VARV) and 
VACV. 
 
 1.2. VACV: eradication of smallpox and new developments 
 
VARV is the etiologic agent of smallpox, a highly contagious human disease with a 
mortality rate of up to 40% (Behbehani, 1983). Edward Jenner introduced vaccination 
as a preventative measure against smallpox in 1796. After inoculation of a child with 
material from the blisters of a milkmaid infected with cowpox virus, the child was 
protected from subsequent challenge with variolous material and thus immune to 
smallpox (reviewed in (Baxby, 1977)). It is now known that the basis for this 
protection is antigenic similarity between VARV and cowpox virus (CPXV). In 1939, 
an analysis of the vaccine stocks used for vaccination against smallpox during the 20th 
century revealed that they did not contain CPXV, but rather another OPV of unknown 
origin, thereafter named VACV (Downie, 1939). A vaccination programme instigated 
by the World Health Organization (WHO) eventually eradicated smallpox in 1977 
(Fenner et al., 1988), and historically, is still the only human disease to have been 
eradicated through vaccination.   
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After the eradication of smallpox, interest in VACV has continued due to the 
development of recombinant VACVs as candidate vaccines for a range of infectious 
diseases, such as those caused by hepatitis B virus (Smith et al., 1983), as oncolytic 
viruses to treat cancer (Breitbach et al., 2011), and because VACV is an excellent 
model for studying virus-host interactions (Shen & Nemunaitis, 2005; Zhang et al., 
2009). Indeed, VACV has a fascinating repertoire of strategies to evade the host 
immune response and the study of these has contributed to our understanding of virus-
host interactions and virus pathogenesis. Within the wide array of VACV 
immunomodulators studied, several secreted proteins have been discovered which 
bind directly to host cytokines, chemokines, inferferons (IFN) or complement factors. 
Others remain inside the infected cell to prevent apoptosis or innate immune 
signalling (reviewed in (Moss & Shisler, 2001; Seet et al., 2003)). A translational 
aspect of this work is that VACV vaccines with improved safety and immunogenicity 
profiles may be created by selectively removing some of these immunomodulatory 
genes. 
 
1.3. VACV genome organisation 
 
The first VACV genome to be sequenced was that of VACV strain Copenhagen 
(COP), which is 191 kb in size and encodes for approximately 200 closely-packed 
ORFs (Perkus et al., 1990). Like other OPVs, the VACV-COP genome contains a 
highly conserved central region representing about half the total number of ORFs and 
whose protein products are required for VACV transcription, replication and 
assembly (Upton et al., 2003; Gubser et al., 2004). Approximately 90 of the genes 
from this central genomic location are conserved between all chordopoxviruses 
(Upton et al., 2003). In contrast, the less conserved terminal regions encode for non-
essential proteins implicated in host-range restriction, immunomodulation and virus 
virulence (Wittek, 1982). VACV genes do not contain introns and there has been no 
evidence to suggest that they are spliced and this is consistent with the cytoplasmic 
site of virus replication and transcription. The left and right termini of the genome 
contain inverted terminal repeats (ITRs) and genes that reside within these locations 
are diploid (Wittek et al., 1980). As a result of recombination and terminal 
transpositions from one end of the genome to the other, the lengths of the ITRs vary 
considerably (<0.1 to 12.4 kb) between poxviruses. At the genomic termini, the DNA 
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strands are covalently linked by AT-rich incompletely base-paired hairpin loops, and 
these structures play an important role in VACV DNA replication (Baroudy et al., 
1982). Adjacent to the hairpin loops are conserved concatamer resolution sites that are 
required for the resolution of concatamer intermediates formed during DNA 
replication (Merchlinsky & Moss, 1989).    
 
1.4. VACV virion structure 
 
Due to its large virion size, VACV was the first animal virus to be observed by light 
microscopy (Buist, 1887). When visualised by electron microscopy (EM), VACV 
virions appear as brick-shaped particles of approximately 360 x 270 x 250 nm 
(Cyrklaff et al., 2005). There are different forms of VACV particle: intracellular 
mature virus (IMV), intracellular enveloped virus (IEV) and extracellular virus – 
which includes cell-associated enveloped virus (CEV) and extracellular enveloped 
virus (EEV; Morgan et al., 1954; Dales & Siminovitch, 1961). The most abundant 
and infectious form of virus particle is the IMV, consisting of a biconcave core 
surrounded by two amorphous lateral bodies and a single lipid bilayer and is retained 
inside the infected cell until lysis (Dubochet et al., 1994; Hollinshead et al., 1999). 
The virion core contains the VACV genome, structural proteins and enzymes required 
for the transcription of early genes (Condit et al., 2006). The IEV is formed by the 
wrapping of an IMV particle with additional lipid membranes derived from the trans-
Golgi network (TGN) or early endosomes, enabling effective virus transport using 
microtubules to the cell surface (Schmelz et al., 1994). Once the IEV has reached the 
cell surface, fusion of the outer virion membrane with the plasma membrane results in 
either a CEV, which remains attached at the cell surface, or an EEV that is released 
from the cell (Blasco & Moss, 1992). Whilst EEV contribute most to virus spread in 
vivo, IMV are stable outside the host and this feature, plus its abundance, make it the 
likely form mediating transmission between hosts (Payne, 1980).        
 
1.5. VACV life cycle 
 
The life cycle of VACV is divided into several steps: virus binding, entry, uncoating, 
gene expression, DNA replication, virion assembly and release. A schematic 
representation of these steps is shown in Figure 1.1. 
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Figure 1.1. The VACV life cycle. An IMV or EEV particle binds to the plasma 
membrane, loses its membrane(s) and the virus core is transported to a perinuclear 
region of the infected cell on microtubules. Within virus factories, the core is 
uncoated, early genes are expressed and VACV genomic DNA is replicated. VACV 
DNA is then encapsidated by a spherical structure comprised of proteins and lipids, 
forming an IV particle. Morphological transition of an IV particle to an IMV particle 
is preceded by condensation of the DNA-nucleoprotein complex and its association 
with structural proteins to form an electron-dense core, yielding the archetypal brick-
shaped structure of the IMV particle. Some IMVs are transported away from the virus 
factory and wrapped in a double membrane derived from early endosomes or the 
TGN, forming IEV particles. IEVs are then transported to the cell surface on 
microtubules where the outer membrane of each IEV fuses with the plasma 
membrane exposing a CEV on the cell surface. Polymerisation of actin tails beneath 
CEVs can push these virus particles away from the cell surface and into neighbouring 
cells. If a CEV is released from the original cell it becomes an EEV. 
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1.5.1. VACV binding, entry and uncoating 
 
The first step in the virus life cycle is the binding of VACV to permissive cells. 
Establishing the exact mechanism of VACV binding has been complicated due to the 
differences in membrane proteins and number of lipid membranes between the 
different forms of VACV virion. Nevertheless, it is known that IMV and EEV bind to 
different cellular receptors, although the identities of these has remained elusive 
(Vanderplasschen et al., 1998a). Given that VACV can infect a large variety of cell 
types, this would seem to suggest either that the viral receptor is ubiquitously 
expressed or that VACV can bind multiple receptors (Moss, 2007). Previous studies 
have demonstrated that cell surface glycosaminoglycans (GAGs) can interact with 
several VACV IMV membrane proteins (Hsiao et al., 1998), although these 
interactions are not essential for virus infectivity (Carter et al., 2005). Cholesterol-
containing lipid rafts (Chung et al., 2005), extracellular lamin (Chiu et al., 2007) and 
glomulin (Rahbar et al., 2012) have also been reported to affect VACV entry.     
 
In accordance with other enveloped viruses, the IMV particle is thought to enter into 
the cytosol of infected cells following fusion of the outer viral membrane with either 
the plasma membrane (Carter et al., 2005) or that of an endocytic vesicle (Townsley 
et al., 2006). Determination of which pathway is utilised by VACV is dependent upon 
the strain of virus and cell-type infected (Moss, 2007). Since the EEV particle 
contains two lipid membranes, this raises a topological problem with regard to its 
entry into cells. Fusion of the outer membrane with the plasma membrane, for 
example, would result in the deposition of an IMV particle into the cytosol leaving yet 
another lipid membrane still to be removed before release of the virus core. To solve 
this difficulty, two models of EEV entry have been proposed. In the first model 
proposed by Law et al (2006), the outer membrane of the EEV particle becomes 
disrupted at the point of contact between the virus and host cell, exposing the IMV 
particle to the plasma membrane. The virus core can then enter the cytosol by simple 
membrane fusion between the IMV and plasma membranes. In the second model, an 
EEV particle is endocytosed and then the outer EEV membrane is degraded by 
acidification within the endosomal vesicle (Ichihashi, 1996; Vanderplasschen et al., 
1998; Townsley & Moss, 2007). Degradation of the outer EEV membrane releases an 
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IMV particle that can subsequently deposit the virus core within the cytosol by simple 
membrane fusion between the IMV and endosomal membranes.  
 
The initial stage of core uncoating involves the proteolysis of some virion proteins 
(Zaslavsky, 1985). After this, the virus core is disassembled to allow gene 
transcription. Following expression of early proteins such as DNA polymerase, the 
virus DNA is replicated. Intermediate proteins are required for the expression of late 
virus proteins that are packaged into new infectious virions (Moss 2007; section 
1.5.2.).  
 
1.5.2. VACV gene expression 
 
The transcription of VACV genes occurs in a tightly regulated temporal fashion and 
can be divided into three major classes: early, intermediate and late (reviewed in 
Broyles, (2003)). Differential transcription of these gene classes is afforded by stage-
specific transcription factors. In addition, VACV mRNAs are capped and 
polyadenylated like their eukaryotic counterparts (Wei & Moss, 1975; Broyles & 
Moss, 1986).  
 
The transcriptional complex required for the transcription of VACV early genes is 
pre-packaged into the virus core and consists of a virally-encoded DNA-dependent 
RNA polymerase, transcription factors and capping and poly(A) polymerase enzymes. 
Transcription of VACV early genes, which account for approximately half of the total 
number of genes, begins immediately after infection. It has been suggested by 
Assarsson et al (2008) that VACV early genes can be subdivided into immediate 
(within 0.5 h p.i.) and delayed (within 2 h p.i.) early genes, depending on when their 
mRNA can be detected. In any event, VACV early genes encode for proteins required 
for intermediate gene transcription, DNA replication, and immune evasion (Broyles, 
2003).  
 
Intermediate gene transcription begins after VACV DNA replication. One suggestion 
provided for this is that the parental DNA template is sequestered by residual virion 
components, thus preventing its interaction with newly synthesised transcriptional 
complexes (Keck et al., 1990). Therefore, VACV replication is required to provide a 
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suitably naked DNA template before the transcription of intermediate genes can 
begin. Intermediate genes encode for the late gene transcription factors (Baldick & 
Moss, 1993) enabling transcription of late genes. Late mRNAs are first detected from 
between 2 and 4 h p.i. (depending on the multiplicity of infection and cell type used) 
and encode for structural proteins (core and envelope proteins), enzymes and 
transcription factors that become packaged into progeny virions, which enable early 
gene transcription after infection of new cells (Assarsson et al., 2008; Broyles, 2003). 
 
1.5.3. VACV DNA replication 
 
To enable DNA replication within the cytoplasm, VACV encodes its own enzymes 
including DNA polymerase (Earl et al., 1986), helicases (Koonin & Senkevich, 
1992), DNA ligase (Kerr & Smith, 1989), type I topoisomerase (Shuman, 1989), 
single-stranded (ss)DNA binding protein (Rochester & Traktman, 1998), processivity 
factors (Upton et al., 1993; Klemperer et al., 2001) and proof-reading enzymes 
(Broyles, 1993). In addition, VACV also encodes enzymes involved in the synthesis 
of nucleoside triphosphate precursors including thymidine kinase (Weir et al., 1982), 
thymidylate kinase (Smith et al., 1989) and ribonucleotide reductase (Slabaugh et al., 
1988). VACV DNA replication begins within cytoplasmic viral factories between 1 
and 2 h p.i. and generates approximately 10,000 genomic copies per cell, around half 
of which subsequently become incorporated into newly assembled virions (Salzman, 
1960; Joklik & Becker, 1964). 
 
VACV DNA replication can be divided into two main functional stages: synthesis of 
concatameric nascent genomes and resolution of concatameric genome intermediates 
to monomeric unit lengths. The generally accepted model for VACV replication is 
based upon the rolling-hairpin strand-displacement mechanism used by parvoviruses 
(Tattersall & Ward, 1976). This model proposes that a nick is introduced into one 
DNA strand near the terminal hairpin loop generating a free 3’-OH group which 
serves as a primer for VACV-encoded DNA polymerase (Moyer & Graves, 1981). 
Whilst a complementary strand is elongated towards the opposite hairpin loop, the 
other DNA strand is displaced. The parental and nascent DNA strands are then 
denatured and re-folded into new hairpin loops that allow the remainder of the VACV 
genome to be copied. During DNA replication, genome concatamers are formed in a 
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head-to-head or tail-to-tail fashion, which are then resolved into unit lengths by 
enzymes that recognise palindromic structures containing a highly conserved 
concatamer resolution sequence (Merchlinsky & Moss, 1989).      
 
1.5.4. VACV assembly, transport and release 
 
The formation of new virus particles is characterised by a series of complex steps 
(reviewed in (Condit et al., 2006)). The appearance of crescent-shaped structures 
within viral factories, which later extend to form non-infectious immature virus (IV) 
particles, marks the first step of virus assembly. The IV particle contains the virus 
core, within which resides a complete copy of the VACV genome, and the 
transcriptional machinery required for the expression of VACV early genes. 
Morphological transition of an IV particle to an IMV particle is preceded by 
condensation of the DNA-nucleoprotein complex and its association with structural 
proteins to form an electron-dense core, yielding the archetypal brick-shaped structure 
of the IMV particle. There is a concomitant proteolysis of some core proteins (Yang, 
2007) and incorporation of others into the membrane (Sodeik et al., 1995), generating 
a fully-formed, infectious IMV particle. 
 
The majority of virions remain as IMVs, however a subset are transported away from 
viral factories using microtubules to a site where they are wrapped with a double 
membrane derived from either an endosome (Tooze et al., 1993) or the TGN 
(Schmelz et al., 1994) forming IEV. At least nine VACV proteins are present in or 
associated with this membrane (reviewed in (Roberts & Smith, 2008)). The newly 
formed IEV particles are then transported on microtubules to the cell surface in a 
process using VACV proteins F12 (Zhang et al., 2000) and A36 (Ward & Moss, 
2001), where their outer membrane fuses with the plasma membrane. Those virus 
particles that remain attached to the cell surface form CEVs (Smith & Law, 2004); 
those that are released form EEVs that are responsible for the long-range 
dissemination of virus within an infected host (Smith et al., 2002). Induction of actin 
tail formation beneath the plasma membrane surface is responsible for pushing CEVs 
towards adjacent cells and is thus responsible for the infection of neighbouring cells 
and plaque size (Frischknecht et al., 1999).  
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Recently, our laboratory has shown that repulsion of superinfecting virions is 
responsible for the enhanced spread of VACV (Doceul et al., 2010). Newly-infected 
cells express two surface-bound viral proteins – A33 and A36 – that mark the cell as 
infected and promote CEV-induced actin tail formation. The induction of actin tails 
push incoming virions away from the infected cell into uninfected neighbouring cells. 
By re-directing potential superinfecting virions into uninfected cells, the spread of 
VACV is four-fold faster than would be permitted by its replication kinetics alone. 
 
1.6. Immune response to infection 
 
The immune response to infection can be broadly divided into two components: 
innate immunity and adaptive immunity. The immediate detection of microbial 
assault, recruitment of immune cells to sites of infection and activation of adaptive 
immunity, are all within the remit of the innate immune system, although it does not 
confer long-lasting protective immunity. Crucially, the detection of pathogens by the 
innate immune system is partially mediated by pattern-recognition receptors (PRRs; 
reviewed in (Medzhitov, 2009)) that detect pathogen-associated molecular patterns 
(PAMPs). The diverse range of PRRs includes Toll-like receptors (TLRs), retinoic 
acid-inducible gene (RIG-I)-like receptors (RLRs), nucleotide-binding 
oligomerisation domain-containing protein (NOD)-like receptors (NLRs) and 
cytoplasmic DNA sensors. Engagement of a PAMP by its respective PRR results in 
an intracellular signalling cascade that results in the activation of a number of 
transcription factors, including nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-!B) and the interferon (IFN) regulatory factors (IRFs). As a result of the 
activation of these transcription factors, a transcriptional program is induced that 
includes the production of proinflammatory mediators and type I IFNs that recruit and 
activate cells of the immune system and restrict viral replication. 
 
The second arm of the immune response, adaptive immunity, is characterised by its 
delayed onset, targeting of pathogen-specific antigens and immunological memory 
(DeFranco et al., 2007). The principal effector cells of the adaptive immune system 
are T and B lymphocytes, which execute cell-mediated and humoral immune 
responses, respectively. Antigen presenting cells (APCs), such as dendritic cells 
(DCs) and macrophages, capture antigens and, using major histocompatibility 
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complex (MHC) class II proteins, present them on their cell surface to enable their 
recognition by T cells. Cluster of differentiation (CD)4+ T cells recognise antigen 
displayed in association with MHC class II molecules and then develop into either T 
helper (Th) subtype 1 (Th1) or 2 (Th2) cells, depending upon the local cytokine 
environment (reviewed in (Chtanova & Mackay, 2001)). This regulatory process is 
essential since Th1 and Th2 cells shape the adaptive immune response by driving the 
induction of either cell-mediated or humoral immunity, respectively. Amongst the 
main effectors of cell-mediated immunity are cytolytic CD8+ T cells, which recognise 
antigen in association with MHC class I molecules, and are thus particularly 
important in the destruction of virus-infected cells. The effectors of humoral 
immunity are B cells that secrete antigen-specific antibodies (Abs), which either 
neutralise pathogens directly, prepare them for opsonisation by phagocytes or activate 
complement (Ravetch & Bolland, 2001).     
 
1.7. Pathogen detection 
 
1.7.1. TLRs 
 
TLRs are transmembrane proteins that detect PAMPs through their leucine-rich 
repeats (LRRs) and signal through a cytoplasmic Toll/interleukin 1 receptor (TIR) 
domain (Takeda et al., 2003). The TLRs were named after the Drosophila Toll 
receptor protein (initially discovered for its role in embryogenesis) following the 
discovery of its contribution to innate immunity in adult flies (Belvin & Anderson, 
1996; Lemaitre et al., 1996). Thirteen TLRs have been identified in mammals and 
they recognise components of microbial cells walls or pathogen-derived nucleic acids 
(reviewed in (Waltenbaugh et al., 2008)). Escape from detection by TLRs is 
extremely difficult, since they have evolved to recognise molecules essential for the 
survival of pathogens. For example, lipopolysaccharide (LPS), the main constituent of 
the outer membrane of Gram-negative bacteria, is a major ligand for TLR4 and 
mutations that prevent its synthesis are almost universally lethal to these bacteria. 
TLRs 1, 2, 4, 5 and 6 are mainly present at the cell surface and recognise bacterial, 
fungal and protozoan structural PAMPs. In contrast, TLRs 3, 7, 8 and 9 are present 
exclusively within endocytic compartments and recognise bacterial and viral nucleic 
acids (Kumar et al., 2011). Current evidence suggests that TLRs function as either 
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homodimers or heterodimers and that full ligand responsiveness may be dependent 
upon additional co-receptors. For instance, the recognition of LPS by TLR4 requires 
myeloid differentiation protein (MD)-2 (Nagai et al., 2002). TLR signalling is divided 
into two different signalling pathways: the myeloid differentiation primary response 
gene (MyD88) pathway and the TIR-domain-containing adaptor-inducing interferon-
" (TRIF) pathway. Whilst both pathways culminate in the activation of NF-!B, the 
TRIF pathway also activates the kinases TANK-binding kinase 1 (TBK1) and 
receptor-interacting protein 1 (RIP1), leading to the activation of IRF3 (Waltenbaugh 
et al., 2008).         
 
1.7.2. RLRs 
 
Important sensors of RNA virus infection are the cytoplasmic RLRs (Kato et al., 
2005). The RLR family of PRRs currently consists of three members: retinoic acid 
inducible gene-1 (RIG-I; Yoneyama et al., 2004), melanoma differentiation-
associated gene 5 (MDA5; Gitlin et al., 2006) and laboratory of genetics and 
physiology 2 (LGP2; Rothenfusser et al., 2005). Once viruses have entered the 
cytoplasm of infected cells, virus double-stranded (ds)RNA can be detected by RLRs 
and this results in the activation of antiviral signalling pathways. RIG-I, MDA5 and 
LGP2 all contain a DExD/H RNA helicase domain that is essential for the binding of 
dsRNA, however only RIG-I and MDA5 contain an N-terminal tandem caspase 
activation and recruitment domain (CARD), which is required for downstream 
signalling.  
 
In resting cells RIG-I and MDA5 are monomeric but after binding RNA, 
conformational changes are induced in these proteins that exposes their CARD 
domains leading to their association with the CARD-containing mitochondrial 
antiviral signalling protein (MAVS; Seth et al., 2005). MAVS is an adapter protein 
that localises to the peroxisome and mitochondrion, where it is thought to contribute 
to an early IFN-independent and to a delayed IFN-dependent antiviral response, 
respectively (Dixit et al., 2010). Whilst RIG-I was first thought to only bind uncapped 
single-stranded (ss)RNA bearing a 5’-triphosphate (Hornung et al., 2006), it was 
shown subsequently to recognise dsRNA containing a 5’-triphosphate moiety 
(Ablasser et al., 2009; Schmidt et al., 2009). Protein MDA5 on the other hand, 
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apparently only recognises longer stretches of dsRNA that need not be 
triphosphorylated (Kato et al., 2008). Signalling through the inhibitor of nuclear 
factor kappa-B kinase (IKK) complex (consisting of three subunits: alpha (IKK#), 
beta (IKK") and gamma (IKK%), also known as NEMO) and TBK-1 activates NF-!B, 
IRFs and mitogen-activated protein kinases (MAPKs), ultimately resulting in the 
induction of type I IFN and inflammatory cytokines (Kawai et al., 2005; Xu et al., 
2005). Unlike RIG-I and MDA5, LGP2 does not contain an N-terminal CARD and 
thus does not associate with MAVS to mediate downstream signalling events. 
Consistent with an apparent lack of signalling potential, LGP2 has been proposed to 
function as a negative regulator of RIG-I and MDA5 (Rothenfusser et al., 2005). 
More recently however, some studies have indicated that LGP2 may in fact have a 
potentiating  effect on RIG-I and MDA5 signalling (Satoh et al., 2010).   
 
Host RNAs do not activate RLRs since these are generally ssRNAs and have 
protective ‘caps’ at their 5’ ends: host mRNAs contain a 7-methylguanosine 5’ cap 
(Kapp & Lorsch, 2004) and tRNAs contain modified bases (e.g. pseudouridine) that 
are not recognised by RIG-I and MDA5 (Mengel-jùrgensen & Kirpekar, 2002). 
Furthermore, host rRNAs bind to ribosomal proteins to form ribonucleoprotein 
complexes that are thus masked from detection (Lodish et al., 2000). 
 
1.7.3. NLRs 
 
The defining feature of NLRs is that, so far, they have been shown only to detect 
bacterial infection. There are at least 23 members of the NLR family encoded in the 
human genome, each having a tripartite domain structure. The N-terminal domain 
contains an effector Pyrin (PHD) or CARD domain that regulates adaptor protein 
binding and thus downstream signalling; the C-terminal domain contains a series of 
LRRs responsible for ligand binding and the central domain contains a nucleotide-
binding protein (NBP) domain that is thought to facilitate self-oligomerisation and the 
formation of active receptor complexes (Ting & Davis, 2005). The NLR family can 
be divided into five subfamilies based upon their N-terminal structures (Creagh & 
Neill, 2006): NLRA, NLRB, NLRC, NLRP and NLRX. Ligand engagement by NLRs 
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results in the activation of NF-!B and MAPKs leading to the production of 
inflammatory cytokines and the formation of inflammasomes (Davis et al., 2011). 
 
The first NLRs discovered were NOD1 and NOD2, members of the NLRC subfamily 
that detect subcomponents of bacterial peptidoglycan, and when stimulated lead to the 
activation of NF-!B and MAPKs (Girardin et al., 2003a; Girardin et al., 2003b). 
Upon ligand binding, some NLRs cause the release of the interleukin (IL)-1 family of 
proinflammatory cytokines (IL-1, IL-18 and IL-33) through the formation of 
inflammasomes (Kawai & Akira, 2009). This process is dependent on the recruitment 
of caspase-1 that mediates the processing of pro-forms of these cytokines into their 
mature bioactive forms that are secreted from the cell (Yu & Finlay, 2008). The 
inflammasome formed by NLRP3 is triggered by diverse PAMPs that are also 
recognised by TLRs including LPS, peptidoglycan, lipoteichoic acid and muramyl 
dipeptide but also by various types of crystals (e.g. silica, asbestos and alum; 
Kanneganti et al., 2006; Martinon et al., 2004; Dostert et al., 2008). The NLRP1 and 
NLRC4 inflammasomes are triggered by Bacillus anthracis lethal toxin (Boyden & 
Dietrich, 2006) and flagellin (Miao et al., 2006), respectively, although additional 
ligands are likely.  
 
1.7.4. Cytoplasmic DNA sensors 
 
Whilst the sensing of cytoplasmic RNA by RLRs is well characterised (see 1.7.2), the 
mechanisms underlying the sensing of DNA are less defined. It has been known for 
over a decade now that unmethylated CpG-rich DNA is a potent trigger of TLR9-
based immune responses, particularly within cells of the immune system such as B 
cells and plasmacytoid DCs (Hemmi et al., 2000). However the finding that immune 
responsiveness to ectopic DNA, in the form of IRF3-dependent type I IFN induction, 
is not compromised in cells lacking TLR9 indicated that other cytoplasmic DNA 
sensors must exist (Ishii et al., 2006; Stetson & Medzhitov, 2006). Significant 
progress has since been made in attempting to identify these novel cytoplasmic DNA 
sensors. 
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DNA-dependent activator of IRFs (DAI) was the first reported molecule to function 
as a cytoplasmic DNA sensor (Takaoka et al., 2007) and was shown to bind both B- 
and Z-form DNA and lead to the IRF3-dependent induction of type I IFN. However, 
the later findings that DAI is dispensable for DNA-mediated immune responses in 
vitro and in vivo suggested that it is not the only cytoplasmic DNA sensor leading to 
type I IFN induction, prompting the search for additional sensors (Wang et al., 2008; 
Ishii et al., 2008).       
 
Absent in melanoma 2 (AIM2) is a member of the PHYIN family of proteins (pyrin 
and HIN200 domain-containing) and links dsDNA detection to inflammasome 
formation. The two C-terminal HIN domains are responsible for the binding of 
cytoplasmic dsDNA and AIM2 has been shown to detect certain dsDNA viruses, such 
as mouse cytomegalovirus (MCMV) and VACV in macrophages (Fernandes-Alnemri 
et al., 2009; Hornung et al., 2009; Rathinam et al., 2010). AIM2 is the only member 
of the PHYIN family that is cytoplasmic and it interacts with apoptosis-associated 
speck-like protein containing a CARD (ASC) leading to the cleavage of caspase-1 
and formation of the AIM2 inflammasome (Hornung et al., 2009). Nevertheless, since 
AIM2 inflammasome formation is independent of IRF3, this indicates that there are 
additional DNA sensors that lead to type I IFN induction. 
 
Two independent studies in 2009 demonstrated that RIG-I is involved in the detection 
of DNA viruses (Ablasser et al., 2009; Chiu et al., 2009). The authors of these studies 
showed that during infection, host RNA polymerase III (RNA Pol III) transcribes 
virus DNA to produce 5’ tri-phosphate dsRNA that is subsequently detected by RIG-
I. The natural ligand of RNA Pol III appears to be AT-rich DNA thereby explaining 
why its synthetic analogue, poly (dA:dT), is also immunostimulatory to RIG-I (Chiu 
et al., 2009). To complicate matters, the fact that type I IFN is still induced in mouse 
myeloid DCs in response to dsDNA in a RIG-I-independent manner, illustrates that 
RNA Pol III is yet another example of a functionally redundant DNA sensor 
(Hornung & Latz, 2010). 
 
Interferon gamma-inducible protein 16 (IFI16), like AIM2, is a PHYIN protein that 
binds cytoplasmic DNA via its two HIN domains and is necessary for the activation 
of NF-!B and IRF3 in response to HSV infection (Unterholzner et al., 2010). Whilst 
! $#!
Unterholzner et al (2010) reported that IFI16, unlike AIM2, does not appear to 
interact with the ASC in order to mediate the formation of inflammasomes, a later 
study subsequently found that it does so in response to KSHV infection (Kerur et al., 
2011).   
 
Interestingly, leucine-rich repeat (in Flightless 1) interacting protein-1 (LRRFIP1) 
appears to bind both cytoplasmic DNA and RNA but does not regulate the activities 
of either NF-!B or IRF3 directly (Yang et al., 2010). Instead, LFFFIP1 interacts with 
and promotes the activation of "-catenin, which in turn associates with IRF3 in the 
nucleus of cells. Activated "-catenin subsequently enhances IFN" transcription 
through its recruitment of the co-activator CREB-binding protein (CBP)/p300 to the 
IFN" promoter. 
 
Recently, the ER-associated transmembrane protein stimulator of IFN genes (STING) 
has been identified as an adaptor protein for receptors of cytoplasmic DNA based on a 
functional screen for activators of the IFN" promoter (Ishikawa & Barber, 2008). The 
over-expression of STING has been shown in numerous studies to lead to the 
activation of NF-!B and IRF3 and thus to induce type I IFN production (Ishikawa & 
Barber, 2008; Sun et al., 2009; Zhong et al., 2008). The centrality of this molecule in 
integrating the signalling from various PRRs is underlined by the fact that STING-
deficient mice are susceptible to various microbial infections, including those caused 
by herpes simplex virus (HSV), vesicular stomatitis virus (VSV) and Listeria 
monocytogenes (Ishikawa & Barber, 2008; Ishikawa et al., 2009).     
 
Most recently, Ku70 has been described as a cytoplasmic DNA sensor in HEK293T 
cells that induces type III rather than type I IFN (Zhang et al., 2011). Independently, 
our laboratory has shown that the DNA protein kinase (DNA-PK) complex, 
comprising Ku70, Ku80 and the DNA-PK catalytic subunit (DNA-PKcs), is an 
important cytoplasmic DNA sensor in murine embryonic fibroblasts (MEFs) and 
mature skin fibroblasts that induces type I IFNs, CXCL-10 and IL-6 in a pathway 
dependent upon STING, TBK1 and IRF3 (Ferguson et al, 2012).  
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1.8. Cells of the innate immune system 
 
The innate immune system is the first immunological defence against infection and its 
principal functions include pathogen detection, pathogen destruction and activation of 
the adaptive immune system. Cells that participate in innate immune responses 
include macrophages, neutrophils, dendritic cells (DCs) and natural killer (NK) cells. 
 
1.8.1. Macrophages 
 
Macrophages are a type of long-lived professional phagocyte that can be divided into 
subpopulations based upon their tissue distribution and function. For example, 
osteoclasts and alveolar macrophages are tissue-resident macrophages of bone and the 
lungs, respectively (Gordon & Taylor, 2005). The principal functions of macrophages 
are phagocytosis, the induction of inflammation and antigen presentation. 
Extracellular pathogens or whole infected cells may be phagocytosed by macrophages 
into intracellular phagosomes and are subsequently destroyed following fusion of the 
phagosomes with lysosomes. Macrophages also play a major role in the recruitment 
of other leukocytes to sites of infection through the production of proinflammatory 
cytokines and chemokines. Being a type of professional APC, macrophages activate 
the adaptive immune system by displaying microbial peptides in association with 
MHC class II molecules to T cells. Antigen cross-presentation by macrophages occurs 
within 1 h of VACV infection (Ramirez & Sigal, 2002) and mice depleted of 
macrophages are significantly impaired in VACV clearance, demonstrating that these 
cells are important for protection against this virus (Rivera et al., 2007). 
 
1.8.2. Neutrophils 
 
Neutrophils are the most abundant type of white blood cell in mammals and are 
amongst the first cells to arrive at sites of microbial infection. Vital to the innate 
immune response, neutrophils perform three functions. Firstly, like macrophages, they 
are professional phagocytes and are thus capable of internalising microbes such as 
VACV (West et al., 1987) into phagosomes (Lee et al., 2003). Secondly, neutrophils 
degranulate releasing an assortment of antimicrobial peptides, such as cathepsins, 
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defensins and serine proteases into the extracellular environment (Faurschou & 
Borregaard, 2003). Thirdly, neutrophils can release a web-like structure of DNA 
composed of chromatin and serine proteases that trap and kill microbes (Brinkmann et 
al., 2004). 
 
1.8.3. Dendritic cells 
 
DC progenitors within the bone marrow enter the circulation and home to tissues 
where they reside as immature sentinel cells with phagocytic potential until they 
encounter tissue damage or pathogens. Importantly, DCs reside within tissues, such as 
the skin and respiratory tract, which are continuously in contact with the extracellular 
environment and that are therefore prone to microbial infection (Banchereau & 
Steinman, 1998). Following pathogen encounter and cell activation, DCs migrate to 
lymphoid tissues such as the spleen and lymph nodes where they finish their 
maturation (Kitajima et al., 1996), release chemokines (Adema et al., 1997) and 
activate lymphocytes by presenting antigen and co-stimulatory molecules to T and B 
cells (Banchereau & Steinman, 1998). DCs are important for the defence against 
viruses. For example, DC depletion in mice leads to increased VACV-induced weight 
loss and morbidity due to decreased IFN% production by T cells (Liu et al., 2008).     
 
1.8.4. NK cells 
 
Whilst NK cells belong to the lymphoid lineage, they lack the capability to recombine 
receptor genes from their germline configuration and in this regard are more similar to 
innate, rather than adaptive, immune cell types (Herberman et al., 1975). Another 
hallmark of NK cells is their ability to lyse virus-infected cells immediately, without 
prior activation and clonal activation (Scalzo, 2002). The main functional roles of NK 
cells are to destroy infected and cancerous cells (Scalzo, 2002), to secrete IFN% to 
drive Th1 cell-mediated immune responses (Mocikat et al., 2003), to activate APCs 
resulting in upregulated MHC class I expression (Wallach et al., 1982), to activate 
macrophages allowing their destruction of intracellular pathogens (Filipe-Santos et 
al., 2006) and to induce an antiviral state within infected and neighbouring cells 
(Maher et al., 2007). The importance of NK cells to the eradication of virally-infected 
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cells is underscored by the fact that individuals who are born with a congenital 
depletion of NK cells are prone to recurrent herpesvirus infections (Biron et al., 
1989). Furthermore, depletion of NK cells from mice renders them more susceptible 
to VACV infection (Bukowski et al., 1983).   
 
1.9. Cells of the adaptive immune system 
 
The adaptive immune response is underpinned by the identification of pathogens 
through the use of antigen-specific receptors generated by somatic hypermutation and 
V(D)J recombination. Another key facet is immunological memory whereby repeat 
exposure to the same type of pathogen elicits an immediate, potent and targeted 
immune response that is less dependent upon innate immune intervention. The main 
cells of the adaptive immune system are lymphocytes: T and B cells.  
 
1.9.1. T cells 
 
T cells assist in the clearance of pathogens through their roles in cell-mediated 
immunity and by promoting the development of B cells into antibody-secreting 
plasma cells. Microbial peptides displayed in association with MHC molecules are 
recognised by the antigen-specific T cell receptor (TCR), which is generated by the 
V(D)J recombination. There are several types of T cell that can be distinguished 
based upon their immune function. Cytotoxic T cells (CTLs) can be identified through 
their surface expression of the CD8 glycoprotein and destroy virally-infected or 
tumour cells. CTLs recognise antigen presented in association with MHC class I 
molecules (Barry & Bleackley, 2002). T helper (Th) cells, by contrast, can be 
identified by their cell surface expression of CD4 and recognise antigen presented in 
association with MHC class II molecules. Th cells assist in shaping the adaptive 
immune response by activating T cells and macrophages and by driving the 
differentiation of B cells into antibody-secreting plasma cells. There are several 
subsets of Th cell that are distinguished by the cytokines they secrete and by their 
promotion of either cell-mediated (e.g. Th1) or humoral (e.g. Th2) immune responses 
(Murphy & Reiner, 2002). Memory T cells persist long after the resolution of a 
primary infection but expand rapidly to high number upon re-exposure to the same 
antigen and provide rapid protection (Sallusto et al., 2004). Regulatory T cells (Treg) 
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have a major role in suppressing cell-mediated immune responses towards the end of 
an infection and contribute to immunological tolerance of self-antigens (Vignali et al., 
2008).           
 
1.9.2. B cells 
 
B cells are responsible for mediating the humoral immune response to infection and 
are distinguished from T cells by the presence of a B cell receptor (BCR). The three 
main functions of B cells are to secrete antigen-specific antibody, behave as a type of 
APC by displaying microbe-derived peptides and to contribute towards 
immunological memory. During B cell development the variable regions of the heavy 
and light immunoglobulin chains, which constitute the BCR, undergo V(D)J 
recombination and this generates unique antigen-specificity (Kurosaki et al., 2010). 
Following antigen recognition, B cells must be activated in either a thymus-dependent 
or thymus–independent manner before clonal expansion and terminal differentiation 
can occur. In the thymus-dependent model, an antigen-specific Th cell forms an 
immunological synapse with a B cell and this provides the secondary signal required 
for its development into a plasma or memory cell. In the thymus-independent model, 
certain antigens such as LPS can induce antibody secretion in the absence of Th cells 
owing to extensive BCR cross-linking (Baumgarth, 2000). Antibodies belong to a 
certain isotype (IgG, IgM, IgA, IgD or IgE), with different isotypes having particular 
properties, functions and functional locations. The three primary functions of 
antibodies are to bind pathogens directly thereby neutralising their infectivity, to 
opsonise pathogens leading to their phagocytosis and to activate complement 
(DeFranco et al., 2007).              
 
1.10. Complement 
 
The complement system forms part of the innate immune response and is particularly 
important in the initial containment of microbe numbers during first contact with a 
pathogen. The three main functions of the complement system are to opsonise 
pathogens leading to their phagocytosis, to induce TNF# release by mast cells leading 
to neutrophil recruitment and to induce lysis of target cells (Ricklin et al., 2010). 
Three pathways can activate the complement system but all converge on the 
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generation of C3 convertase. In the classical pathway, C1q of the complement 
component C1 binds to Ab already attached to a pathogen, leading to the activation 
and fixing of C1, C2 and C4. The alternate pathway is initiated by the spontaneous 
activation of C3 and the lectin pathway is initiated by the recognition of lectin on 
pathogen surfaces (Sarma & Ward, 2011). Following the generation of C3 convertase, 
a membrane attack complex (MAC) is assembled that introduces pores directly into 
the membranes of pathogens or into infected cells and this results in their osmotic 
lysis.    
 
1.11. Apoptosis 
 
Apoptosis is a form of programmed cell death that differs from necrosis in that it is 
strictly controlled and does not lead to inflammation. The main functions of apoptosis 
are to remove unwanted cells during development, maintain tissue homeostasis by 
eliminating old or damaged cells and to contribute to the immune response by 
eliminating cells infected with intracellular pathogens. Hallmarks of apoptosis include 
cell shrinkage, chromatin condensation, nuclear fragmentation and the break-up of 
cells into membrane-enclosed vesicles that are engulfed by phagocytic cells - without 
the leakage of cell contents that would otherwise lead to inflammation and tissue 
damage. Two types of pathway control apoptotic signalling: the intrinsic pathway and 
extrinsic pathway. The extrinsic pathway is triggered by the binding of death 
receptors to their extracellular ligands, including the TNF receptor (TNFR)/TNF# 
(Carswell et al., 1975), Fas receptor (FasR)/FasL (Yonehara et al., 1989) and TNF-
related apoptosis-inducing ligand receptor (TRAIL-R)/TRAIL (Wiley et al., 1995). 
Receptor-binding results in receptor oligomerisation, assembly of the death-inducing 
signalling complex (DISC), activation of caspases and the induction of apoptosis 
(Kischkel et al., 1995). The intrinsic pathway is initiated by a variety of stimuli 
including oxidative stress, infection and cytotoxic drugs, and this results in an 
opening of the mitochondrial permeability transition (MPT) pore. Once the MPT has 
been opened, pro-apoptotic factors are released from the intermembrane space, 
including cytochrome c, and these activate apoptosis protease-activating factor 1 
(Apaf-1) and procaspase-9, forming the ‘apoptosome’ (Hill et al., 2004). The Bcl-2 
family of proteins regulate apoptosis by the intrinsic pathway through governing 
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mitochondrial membrane permeability and can be either pro- (e.g. Bax, Bid and Bad) 
or anti- (e.g. Bcl-2, Bcl-x and Bcl-w) apoptotic (Cory & Adams, 2002).  
 
1.12. NF-!B signalling pathway 
 
NF-!B was first discovered as a transcription factor that interacts with the 
immunoglobulin light-chain enhancer in B cells (Sen & Baltimore, 1986) and has 
subsequently been demonstrated to have a key role in regulating the immune response 
to infection (reviewed in (Hayden & Ghosh, 2012)). The NF-!B family of 
transcription factors consists of p65 (RelA), RelB, c-Rel, p50 and p52, all of which 
have a C-terminal Rel-homology domain (RHD) responsible for homodimerisation 
and heterodimerisation. Most commonly, p65 and c-Rel heterodimerise with p50, 
whilst RelB heterodimerises with p52 (Vallabhapurapu & Karin, 2009).  
 
Although the various NF-!B subunits contain a nuclear localisation signal (NLS), in 
the absence of stimulation they are retained within the cytoplasm in an inactive state 
by a family of proteins, termed inhibitor of !Bs (I!Bs), of which I!B# is the 
prototypical member. The activation of NF-!B can proceed via two distinct signalling 
pathways that differ in respect to their stimuli, the IKK components utilised and NF-
!B subunits targeted (reviewed in (Scheidereit, 2006)). In the canonical model of NF-
!B activation, stimulation with proinflammatory cytokines (TNF# or IL-1"), 
microbial PAMPs (e.g. LPS) or cellular stress signals result in signalling cascades that 
converge at the IKK complex. This complex is composed of two effector subunits 
(IKK# and IKK") and one regulatory subunit (NF-!B essential modulator (NEMO); 
also known as IKK%). Activation of IKK" results in the phosphorylation of I!Bs at 
conserved serine residues (S32 and S36 in I!B#), leading to their polyubiquitination 
and degradation by the 26S proteasome. Freed of inhibition by I!B proteins, NF-!B 
dimers translocate to the nucleus where they bind to !B sites within the enhancers and 
promoters of NF-!B-inducible genes, such as IL-6, and activate their transcription 
(Figure 1.2).   
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Figure 1.2. A summary of NF-!B signalling. Following the stimulation of cell 
surface (IL-1R, TLRs and TNFR) and intracellular (TLR3, TLR4 and RLRs) PRRs, 
signalling converges on the IKK complex composed of IKK#, IKK" and NEMO. 
Once activated, IKK" phosphorylates I!B# at serine residues S32 and S36 leading to 
its polyubiquitination and subsequent degradation by the 26S proteosome.  NF-!B 
dimers freed of inhibition by I!B# translocate to the nucleus where they bind to !B 
sites within the enhancers and promoters of NF-!B-inducible genes and activate their 
transcription. 
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Extracellular ligand binding to the IL-1 receptor (IL-1R) and TLRs 1, 2, 4 and 6 
results in TIR clustering and recruitment of the MyD88 adaptor protein (Medzhitov et 
al., 1998). The IL-1R-associated kinase 4 (IRAK4) is then recruited to MyD88, which 
seeds the formation of the MyD88-IRAK4-IRAK2 complex. Signal transduction 
through this complex leads to the activation and ubiquitination of TNF receptor-
associated factor 6 (TRAF6) and IRAK1 (Deng et al., 2000), and activation of the 
transforming growth factor-" (TGF-")-activating kinase 1 (TAK1) complex 
(Kanayama et al., 2004). The TAK1 complex is composed of TAK1, TAB2 and 
TAB3 and is responsible for activating the IKK complex (Kanayama et al., 2004). 
Engagement of the TNF receptor (TNFR) results in TIR clustering and recruitment of 
the TNF receptor type 1-associated death domain protein (TRADD) and TRAF2. This 
activates the kinase RIP1 and signal transduction through the TAK1 and IKK 
complexes leads to NF-!B activation (Figure 1.2).  
 
All of the TLRs can induce NF-!B activation, with the exception of TLR3, by 
recruiting MyD88 (Medzhitov et al., 1998). In contrast, TLR3 recruits TRIF to 
activate downstream signalling leading to activation of the IKK complex (Oshiumi et 
al., 2003a). In addition, TLRs 1, 2, 4 and 6 require the TIR domain-containing 
adaptor protein (TIRAP) to link extracellular ligand binding to MyD88 signalling 
(Horng et al., 2001). It is noteworthy that TLR4 can activate NF-!B in both a 
MyD88-dependent and –independent manner. In the latter case it signals through 
TRIF but only after first engaging the TIR domain-containing TRIF-related adaptor 
molecule (TRAM; Figure 1.2; Oshiumi et al., 2003b).  
 
In the non-canonical model, receptor engagement by certain members of the TNF 
family of proteins, such as CD40L, B cell activating factor belonging to the TNF 
family (BAFF) or lymphotoxin-" result in NF-!B activation that is dependent on 
IKK# but independent of IKK" and NEMO. In this signalling cascade, NF-!B-
inducing kinase (NIK) activates IKK#, which then phosphorylates p100 leading to its 
conversion into a mature p52 subunit. The p52 subunit then heterodimerises with 
RelB and translocates to the nucleus where it regulates the transcription of a distinct 
class of NF-!B-inducible genes (Figure 1.2; Scheidereit, 2006). 
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Activation of the RLRs RIG-I and MDA5 result in NF-!B activation through MAVS, 
which contains a TRAF-interaction motif that permits its binding to TRAF6. 
Subsequently, TRADD, Fas-associated protein with death domain (FADD), caspase-8 
and caspase-10 are recruited by MAVS and TRAF6 leading to activation of the IKK 
complex and NF-!B (Figure 1.2; Takahashi et al., 2006).  
 
1.13. IRF3 signalling pathway 
 
The IRF transcription factors play essential roles in innate immune signalling and are 
required for induction of type I IFNs. Common to each member of the IRF 
transcription factor family is an N-terminal DNA binding domain (DBD). The DBD 
contains a helix-turn-helix motif needed to recognise a consensus sequence within the 
promoter of IRF-inducible genes (e.g. IFN-stimulated gene 56.1 (ISG56.1). 
 
Although IRF3 contains an NLS, it is retained largely within the cytoplasm of resting 
cells due to the presence of a nuclear export signal (NES). The activation of IRF3 can 
be induced by stimulation of a variety of PRRs including RIG-I, MDA5, TLRs 3 and 
4 and cytoplasmic DNA sensors. During IRF3 activation, it is phoshorylated by the 
non-canonical IKK family of kinases: TRAF family member-associated NF-!B 
activator (TANK)-binding kinase 1 (TBK1) and IKK& (Fitzgerald et al., 2003; 
Sharma et al., 2003). Phosphorylation of the C-terminal region induces a 
conformational change within IRF3 that exposes the IRF-association domain 
responsible for homodimerisation and the DBD. Following nuclear translocation, 
activated IRF3 dimers bind to the promoters of IRF3-inducible genes (Figure 1.3; Lin 
et al., 1999).  
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Figure 1.3. A summary of IRF3 signalling. Following the stimulation of TLRs, 
RLRs and cytoplasmic DNA sensors, signalling converges on the non-canonical IKK 
proteins, TBK1 and IKK& via the TRAF3 adaptor protein. TRAF3 subsequently 
phosphorylates and activates IRF3 inducing its homodimerisation and nuclear 
translocation. Once within the nucleus, the IRF3 homodimer binds to IRF3-inducible 
genes and activates their transcription. In addition, TLR3 can activate IRF3 in an 
alternative pathway that involves the protein kinases, P13K and Akt. 
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In contrast to the canonical IKKs that require a single regulatory subunit for NF-!B 
activation, the non-canonical IKKs need to recruit several adaptor proteins for IRF3 
activation to occur. To-date, the NF-!B-activating kinase-associated protein 1 (NAP1; 
Fujita et al., 2003), similar to NAP1 TBK1 adaptor (SINTBAD; Ryzhakov & 
Randow, 2007), TANK (Pomerantz & Baltimore, 1999) and DEAD box protein 3 
(DDX3; Soulat et al., 2008) have all been implicated as adaptor proteins. Current 
efforts are on-going to elucidate the exact requirements of each adaptor protein since 
the current literature would suggest assembly of the adaptor complex is differentially 
influenced depending on which PRR has been stimulated.      
 
Signalling downstream of TLRs 3 and 4 is mediated by the recruitment of TRAF3 via 
the adaptor protein TRIF and this leads to activation of the non-canonical IKKs 
(Oganesyan et al., 2006). The importance of TRAF3 in IRF3 signalling is 
demonstrated by its requirement for signalling downstream of RLRs and cytoplasmic 
DNA sensors, by interacting with MAVS (Saha et al., 2006) and STING (Ishikawa et 
al., 2009), respectively. Furthermore, an alternative route to IRF3 activation by TLR3 
exists that is dependent upon phosphatidylinositol-3 kinase (P13K) recruitment and 
the terminal kinase, Akt (Figure 1.3; Sarkar et al., 2004). 
 
1.14. MAPK signalling pathways 
 
The production of proinflammatory cytokines and type I IFN are also positively 
regulated by the MAPK signalling pathways. MAPKs are a group of serine/threonine 
kinases that are highly conserved amongst eukaryotes and signal through one of three 
pathways: the extracellular-signal-regulated kinase (ERK) pathway, the JUN N-
terminal kinase (JNK) pathway and the p38 pathway (reviewed in (Johnson & 
Lapadat, 2002). MAPKs are activated through a series of sequential phosphorylation 
events that begins with the phosphorylation of MAPK kinases (MAPKKs) by MAPK 
kinase kinases (MAPKKKs). Activated MAPKKs then phosphorylate and activate 
MAPKs at threonine and tyrosine residues within a conserved T-X-Y motif (where X 
is E in ERK, P in JNK and G in p38).  
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MAPKs are activated downstream of TLRs by TAK1, itself a type of MAPKKK, 
which activates the canonical IKK complex and the MAPKKs, MKK3 and MKK6. 
Signalling through MKK3 and MKK6 leads to the activation of JNK and p38 and 
ultimately of the transcription factor, activator protein 1 (AP-1; Holtmann, 2000). In 
addition, stimulation of the RLRs RIG-I and MDA5 result in the activation of 
MAPKs in a pathway dependent on MAVS, TRAF6 and the MEKK1 (Yoshida et al., 
2008).  
 
1.15. IFNs 
 
IFN, the first cytokine discovered, was identified over 50 years ago as a factor 
secreted from influenza virus-infected cells and that induced  resistance to virus 
infection in neighbouring, uninfected cells (Isaacs & Lindenmann, 1957). The name 
IFN is thus derived from the ability of this family of proteins to interfere with virus 
replication. There are three types of IFN, termed type I IFN, type II IFN and type III 
IFN that are differentiated based on the type of receptor through which they signal. 
 
The type I IFN cytokine family consists of IFN# (multiple subtypes), IFN", IFN', 
IFN&, IFN!, IFN( and IFN), however the latter two are not found in humans. 
Notably, whilst IFN# and IFN" can be secreted by most cell types, the others are cell- 
and species- specific (Pestka et al., 2004). The transcription factors required for IFN" 
induction include NF-!B, IRF3 and AP-1(Lenardo et al., 1989; Wathelet et al., 1998; 
Hiscott, 2007). All type I IFNs share the same heterodimeric IFN#/" receptor 
(IFNAR) that is composed of two chains, IFNAR1 and IFNAR2. IFN# or IFN" 
engagement leads to receptor dimerisation and the phosphorylation of two receptor-
associated Janus activated kinases (JAKs), tyrosine kinase-2 (TYK2) and JAK1. This 
results in the recruitment and phosphorylation of the transcription factors, signal 
transducer and activator of transcription 1 (STAT1) and 2 (STAT2; Pestka, 2007). 
The activated STAT1/STAT2 heterodimer then translocates to the nucleus where it 
associates with IRF9, forming the heterotrimeric complex ISG factor 3 (ISGF3). 
ISGF3 binds to ISRE sites within the upstream regulatory sequences of interferon-
stimulated genes (ISGs; Figure 1.4; Kessler et al., 1990). 
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Figure 1.4. A summary of IFN signalling. Following binding of type I IFN (IFN# 
and IFN") to the type I IFN receptor (IFNAR), a STAT1 and STAT2 heterodimer is 
formed that is subsequently phosphorylated by the kinases JAK1 and TYK2. IRF9 is 
recruited to the STAT1 and STAT2 heterodimer, forming the ISGF3 complex, which 
then translocates to the nucleus, binds to ISRE-dependent ISGs and activates their 
transcription. Binding of IFN* to the heterodimeric IL-10R/IL-28R activates the same 
signalling pathway. For type II IFN signalling, after the binding of IFN% to the 
IFNGR, a STAT1 homodimer is formed (termed the GAF complex) that translocates 
to the nucleus and binds to GAS-dependent ISGs activating their transcription. 
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IFN% is the sole member of the type II IFN cytokine family and is principally 
produced by activated T cells and NK cells. The production of IFN% is dependent on 
cytokines, mainly IL-12 and IL-18 (originally called IFN% inducing factor), rather 
than on PAMP stimulation. The heterodimeric IFN% receptor (IFNGR) is composed of 
the IFNGR1 and IFNGR2 chains. Following binding of dimeric IFN% to the IFNGR, 
JAK1 and JAK2 are recruited to the cytoplasmic tail of the receptor where they 
become phosphorylated, leading to the downstream phosphorylation and 
homodimerisation of STAT1.  This results in formation of a complex termed the 
gamma-activated factor (GAF; Decker et al., 1991). Following translocation of GAF 
to the nucleus, it binds to the gamma-activated site (GAS) present in the promoters of 
a subset of ISGs (Figure 1.4; Fensterl & Sen, 2009). IFN% plays important roles in the 
functions of NK and B cells, increases the expression of MHC molecules on APCs 
and promotes the cell-mediated immune response by driving development of the 
CD4+ Th1 phenotype (Schroder et al., 2004).  
 
Like type I IFN, type III IFNs are expressed by most cell types and are induced in 
response to viral and bacterial infection. Each member of the family of type III IFNs, 
consisting of IFN*1, IFN*2 and IFN*3, binds to the heterodimeric IFN* receptor and 
induces a signalling cascade identical to that induced by type I IFNs (Figure 1.4; 
Fensterl & Sen, 2009).   
 
1.16. IFN-stimulated genes 
 
Following the binding of IFNs to their cell surface receptors an antiviral state is 
induced by the upregulation of ISGs. Amongst the best characterised ISGs are: 
protein kinase R (PKR), 2’-5’-oligoadenylate synthetase (2’-5’-OAS), ISG15 and 
apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3) 
proteins. 
 
PKR recognises and is activated by dsRNA produced during infection. After binding 
dsRNA, PKR phosphorylates eukaryotic initiation factor 2# (eIF-2#) thereby 
inhibiting the translation of viral, as well as cellular, mRNAs (Pindel & Sadler, 2011). 
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The replication of RNA viruses such as HCV and of the DNA virus HSV-1 are 
inhibited by PKR activity (Balachandran et al., 2000).   
 
The 2’-5’-OAS enzymes are activated by dsRNA as well and these function to 
catalyse the conversion of ATP into 2’-5’-oligoadenylates, which contain a 2’-5’ 
instead of the normal 3’-5’ phosphodiester bond (Hovanessian & Justesen, 2007).  
This subsequently activates the latent ribonuclease RNAseL resulting in the 
degradation of cellular and viral ssRNA and thus inhibits protein synthesis. The 
cleavage products generated by 2’-5’-OAS enzymes additionally serve as activating 
ligands for RIG-I and MDA5 (Malathi et al., 2007). 
 
ISG15 is a ubiquitin-like protein that is covalently attached to other proteins, such as 
RIG-I and PKR, by E3 ubiquitin ligase enzymes. ISG15 is thought to have an 
activating or protective influence on the proteins to which it becomes attached by 
either modifying signalling events or by preventing their degradation (Zhao et al., 
2005). It has been demonstrated that ISG15 can potentiate the IFN response when 
bound to IRF3 by preventing its virus-induced degradation (Lu et al., 2006).   
 
The APOBEC3 proteins are a conserved family of deoxycytidine deaminases that 
convert cytosine into uracil residues. These enzymes play an important role in the 
innate immune response to retroviruses by deaminating cytosines in nascent DNA 
produced during reverse transcription. The accumulation of mutations in viral cDNA 
thereby prevents normal replication. Moreover, the accumulation of uracil residues 
has been hypothesised to trigger the degradation of retroviral DNA, thus inhibiting its 
integration into the host genome (Cullen, 2006).    
 
1.17. VACV immunomodulation 
 
For a productive virus infection to occur in the face of an onslaught from the innate 
and adaptive immune systems, viruses must evade or subvert key components 
mediating the host antiviral response. To accomplish this, viruses containing larger 
genomes, such as VACV, express a raft of diverse immunomodulatory proteins. Some 
of these immunomodulatory proteins target primary mediators of innate immunity, 
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such as cytokines, chemokines, interferons and complement, whilst others prevent 
intracellular signalling pathways leading to their production.  
 
1.17.1. Inhibition of chemokines 
 
Chemokines are a family of small heparin-binding proteins that are grouped according 
to the positions of conserved cysteines (Ransohoff, 2009). These proteins play a 
crucial role in the mobilisation of leukocytes to sites of infection so, unsurprisingly, 
VACV has evolved countermeasures to inhibit their activities. VACV encodes a 
secreted CC chemokine binding protein (vCKBP) that binds to a wide range of CC 
chemokines (including CCL2, CCL3, CCL5 and CL11) with high affinity to inhibit 
their function (Graham et al., 1997; Alcamí et al., 1998). Expression of vCKBP 
reduced the recruitment of eosinophils and leukocytes to the lungs of mice infected 
with a VACV  and thereby reduced immune pathology (Reading et al., 2003). VACV 
protein A41 is a virulence factor that shares some sequence similarity with vCKBP 
(Ng et al., 2001) and also binds several CC chemokines (including CCL21, CCL25, 
CCL26 and CCL28) with moderate affinity to prevent their interaction with cell 
surface glycosaminoglycans (Bahar et al., 2008; Clark et al., 2006).  
 
1.17.2. Inhibition of apoptosis 
 
Apoptosis is an effective mechanism of removing virally-infected cells from the host , 
thereby preventing their replication, dissemination and persistence within the cell 
(Roulston, 1999). Therefore, it comes as no surprise that VACV is known to express 
several proteins that inhibit apoptosis. The serine protease inhibitors (serpins) are a 
family of proteins that regulate proteolytic cascades involved in inflammation, 
complement activation and apoptosis. Three serpin-like proteins are encoded by 
VACV; SPI-1 (B23), SPI-2 (B13) and SPI-3 (K2). SPI-2 reduces TNF#- and Fas-
mediated apoptosis in VACV-infected cells (Dobbelstein & Shenk, 1996) and also 
inhibits cleavage of pro-IL-1" precursors into mature IL-1" by caspase-1 (Kettle et 
al., 1997). Furthermore, the CPXV orthologue of SPI-2, the cytokine response 
modifier A (CrmA), inhibits the function not just of caspase-1 (Rai et al., 1992) but 
also of caspase-8 (Zhou et al., 1997). Moreover, CrmA interacts with granzyme B, 
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one of the main constituents of cytolytic granules, and in this way prevents apoptosis 
of virally-infected cells by CTLs and NK cells (Quan et al., 1995). Cells infected with 
a mutant rabbitpox virus (RPXV) lacking SPI-1 also undergo early apoptosis, 
demonstrating that this protein is also likely to have an anti-apoptotic function 
(Brooks et al., 1995).  
 
VACV also encodes proteins that have a Bcl-2-like fold and inhibit the pro-apoptotic 
activity of their cellular counterparts. VACV strain Copenhagen (COP) protein F1 
localises to the mitochondrion where it interacts with the BH3 domain of the Bcl-2 
protein Bak (Postigo et al., 2006; Wasilenko et al., 2005). Further, F1 inhibits Bax-
dependent apoptosis, possibly by interacting with Bim (Taylor et al., 2006). As a 
result of these interactions, the release of cytochrome c is inhibited, thus preventing 
initiation of the apoptotic signalling cascade. Similarly, N1, a well-characterised 
virulence factor, functions by binding and inhibiting the pro-apoptotic Bid and Bad 
proteins (Maluquer de Motes et al., 2011). Other anti-apoptotic proteins from VACV 
are Golgi anti-apoptotic protein (vGAAP), which inhibits both the extrinsic and 
intrinsic pathways of apoptosis (Gubser et al., 2007) and E3, which inhibits PKR-
induced apoptosis in HeLa cells (Kibler et al., 1997).    
 
1.17.3. Inhibition of complement  
 
An effective countermeasure to complement activation is provided by the VACV-
encoded complement control protein (VCP). VCP is a 35-kDa protein that is secreted 
from infected cells and that contains four short consensus repeat domains (SCRs), 
which are also present within eukaryotic complement regulatory proteins (Kotwal et 
al., 1990). VCP functions by binding complement proteins C3b and C4b and 
accelerating their decay, thereby inhibiting both the classical and alternative pathways 
of complement activation. VCP is also a virulence factor since it inhibits the 
complement-enhanced neutralisation of VACV virions in vivo (Isaacs et al., 1992). 
Furthermore, whilst IMV particles are sensitive to antibody-independent complement, 
EEV particles are more resistant due to the incorporation of complement regulatory 
proteins CD55 and CD59 into their outer membrane (Vanderplasschen et al., 1998b). 
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1.17.4. VACV inhibitors of NF-!B activation 
 
Given that NF-!B is an important transcription factor necessary for the expression of 
proinflammatory molecules and for robust type I IFN induction (Hiscott, 2007), it is 
therefore not surprising that VACV encodes proteins that inhibit its activation. VACV 
encodes both intracellular (A46, A49, A52, N1, B14, M2, K1, K7 and E3) and 
extracellular (B15, CrmC and CrmE) proteins that function to inhibit NF-!B 
activation (Figure 1.5). 
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Figure 1.5. VACV inhibition of NF-!B activation. A diagrammatic representation 
of NF-!B signalling pathways induced by various ligands are shown. Multiple 
components of NF-!B signalling are inhibited by VACV, which encodes soluble 
decoy receptors (e.g. B15) and inhibitors of intracellular signalling (e.g. B14), 
highlighted in red boxes, and these are described in the text. 
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One strategy used by VACV is to secrete various soluble cytokine-binding proteins 
and decoy receptors that prevent proinflammatory cytokines from reaching their 
cellular receptors and inducing NF-!B activation. For example, protein B15 is a 
decoy viral IL-1R (vIL-1R) that inhibits IL-1"-mediated NF-!B activation by binding 
with high affinity to IL-1", thereby preventing the binding of this cytokine to the IL-
1R (Alcami & Smith, 1992; Spriggs et al., 1992). Poxviruses also secrete decoy TNF 
receptors (vTNFRs) to sequester extracellular TNF# preventing its binding to the cell 
surface TNFR. Although the majority of VACV strains do not encode vTNFRs, both 
soluble and cell surface vTNFRs have been found to be expressed by strains USSR, 
Lister and Evans and these activities map to the CrmC and CrmE genes. These decoy 
vTNFRs exhibit N-terminal structural homology to the extracellular p55 and p75 
domains of their cellular counterparts but lack the C-terminal cytoplasmic domain 
necessary for signal transduction (Alcamí et al., 1999; Reading et al., 2002).  CrmE is 
also a virulence factor since mutant viruses lacking CrmE are attenuated in vivo, 
suggesting that IL-1" is important in the immune response to VACV infection 
(Reading et ai., 2002). 
 
The second strategy used by VACV to prevent NF-!B activation is to express 
proteins that inhibit intracellular signalling events downstream of receptor 
engagement. Protein A52 binds TRAF6 and IRAK2 and inhibits NF-!B activation 
downstream of TLRs and the IL-1R (Bowie et al., 2000; Harte et al., 2003). Protein 
A46 targets several TIR domain-containing proteins, such as the adaptors MyD88, 
TIRAP, TRIF and TRAM, thereby allowing it to interfere with NF-!B activation 
downstream of multiple TLRs (Bowie et al., 2000; Stack et al., 2005). Protein B14 
binds to IKK" and inhibits its activation and the consequential phosphorylation of 
I!B# (Chen et al., 2006, 2008). Protein N1 was reported to bind the IKK complex 
(DiPerna et al., 2004) but this has been disputed (Chen et al., 2008) and so the 
mechanism by which N1 inhibits NF-!B activation remains uncertain. Protein M2 
reduces ERK2 phosphorylation induced by phorbol myristate acetate and prevents 
p65 nuclear translocation (Gedey et al., 2006). Proteins K7 and K1 inhibit NF-!B 
activation either by inhibiting TLR-induced signalling (K7; Schröder et al., 2008) or 
by preventing I!B# degradation (K1; Shisler & Jin, 2004). Protein E3 inhibits NF-!B 
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activity in both PKR-dependent and -independent manners (Myskiw et al., 2009), and 
also by antagonising the RNA Pol III–dsDNA-sensing pathway (Valentine & Smith, 
2010). Finally, A49 has been demonstrated in our laboratory to bind "-transducin 
repeats-containing protein ("-TrCP), thereby preventing the ubiquitination and 
degradation of phosphorylated-I!B# (Maluquer de Motes, manuscript submitted). All 
of the aforementioned VACV immunomodulatory proteins, with the exception of M2, 
have been demonstrated to be virulence factors in vivo. 
 
1.17.5. VACV inhibitors of PKR 
 
Although VACV is a DNA virus, it is known that most intermediate and late gene 
transcripts fail to terminate at specific sites and so run through downstream genes. 
Consequently they can hybridise with transcripts from the other DNA strand to form 
dsRNAs (Moss, 2007). VACV encodes two proteins that interfere with the activity of 
PKR and thus serve to inhibit the antiviral immune response. Protein E3 prevents the 
activation of PKR by binding to and sequestering dsRNA (Chang et al., 1992). On the 
other hand protein K3 acts to prevent eIF-2# phosphorylation by functioning as a 
pseudosubstrate for PKR and this therefore serves to avert PKR-mediated 
translational inhibition of VACV mRNA (Langland & Jacobs, 2002). 
 
1.17.6. VACV inhibitors of DNA sensing and IRF3 activation 
 
Inhibition of cytoplasmic DNA sensing is of importance to VACV since it is a 
dsDNA virus with a cytosolic site of replication. Owing to the fact that cytoplasmic 
DNA sensors have only been identified recently, the modulation of these by VACV is 
not well understood. Nonetheless, VACV encodes two proteins, E3 and C16, which 
inhibit IRF3-dependent type I IFN induction in response to DNA (Figure 1.6). In 
addition, B13 blocks caspase-1 activation resulting from AIM2 activation of the 
inflammasome (Kettle et al., 1997). 
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Figure 1.6. VACV inhibition of DNA sensing and IRF3 activation. A 
diagrammatic representation of IRF3 signalling pathways induced by various ligands 
are shown. Multiple components leading to IRF3 activation are inhibited by VACV, 
which encodes inhibitors of cytoplasmic DNA sensors (e.g. C16), RLRs (E3) and 
TLRs (A46). In addition, other VACV proteins inhibit IRF3 activation by interacting 
with components of the non-canonical adaptor complex (C6 and K7). These various 
VACV immunomodulatory proteins are highlighted in red boxes, and are described in 
the text. 
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The N terminus of VACV protein E3 contains amino acid and structural similarity to 
the Z-DNA binding domain of DAI and has been demonstrated to inhibit DAI 
activation by preventing its interaction with DNA (Wang et al., 2008). In addition, E3 
inhibits the RNA Pol III-dependent pathway of DNA sensing by sequestering RNA 
transcripts generated by RNA Pol III transcription of foreign DNA, preventing its 
recognition by RIG-I and MDA5 (Valentine & Smith, 2010). Thirdly, Guerra et al 
(2008) have determined that E3 can inhibit the antiviral action of ISG15 in MEFs. In 
this study, an interaction between the C-terminal domain of E3 and ISG15 was 
established by co-immunoprecipitation.   
 
Another VACV protein recently demonstrated to inhibit cytoplasmic DNA sensing is 
C16 (Nicholas Peters, unpublished data), a virulence factor that is expressed early 
after infection and that modulates the host immune response to infection in vivo (Fahy 
et al., 2008). Protein C16 inhibited the IRF3-dependent innate immune response to 
ectopic DNA (Nicholas Peters, unpublished data) by inhibiting the recognition of 
dsDNA by DNA-PK (Ferguson, et al 2012). Mechanistically, this was attributable to 
the binding of C16 to Ku70 and Ku80 during infection, thus preventing their 
association with cytoplasmic DNA (Nicholas Peters, unpublished data).   
 
Whilst IRF3 can be activated in response to cytoplasmic DNA, it can also be activated 
following stimulation of cytoplasmic (RIG-I and MDA5) and membrane bound 
(TLR3) RNA sensors and also by bacterial LPS (TLR4). Four VACV-encoded 
proteins, E3, K7, A46 and C6, have been described that can prevent the activation of 
IRF3 following stimulation of these PRRs (Figure 1.6).  
 
As described above, VACV protein E3 is thought to sequester dsRNA produced by 
RNA Pol III, thereby preventing signalling downstream of RIG-I and MDA5 and the 
activation of IRF3. VACV protein A46 is expressed early after infection and interacts 
with several TIR containing proteins, such as MyD88 and TIRAP, allowing it to 
inhibit the activation of NF-!B (section 1.17.4.; Bowie et al., 2000; Stack et al., 
2005). However, since A46 interacts with the TIR-containing protein TRIF as well, it 
can also inhibit IRF3 activation downstream of TLR3 and TLR4. Similarly, in 
addition to inhibiting the activation NF-!B downstream of the IL-1R and multiple 
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TLRs by interacting with IRAK2 and TRAF6, K7 can also bind to DDX3 and thus 
inhibit the activation of IRF3 downstream of multiple DNA and RNA sensors 
(Schröder et al., 2008). 
 
VACV protein C6, a predicted member of the VACV Bcl-2-like protein family and a 
virulence factor, also inhibits the activation of IRF3 (Unterholzner et al., 2011). 
Protein C6 is expressed early after infection and exerts its inhibitory effects by 
preventing signalling downstream of the kinases TBK1 and IKK& by interacting with 
several adaptor molecules (SINTBAD, TANK and NAP1) essential for the activation 
of these kinases. 
 
1.17.7. VACV inhibitors of IFN signalling 
 
VACV is known to encode both extracellular and intracellular proteins that interfere 
with IFN signalling (Figure 1.7).  
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Figure 1.7. VACV inhibition of IFN signalling. A diagrammatic representation of 
IFN signalling pathways are shown and VACV inhibitors are highlighted in red 
boxes. VACV protein B8 is a decoy IFN% receptor that is secreted from infected cells 
and that prevents IFN% receptor engagement. In addition, B18 is a soluble type I IFN 
receptor that can be either secreted or retained on the surface of infected cells that 
binds IFN# and IFN" with high affinity. VH1 is a VACV-encoded intracellular 
phosphatase that functions by de-phosphorylating STAT1 and STAT2, thus 
preventing their nuclear translocation. 
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VACV protein B8 is a decoy IFN% receptor that is secreted from infected cells, which 
binds to and inhibits the activity of IFN% by preventing its interaction with its cellular 
receptor (Alcami & Smith, 1995). B8 can inhibit the activity of human, bovine, 
equine, ovine and rat (but not murine) IFN% demonstrating that it has cross-species 
reactivity (Mossman et al., 1995; Symons et al., 2002). Another VACV-encoded 
protein with a similar function is B18, a soluble type I IFN receptor, which can be 
either secreted or retained on the surface of infected cells. B18 binds IFN# and IFN" 
with high affinity and thus prevents IFN signalling (Colamonici et al., 1995; Symons 
et al., 1995; Alcami et al., 2000). Although B18 and B8 have a similar function, their 
protein structures are very different. Whilst B8 exhibits sequence and structural 
similarity to the binding pocket of the cellular IFN% receptor, B18 does not have any 
similarity to the type I IFN receptor, but instead belongs to the immunoglobulin 
superfamily (Smith & Chan, 1991; Alcami & Smith, 1995; Symons et al., 1995). 
 
VACV protein VH1 is an intracellular phosphatase that can dephosphorylate both 
STAT1 and STAT2 in response to type I and type II IFN receptor engagement (Mann 
et al., 2008; Najarro et al., 2001). It is noteworthy that VH1 is incorporated inside the 
virion during VACV assembly suggesting that its role is to inhibit IFN signalling 
immediately after virus entry into the cell (Lii et ai., 1995). Interestingly, VACV can 
also inhibit the STAT1-independent IFN signalling pathway but the proteins required 
for this have not yet been identified (Mann et al., 2008).   
 
1.18. Hypoxic signalling 
 
Mammalian cells require a constant availability of molecular oxygen (O2) for the 
generation of ATP by mitochondrial oxidative phosphorylation. Under systemic or 
local conditions of low oxygen concentration, termed hypoxia, an essential stress 
response pathway is initiated that ultimately results in the activation of the hypoxia-
inducible factor (HIF) family of transcription factors (Semenza, 2001). Three 
mammalian HIFs have been discovered (HIFs 1 – 3), however HIF-1 has been the 
most intensively studied and its role  in the response to hypoxia the best characterised 
(Ke & Costa, 2006).  
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HIF-1 is a heterodimer comprised of the regulatory HIF-1# and constitutively 
expressed HIF-1" subunits (Wang et al., 1995). Under conditions of normal oxygen 
concentration (normoxia), HIF-1# is constitutively degraded (t1/2 ~ 5 min) and the 
hypoxic transcriptional program is not active (Salceda & Caro, 1997). The 
degradation of HIF-1# takes place after the hydroxylation of proline residues P402 
and P564 within the oxygen-dependent degradation domains (ODDs) by prolyl 
hydroxylase domain-containing enzymes (PHDs), primarily PHD2 (Bruick & 
McKnight, 2001). PHDs belong to the 2-oxoglutarate (2-OG)-dependent dioxygenase 
family of proteins that have an absolute requirement for molecular oxygen for their 
catalytic activities (Epstein et al., 2001). Once hydroxylated, HIF-1# is bound by the 
von Hippel-Lindau (VHL) E3 ubiquitin ligase complex and degraded in a 26S 
proteasome-dependent manner (Salceda & Caro, 1997). Furthermore, "-hydroxylation 
of an asparaginyl residue (N803) in the C-terminal transactivation domain (TAD) of 
HIF-1# by factor inhibiting HIF (FIH), provides an additional means of silencing 
unwanted HIF-1# activity by blocking its interaction with the transcriptional co-
activator CBP/p300 (Lando et al., 2002). Under hypoxic conditions, the activity of 
PHDs is lost due to the lack of molecular oxygen. In this case, HIF-1# is not degraded 
but instead translocates to the nucleus where it dimerises with HIF-1" and binds to 
hypoxia-response elements (HREs) within the enhancers and promoters of hypoxia-
responsive genes to induce their transcription (Figure 1.8; Crews, 1998). 
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Figure 1.8. A summary of oxygen-dependent HIF-1#  regulation. Under normoxic 
conditions, two proline residues (P402 and P564) and an asparaginyl residue (N803) 
of HIF-1# are hydroxylated by PHDs (mainly PHD2) and FIH, respectively. 
Hydroxylated HIF-1# proteins are bound by the VHL E3 ubiquitin ligase complex 
and degraded in a 26S proteasome-dependent manner. Under hypoxic conditions, the 
activities of PHDs and FIH are inhibited due to the lack of oxygen, resulting in no 
HIF-1# hydroxylation and thus HIF-1# proteins are not degraded. Stabilised HIF-1# 
proteins translocate to the nucleus where they heterodimerise with HIF-1" and bind to 
HRE sites within the promoters and enhancers of HIF-1 responsive genes activating 
their transcription. 
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Numerous genes are activated by HIF-1# including those involved in angiogenesis, 
cell survival, glucose metabolism and apoptosis (reviewed in (Ke & Costa, 2006)). 
For example, the expression level of vascular endothelial growth factor (VEGF) is 
upregulated, activating angiogenesis and increasing blood vessel permeability – steps 
designed to increase oxygen and glucose delivery to cells (Pugh & Ratcliffe, 2003). In 
the absence of oxygen, glucose metabolism is switched from the oxygen-dependant 
tricarboxylic acid (TCA) cycle to oxygen-independent glycolysis in a step facilitated 
by the mitochondrial protein PDK-1 (Dang & Semenza, 1999). To make up for the 
shortfall in ATP production generated by oxygen-independent glycolysis, glucose 
uptake is increased by the upregulation of glycolytic enzymes and glucose 
transporters such as GLUT-1 (Wertheimer et al., 1991). Furthermore, autophagy is 
promoted during oxygen stress to recycle non-essential cellular materials and this 
process is supported by the increased expression of the pro-apoptotic protein Bcl-
2/adenovirus E1B 19kDa interacting protein 3 (BNip3; Bruick, 2000). 
 
Over eight decades ago Warburg made a landmark discovery linking increased 
glycolysis to animal tumours, known as the ‘Warburg effect’ (Warburg et al., 1930). 
Although the mechanisms driving the Warburg effect are complex and still not 
completely understood, mitochondrial malfunction (Penta et al., 2001) and hypoxia 
(Guppy, 2002) are believed to be two major factors contributing to this phenotype. 
The rapid proliferation of cancer cells leading to tumour expansion outpaces the 
normal prcocess of neovascularisation required to maintain appropriate blood delivery 
to all areas of the tumour. Insufficient blood supply results in a hypoxic environment 
within the tumour mass, restricting the availability of molecular oxygen for oxidative 
phosphorylation and this impels cancer cells to instead use oxygen-independent 
glycolysis for ATP synthesis (Guppy, 2002). This metabolic shift may also impart 
growth/survival advantages to cancer cells since its decreases the intra- and 
extracellular pH causing apoptosis in non-cancer cells that express functional p53 
(Williams et al., 1999). As described above, HIF-1# is the key mediator of the 
hypoxic response and this transcription factor activates the transcription of a variety 
of genes whose protein products facilitate adaptation to hypoxia and oxygen-
independent ATP synthesis.   
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1.19. Project Aims 
 
Although gene C4L is quite well conserved among OPV species, no previous 
characterisation of the protein or its contribution to virus virulence had been reported. 
Furthermore, C4 is closely related to C16, a protein shown previously to affect virus 
virulence (Fahy et al., 2008). Therefore, it was hypothesised that protein C4 may have 
an important function and thus to be worthy of further investigation.  
 
The aims of this project were to:  
 
• Characterise C4 within VACV-infected cells 
• Study the effect, if any, of C4 on intracellular signalling pathways 
• Identify the binding-partners of C4 
• Investigate the contribution of C4 to virus virulence in vivo  
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Chapter Two 
 Materials and Methods 
 
2.1. Manipulation of nucleic acids 
 
2.1.1 Polymerase chain reaction (PCR) 
 
Each PCR mix consisted of 100 ng DNA template, 5 µl of 10 x HiFi Buffer 
(Invitrogen) or 10 x GoTaq Flexi Buffer (Promega), 2 mM MgSO4, 0.8 mM 
deoxynucleoside triphosphates (dNTPs; Invitrogen), 0.2 µM sense primer, 0.2 µM 
antisense primer (Table 2.1) and 1 U Taq HiFi (Invitrogen) or GoTaq (Promega) 
polymerase, made up to a total volume of 50 µl with deionised distilled H2O (ddH2O). 
A PCR was then performed using a programmable thermocycler with the following 
settings: 95 °C for 5 min, [(95 °C for 0.5 min, 50 °C for 0.5 min and 68 °C for 1.5 
min) for a total of 30 cycles] and 68 °C for 10 min. 
 
2.1.2. Resolution of DNA fragments by agarose gel electrophoresis 
 
PCR products were separated by electrophoresis on a 1 % (w/v) agarose gel at 100 V 
for 45 min in TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA). DNA 
was stained with Syber Safe (Invitrogen), visualised using a long wave UV lamp and 
imaged using Quantity One software (Bio-Rad). 
 
2.1.3. Isolation of DNA from agarose 
 
DNA bands were carefully excised from agarose gels using a clean scalpel. The 
QIAquick Gel Extraction Kit (QIAGEN) was used to isolate DNA from agarose 
according to the manufacturer’s instructions. 
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Table 2.1. Oligonucleotide primer sequences used for plasmid construction 
Plasmid Primers 
Z11!C4 5’ - GCCACGCGTTCCAATTATCTTTACCG -3’ (L-FA) 
5’ - CCCGGGTCCGGAGAGCTCTAGTATTGGTTAAAAATGAAAATG - 3’ 
5’ - GAGCTCTCCGGACCCGGGTTTATATCACTACGG -3’ 
5’ - TAGCGGCCGCGGTGTCCTGTGTTCAGG -3’ (L-FB) 
Z11C4Rev 5’ - GCCACGCGTTCCAATTATCTTTACCG -3’ (L-FA) 
5’ - TAGCGGCCGCGGTGTCCTGTGTTCAGG -3’ (L-FB) 
pUC13-C4TAPRev 5’ - CCGGAATTCGGTGTCCTGTGTTCAGGAGG - 3’ 
5’ - AAGGAAAAAAGCGGCCGCTTCATAATTGAGATTGAT -3’ 
5’ - TCCCCGCGGTATTGGTTAAAAATGAAAAT - 3’ 
5’ - CTAGTCTAGATCCAATTATCTTTACCGATA - 3’ 
C4-N’TAP 5’ - AAGGAAAAAAGCGGCCGCGGACACCATCAAGATCTTCAACC - 3’ 
5’ - CGGTCTAGATCACTCGTAGTTCAGGTTGATGTAG - 3’ 
C4-C’TAP 5’ - CGGGGTACCATGGACACCATCAAGATCTTCAACC - 3’ 
5’ - AAGGAAAAAAGCGGCCGCCTCGTAGTTCAGGTTGATGTAG - 3’ 
C16-N’TAP 5’ - AAGGAAAAAAGCGGCCGCGGACATCTACGACGACAAG - 3’ 
5’ - CGGGGGCCCTCATTTAGGCATGTTGAAGTAG - 3’ 
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Table 2.1. Oligonucleotide primer sequences used for plasmid construction (continued) 
 
Plasmid Primers 
C4-!IL-1Ra 5’ - AAGGAAAAAAGCGGCCGCGGACACCATCAAGATCTTCAACC - 3’ 
5’ - CGGTCTAGATCATTTGAAGGTGAACACGGTGC - 3’ 
C16-!IL-1Ra 5’ - AAGGAAAAAAGCGGCCGCGGACATCTACGACGACAAG - 3’ 
5’ - CGGGGGCCCTCATTTGAAGATGAACACGG - 3’ 
pET28a-C4NHis 5’ - CTAGCTAGCGATACTATTAAAATATTTAATC - 3’ 
5’ - TATTCTTAGCGGCCGCCTATTCATAATTGAGATTGATG - 3’ 
pET28a-C4CHis 5’ - CATGCCATGGGTGATACTATTAAAATATTTAATC - 3’ 
5’ - GGCCTCGAGTTCATAATTGAGATTGATGTAA - 3’ 
pOPINF-C4NHis 5’ - AAGTTCTGTTTCAGGGCCCGGATACTATTAAAATATTTAATC- 3’ 
5’ - ATGGTCTAGAAAGCTTTACTATTCATAATTGAGATTGATG - 3’ 
pOPINE-C4CHis 5’ - AGGAGATATACCATGGATACTATTAAAATATTTAATC - 3’ 
5’ - GTGATGGTGATGTTTTTCATAATTGAGATTGATGTAA - 3’ 
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2.1.4. Quantification of DNA 
 
DNA concentration and purity was measured using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific) according to the manufacturer’s instructions. 
DNA purity was assessed using the OD260/OD280 ratio and verified to be between 1.8 
and 2.0. 
 
2.1.5. Restriction endonuclease digestion 
 
Digestion reactions consisted of 2 µg DNA, 5 µl 10 x restriction endonuclease buffer 
(Roche) and 1 µl of each restriction endonuclease (Roche), made up to a total volume 
of 50 µl with ddH2O. DNA was digested at 37 °C for 2 h, the digestion products were 
analysed by agarose gel electrophoresis (section 2.1.2.) and then purified from the 
agarose gel (section 2.1.3.). 
 
2.1.6. Ligation of DNA fragments 
 
Ligation reactions consisted of 100 ng digested vector DNA, an appropriate mass of 
digested insert DNA (corresponding to a 3:1 molar ratio of insert to vector DNA), 10 
x T4 DNA ligase buffer (Promega) and 1 U T4 DNA ligase (Promega), made up to a 
total volume of 10 µl with ddH2O. Ligation reactions were incubated at 16 °C for 2 h. 
 
2.1.7. Transformation of E. coli 
 
Transformation competent E. coli (XL-10; Stratagene) were thawed on ice and 
incubated with 10 ng of plasmid DNA (Table 2.2) for 30 min. The E. coli were then 
heat-shocked at 42 °C for 45 s and then immediately incubated on ice for a further 2 
min. The E. coli were then supplemented with 300 µl super optimal catabolite (SOC) 
medium and incubated in a shaking incubator set to 37 °C for 1 h. To select for 
transformed E. coli, the bacteria were then spread on to antibiotic-containing agar 
plates and grown at 37 °C overnight. 
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Table 2.2. Plasmids used in this study 
Plasmid Description 
Z11!C4 pCI-based, 300-350 bp flanks of C4 ORF, Ecogpt-EGFP selection marker, AmpR 
Z11C4Rev pCI-based, 300-350 bp flanks + C4 ORF, Ecogpt-EGFP selection marker, AmpR 
pUC13 C4TAPRev pUC13-based, 300-350 bp flanks + C4 ORF + C-terminal TAP-tag, Ecogpt-EGFP selection marker, AmpR 
pcDNA4.0/TO Empty vector control (EV), doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C4-N’TAP C4 with N-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C4-C’TAP C4 with C-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C4-!IL-1Ra C4 (aa 1-305) with N-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C16-N’TAP C16 with N-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C16-C’TAP C16 with C-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C16-!IL-1Ra C16 (aa 1-321) with N-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO C6-C’TAP C6 with C-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO icIL-1Ra icIL-1Ra with N-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO B14-C’TAP B14 with C-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pcDNA4.0/TO GFP-C’TAP GFP with C-terminal TAP-tag, doxycycline-inducible, zeocin selection marker, AmpR 
pOPINF C4NHis C4 with N-terminal His6-tag, StrepR, obtained from D. Stuart (University of Oxford) 
pOPINE C4CHis C4 with C-terminal His6-tag, StrepR, obtained from D. Stuart (University of Oxford) 
pET28a C4NHis C4 with N-terminal His6-tag, KanR 
pET28a C4CHis C4 with C-terminal His6-tag, KanR 
pCI HA-IKK" pCI-based, IKK" with a C-terminal HA-tag, AmpR 
pCI HA-NEMO pCI-based, NEMO with a C-terminal HA-tag, AmpR 
IFN" Luc IFN" promoter fused with firefly luciferase, AmpR, obtained from A. Bowie (Trinity College Dublin) 
ISG56.1 Luc ISG56.1 promoter fused with firefly luciferase, AmpR, obtained from G. Sen (Lerner Research Institute, Ohio) 
NF-#B Luc NF-#B promoter fused with firefly luciferase, AmpR, obtained from A. Bowie 
TK-Ren Luc TK promoter fused with renilla luciferase, AmpR, obtained from A. Bowie 
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2.1.8. Screening of bacterial colonies 
 
To confirm that E. coli contained the plasmid of interest, isolated colonies were 
picked and re-suspended into 4 ml of Luria broth (LB) containing the appropriate 
antibiotic and incubated in a shaking incubator set to 37 °C for 2 h. PCR was then 
performed using 5 µl of bacterial culture as template DNA and the same primers were 
used for ORF amplification. PCR products were analysed using agarose gel 
electrophoresis (section 2.1.2) to confirm the presence of an insert with the expected 
length.  
 
2.1.9. Small- and large-scale preparation of plasmid DNA 
 
Plasmid DNA was purified using the QIAprep Spin Miniprep and Maxiprep kits 
(QIAGEN) according to the manufacturer’s instructions. Minipreps were prepared 
from 4 ml bacterial cultures and used for screening new plasmids. Maxipreps were 
prepared from 250 ml bacterial cultures and used to obtain plasmid concentrations 
appropriate for downstream applications. 
 
2.1.10. Concatamerisation of oligonucleotides 
 
The sense sequence used for concatamer stimulations in this study was 5’-
TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA -3’. Sense 
and antisense oligonucleotides were mixed in a 1:1 molar ratio, heated to 80 °C for 5 
min, annealed at 60 °C for 15 min and then cooled to room temperature. Annealed 
oligonucleotides were phosphorylated by incubation with T4 polynucleotide kinase 
(New England Biolabs) at 37 °C for 30 min and then ligated using T4 DNA ligase 
(Promega) at 16 °C for 16 h. Concatamerisation was confirmed by agarose gel 
electrophoresis (section 2.1.2.).  
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2.1.11.  Phenol-chloroform extraction of DNA  
 
An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1; Fluka) was added 
to a solution of DNA and mixed thoroughly to form an emulsion. The mixture was 
centrifuged at 14,000 x g for 1 min and the aqueous (upper) phase transferred to a 
clean microcentrifuge tube. This was repeated twice more or until no visible protein 
remained at the organic/aqueous interface. Next, an equal volume of 
chloroform:isoamyl alcohol (24:1) was added to the DNA solution and mixed 
thoroughly to form an emulsion. The mixture was centrifuged as before and the 
aqueous phase transferred to a clean microcentrifuge tube. Ammonium acetate was 
then added to a final concentration of 2.5 M. 
 
2.1.12. Ethanol precipitation of DNA 
 
Two volumes of ice-cold ethanol were added to the phenol-chloroform extracted 
DNA solution (section 2.1.11.) and then it was incubated at -20 °C overnight. The 
DNA precipitate was collected by centrifugation at 14,000 x g for 15 min at 4 °C. The 
supernatant was removed and the DNA pellet was washed with 70 % ethanol and 
centrifuged at 14,000 x g for 2 min at 4 °C. The supernatant was removed and the 70 
% ethanol wash repeated once more to remove traces of salt. The supernatant was 
discarded and the remaining 70 % ethanol allowed to evaporate. Finally, the DNA 
was dissolved into a suitable volume of ddH2O. 
 
2.1.13. Extraction of cellular RNA 
 
The RNeasy kit (QIAGEN) was used to extract cellular RNA from cultured cells 
according to the manufacturer’s instructions. RNase-free ddH2O (Sigma) and filter 
tips were used to avoid RNase contamination. 
 
2.1.14. Generation of cDNA 
 
Reverse transcription reactions consisted of 1 µg RNA, 2.5 µM oligo dT and 500 µM 
dNTPs, made up to 13 µl with ddH2O. The reactions were incubated at 65 °C for 5 
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min and then transferred to ice for 1 min. The following components were then added: 
4 µl 5 x First-Strand Buffer (Invitrogen), 5 mM DTT, 40 U RNase OUT (Invitrogen) 
and 50 U SuperscriptIII reverse transcriptase (Invitrogen), made up to a total volume 
of 20 µl with ddH2O. Reverse transcription reactions were incubated at 50 °C for 1 h 
and then 70 °C for 15 min. 
 
2.1.15. Quantitative real time PCR (qRT-PCR) 
 
qRT-PCR was performed in 96-well plates in duplicate on a 7900HT series qPCR 
instrument (Applied Biosystems). Each reaction contained 2 µl cDNA, 10 µl 2 x 
SYBR! Green PCR master mix (Applied Biosystems), 0.5 µM sense primer and 0.5 
µM antisense primer, made up to a total volume of 20 µl with ddH2O. Either relative 
quantification (""Ct="Ct sample of interest - "Ct reference sample) or absolute 
quantification (AQ; "Ct=Ct target gene – Ct endogenous reference gene) was then 
performed. The qRT-PCR programme settings were as follows: 50 °C for 2 min, 95 
°C for 10 min and then 40 cycles of (95 °C for 15 s and 60 °C for 1 min). Data were 
analysed using RQ Manager 1.2 software (Applied Biosystems).  
 
The primers used for qRT-PCR are listed in Table 2.3.  
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Table 2.3. Oligonucleotide primer sequences used for qRT-PCR 
Primer Species Sequence 
IFNB1 Homo sapiens 5’ - ACATCCCTGAGGAGATCAAGCA - 3’  
5’ - GCCAGGAGGTTCTCAACAATAG - 3’ 
NFKB1A Homo sapiens 5’ - GTCCGAGACTTTCGAGGAAAT - 3’ 
5’ - GCCATTGTAGTTGGTAGCCTT - 3’ 
IL6 Homo sapiens 5’ - AGCGACTCACCTCTTCAGAAC - 3’ 
5’ - GCTGCTTTCACACATGTTACTCTT - 3’ 
GAPDH Homo sapiens 5’ - ACCCAGAAGACTGTGGATCG - 3’ 
5’ - TTCTAGACGGCAGGTCAGGT - 3’ 
GLUT-1 Mus musculus 5’ - TGCAGTTCGGCTATAACACC - 3’ 
5’ - ACACCTCCCCCACATACATG - 3’ 
PDK-1 Mus musculus 5’ - GGCGGCTTTGTGAATTGTAT - 3’ 
5’ - ACCTGAATCGGGGGATAAAC - 3’ 
VEGF-A Mus musculus 5’ - CAGGCTGCTGCAACGATGAA - 3’ 
5’ - TTTCTTGCGCTTTCGTTCTT - 3’ 
BNip3 Mus musculus 5’ - GCTCCCAGACACCACAAGAT - 3’ 
5’ - TGAGAGTAGCTGTGCGCTTC - 3’ 
HPRT Mus musculus 5’ - GTTGGATACAGGCCAGACT - 3’ 
5’ - GATTCAACTTGCGCTCATCT - 3’ 
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2.2. Cell culture 
 
2.2.1. Maintenance of cell lines 
 
BSC-1 (African green monkey kidney epithelial cell line), CV-1 (African green 
monkey kidney fibroblast cell line) and HEK293T (human embryonic kidney cell 
line) cells were grown in DMEM (Invitrogen) supplemented with 10 % (v/v) foetal 
bovine serum (FBS) that had been heated at 56 °C for 1 h to inactivate complement 
and penicillin-streptomycin (50 µg/ml; PS; Invitrogen). Xrcc5+/+/Tp53-/- (Ku80+/+) 
and Xrcc5-/-/Tp53-/- (Ku80-/-) mouse embryonic fibroblasts  (MEFs; provided by Prof. 
Paul Hasty, University of Texas, USA) were grown in DMEM supplemented with 15 
% (v/v) FBS and PS. HeLa (human cervical cancer cell line) and RK-13 (rabbit 
kidney cell line) cells were grown in MEM supplemented with 10 % (v/v) FBS, 1:100 
non-essential amino acids (Invitrogen) and PS. The C4-TAP inducible cell line was 
grown in DMEM supplemented with 15 % (v/v) FBS, PS, blasticidin (50 µg/ml) and 
zeocin (100 µg/ml). 
 
All cells were grown at 37 °C in an environmentally controlled incubator (Heraeus) 
and with humidified air containing 5 % (v/v) CO2.  
 
2.2.2. Passage of cell lines 
 
Growth medium was discarded from tissue culture flasks and the cells were washed 
with sterile PBS. Cells were detached by incubation in 0.125 % trypsin + 500 µM 
EDTA (Gibco) at 37 °C for 1 min. Detached cells were collected by centrifugation at 
500 x g for 5 min at 4 °C and re-suspended with an appropriate volume of growth 
medium. Cell numbers were enumerated by trypan blue exclusion and then the 
required number were seeded into a new flask containing fresh growth medium. 
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2.2.3. Transfection of cells with FuGENE-6 and PEI  
 
Cells were seeded at least 24 h before transfection to achieve approximately 60 % 
confluency at the time of transfection. Transfection mixtures were prepared by mixing 
DNA with Opti-MEM! reduced serum medium (Invitrogen; 1 µg DNA per 50 µl 
Opti-MEM). FuGENE-6 transfection reagent (Roche) or polyethylenimine (PEI; 1 
mg/ml; Millipore) was then added to the DNA/Opti-MEM mixture (2 µl transfection 
reagent per 1 µg DNA) and the mixture was vortexed for 3 s. After incubation for 30 
min at room temperature an appropriate volume of fresh growth medium (containing 
2 % (v/v) FBS) was added to the transfection mixture. Medium was aspirated from 
the cells and the transfection mixture was added drop-wise to the cells.  
 
2.2.4. Transfection of cells with calcium phosphate 
 
Cells were seeded at least 24 h before transfection to achieve approximately 50 % 
confluency at the time of transfection. Medium was then replaced with fresh medium 
(containing 10 % (v/v) FBS) prior to preparing transfection mixtures. For 10 cm2 
plates of cells, the transfection mixtures were prepared as follows. Firstly, 5 µg DNA 
+ 445 µl ddH2O + 50 µl 2.5 M CaCl2 were mixed together and incubated at room 
temperature for 20 min. Then an equal volume of HBS (280 mM NaCl, 10 mM KCl, 
1.5 mM Na2HPO4, 12 mM glucose and 50 mM HEPES, pH 7.05) was added to the 
transfection mixtures in a drop-wise manner and incubated at room temperature for 15 
min before being added drop-wise to the cells. Twenty four h later, medium 
containing the transfection mixtures was removed and the cells were washed carefully 
with pre-warmed (37 °C PBS). Fresh medium was then added to the cells and the 
transfected cells were grown for at least a further 24 h before harvesting.  
 
2.3. Protein analysis 
 
2.3.1. Preparation of cell lysates 
 
Protein cell lysates were prepared by firstly aspirating growth medium and washing 
cells twice with ice-cold PBS. An appropriate volume of RIPA lysis buffer (1 % 
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Triton X-100, 150 mM NaCl, 0.5 % sodium deoxycholate, 0.1 % SDS and 50 mM 
Tris-HCl, pH 8.0) supplemented with protease inhibitors (Roche) and, where 
appropriate, phosphatase inhibitors (Roche) was then added to the cells on ice. The 
cells were scraped into the lysis buffer, collected into microcentrifuge tubes and 
incubated on ice for 20 min with occasional inverting. The resultant lysates were 
cleared of genomic DNA and lipid aggregates by centrifugation at 14,000 x g for 20 
min at 4 °C and then the supernatants were transferred to a clean microcentrifuge 
tube. The cleared lysates were stored at -20 °C until use. 
 
2.3.2. Protein quantification 
 
Prior to SDS-PAGE, the protein concentrations of samples were determined to ensure 
equal loading onto gels. The BCA assay kit (Pierce) was used according to the 
manufacturer’s instructions. Briefly, this assay involves the protein-dependent 
reduction of Cu2+ to Cu1+ and then the subsequent detection of cuprous cations by 
bicinchoninic acid (BCA). Protein concentrations of test samples were calculated 
from a standard curve constructed using bovine serum albumin (BSA) standards. 
 
2.3.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
Protein lysates were resolved by SDS-PAGE using 12 % polyacrylamide gels 
(Protogel) assembled into Mini PROTEAN II gel tanks (Bio-Rad).  Cell lysates were 
prepared for electrophoresis by mixing with 4X Laemmli buffer (8 % (w/v) SDS, 20 
% (v/v) "-mercaptoethanol, 40 % (v/v) glycerol, 0.008 % (w/v) bromophenol blue 
and 0.250 M Tris-HCl, pH 6.8) or 4X Nu-PAGE buffer (Invitrogen) and then heating 
the mixture at 100 °C for 5 min.  Protein samples were separated together with 
Precision Plus protein pre-stained standards (Bio-Rad) using a Tris-glycine buffer (25 
mM Tris-HCl, 190 mM glycine and 0.1 % (w/v) SDS, pH 8.3) at 120 V for 1.5 h.   
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  2.3.4. Detection of proteins by Coomassie staining 
 
Polyacrylamide gels were stained for 45 min in Coomassie blue stain (0.25 % (w/v) 
Coomassie brilliant blue R-250 (BDH), 10 % (v/v) acetic acid and 45 % (v/v) 
methanol) and de-stained with wash buffer (10% (v/v) acetic acid and 45 % (v/v) 
methanol) for 12 h.  
 
2.3.5. Detection of proteins by immunoblotting 
 
Proteins to be analysed by immunoblotting were first transferred to a Hybond ECL 
nitrocellulose membrane (GE Healthcare) using a Mini-Electrophoretic Trans-Blot 
apparatus (Bio-Rad). Following protein transfer, membranes were blocked with 5 % 
(w/v) non-fat milk + 0.01 % (v/v) Tween-20 in PBS, pH 7.4 (PBST) for 1 h at room 
temperature with gentle rocking.  Membranes were incubated with primary Ab in 
blocking buffer overnight at 4 °C on a roller. The following morning, membranes 
were washed three times for 5 min each in PBST and then incubated with secondary 
Ab in 5 % (w/v) non-fat milk + PBST for 1 h at room temperature on a roller.  
Membranes were washed as before and then incubated with chemiluminescent HRP 
substrate (1.25 mM luminol, 0.4 mM p-coumaric acid, 0.0075 % (v/v) H2O2 and 0.1 
M Tris-HCl, pH 8.8) for 1 min and exposed to X-ray film. 
 
The Abs used for immunoblotting are listed in Table 2.4. 
 
2.3.6. Detection of membrane-bound proteins by Licor development 
 
The protocol used was identical to section 2.3.5. up to the point of secondary Ab 
incubation. Thereafter, membranes were incubated with a fluorophore-conjugated 
species-specific secondary Ab in 5 % (w/v) non-fat milk + PBST for 1 h at room 
temperature on a roller and protected from light. The membranes were then washed 
three times for 5 min each in PBST, followed by one wash in PBS and were allowed 
to dry at room temperature for 1 h. Images were obtained using a Licor Odyssey 
scanner and band intensities were measured using Odyssey software (Licor 
Biotechnology).  
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Table 2.4. Antibodies used in this study 
Antibody Supplier Dilution 
Mouse anti-tubulin Millipore (05-829) 1:5000 
Mouse anti-FLAG Sigma (F1804) 1:1000 
Mouse anti-D8 mAb 1.1 (Parkinson & Smith, 1994) 1:5000 
Mouse anti-lamin A/C Abcam (ab8984) 1:1000 
Mouse anti-His Millipore (05-949) 1:5000 
Mouse anti-p65 Santa Cruz (sc-8008) 1:1000 
Mouse anti-Ku70 Abcam (ab3114) 1:5000 
Mouse anti-Ku80 Santa Cruz (sc-1484) 1:1000 
Mouse anti-DNAPKcs Thermo Fisher (LVMS423P1) 1:1000 
Mouse anti-HIF-1! BD Biosciences (610958) 1:500 
Mouse anti-HIF-1! Novus Biologicals (NB100-123) 1:500 
Rabbit anti-PHD2 Cell Signalling Technology (32935) 1:1000 
Rabbit anti-C16 Polyclonal serum (Eurogentec; Fahy et al, 2009) 1:5000 
Rabbit anti-I"B! Cell Signalling Technology (9242L) 1:1000 
Mouse anti-phospho-I"B! Cell Signalling technology (9246S) 1:1000 
Mouse anti-HA Covance (16B12) 1:1,000 
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2.3.7. Detection of proteins by silver staining 
 
Proteins separated by SDS-PAGE were visualised by staining using a SilverQuest 
silver staining kit (Invitrogen) according to the manufacturer’s instructions.       
 
2.3.8. Detection of proteins by immunofluorescence 
 
HeLa cells were seeded into 6-well plates (2 x 105 per well) containing 13-mm sterile 
glass coverslips (BDH). After transfection or infection, the medium was aspirated, 
cells were washed twice with ice-cold PBS and then fixed with 4 % (v/v) 
paraformaldehdye (PFA) in PBS for 20 min.  Fixed HeLa cells were washed twice as 
before and stored in PBS at 4 °C until further processing. 
 
Free-aldehydes were quenched with 50 mM NH4Cl for 5 min, cells were washed 
twice with PBS for 5 min each and then were permeabilised with 0.2 % (v/v) Triton 
X-100 for 5 min.  Cells were blocked in PBS containing 10% (v/v) FBS (blocking 
buffer) for 30 min.  Next, the cells were incubated with primary Ab in blocking buffer 
for 1 h inside a moist chamber at room temperature.  The cells were washed three 
times with blocking buffer and then were incubated with secondary antibody for 30 
min.  Cells were washed three times in blocking buffer and three times in PBS for 5 
min each and finally rinsed in ddH2O.  Coverslips were mounted onto microscope 
slides with Mowiol containing 4’,6-diamidino-2-phenylindole (DAPI). Cells were 
imaged using a Zeiss Metaconfocal microscope (Carl Zeiss).  
 
2.3.9. Immunoprecipitation (IP) assays 
 
Cells were washed twice on ice with ice-cold PBS and then scraped into an 
appropriate volume of IP buffer (100 mM NaCl, 50 mM HEPES pH7.5, 1 mM 
EDTA, 0.5 % (v/v) NP-40 and 10 % (v/v) glycerol), supplemented with protease 
inhibitors (Roche). The resultant lysates were cleared of genomic DNA and lipid 
aggregates by centrifugation at 14,000 x g for 20 min at 4 °C and then the 
supernatants were transferred to a clean microcentrifuge tube. Fifty µl of the 
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supernatants were removed and stored at -20 °C (‘Inputs’) and the remainder was 
transferred to clean microcentrifuge tubes for use in the IP assay. Lysates were pre-
cleared with 10 µl of Strep-Tactin Superflow beads (IBA) or protein G sepharose 
beads (GE Healthcare) for 1 h at 4 °C. The beads were then collected by 
centrifugation at 6000 x g for 5 min at 4 °C and the pre-cleared supernatant was 
transferred to a clean microcentrifuge tube. For anti-HA/Ku70/Ku80 IPs, 2.5 µg of 
the mAb was incubated with the lysate overnight at 4 °C and the next day protein G 
beads were added and the mixture was incubated for a further 2 h; for anti-Strep 
affinity purifications (APs), lysates were incubated with Strep-Tactin Superflow 
beads (20 µl per sample) for 2 h at 4 °C. The beads were then washed four times with 
IP buffer and the antibody-antigen complexes eluted from the beads by boiling in 2 x 
SDS-PAGE protein loading buffer.  
 
2.3.10. Enzyme-linked immunosorbent assay (ELISA) 
 
Cytokines in cell culture supernatants were measured using CXCL10 or IL-6 DuoSet 
ELISA kits (R&D Diagnostics) according to the manufacturer’s instructions. 
 
2.4. Recombinant protein production 
 
2.4.1. Plasmid construction 
 
The C4L gene was amplified by PCR from VACV-WR genomic DNA as a template. 
The PCR product was then cloned into the pET28a expression plasmid either 
upstream (pET28a-C4CHis) or downstream (pET28a-C4Nhis) of and in-frame with 
the 6 x His tag. Alternately, C4L was cloned into the N-terminal (pOPINF-C4Nhis) or 
C-terminal (pOPINE-C4CHis) 6 x His tag expression plasmid using the In-
Fusion!HD Cloning Kit (BD Clontech). 
 
The fidelity of C4L within all plasmids was verified by DNA sequencing. 
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2.4.2. Prokaryotic protein expression 
 
The BL21(DE3)-R3/Rosetta strain of E. coli (Rosetta E. coli) was transformed 
(section 2.1.7.) with one of the 6 x His tag C4 expression plasmids (section 2.4.1.) and 
plated onto agar containing chloramphenicol and either kanamycin (pET28a-based 
plasmids) or streptomycin (pOPIN-based plasmids). A single colony was picked and 
used to inoculate 4 ml of Terrific broth (TB) supplemented with the appropriate 
antibiotics. This culture was grown overnight at 37 °C inside a shaking incubator set 
to 200 rpm and then used to inoculate either 50 ml or 500 ml flasks of TB 
supplemented with the appropriate antibiotics. Once the OD600 reached 0.6, a final 
concentration of 0.1 mM isopropyl "-D-1-thiogalactopyranoside (IPTG) was added to 
induce the expression of C4. The culture was incubated at 18 or 37 °C for 4 or 8 h, 
respectively, inside a shaking incubator set to 150 rpm. The cells were harvested by 
centrifugation at 6000 x g for 15 min at 4 °C and then the pellet was stored at -20 °C 
until further processing.   
 
2.4.3. Protein purification by IMAC 
 
The cell pellets were thawed on ice and lysed with either a standard lysis buffer (20 
mM NaH2PO4, pH 7.4, 500 mM NaCl, 1 % Triton (v/v) X-100, 30 mM imidazole and 
2 mM "-mercaptoethanol) or sarkosyl lysis buffer (20 mM NaH2PO4, pH 7.4, 500 
mM NaCl, 10 % (w/v) sarkosyl, 30 mM imidazole and 2 mM "-mercaptoethanol), 
supplemented with protease inhibitors (Roche). The cells were sonicated at 100 W on 
ice until no cell clumps remained and then the suspension was incubated on a roller 
for 8 h at 4 °C to allow for complete lysis to occur. The lysate was then separated into 
soluble and insoluble fractions by centrifugation at 15,000 x g for 1 h at 4 °C. After 
centrifugation, the soluble fraction was transferred to a clean tube. For the subsequent 
purification of sarkosyl-solubilised proteins, the soluble fraction was then diluted with 
native lysis buffer to achieve a final sarkosyl concentration of 1 % (v/v). The 
detergent CHAPS was also added at this stage to a final concentration of 20 mM.  
 
Soluble His-tagged C4 was purified by immobilised metal ion affinity 
chromatography (IMAC) using a 1 ml His-Trap column (GE Healthcare), according 
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to the manufacturer’s instructions. Briefly, the His-Trap column was washed with 5 
column volumes (CVs) of ddH2O and then equilibrated with 10 CVs of 1 % sarkosyl 
lysis buffer. Proteins contained within the soluble fraction were then applied to the 
His-Trap column at a flow rate of 1 ml/min. Non-specifically bound proteins were 
washed off the column with 10 CVs of wash buffer containing 50 mM imidazole. 
After washing the column, immobilised His-tagged C4 was eluted in 0.5 ml fractions 
using 500 mM imidazole. 
 
2.5. Tandem affinity purification (TAP) 
 
2.5.1. Plasmid construction 
 
The sequence of C4L was codon-optimised for expression in mammalian cells 
(GeneArt, Invitrogen) and then subcloned into the mammalian expression vector 
pcDNA4.0/TO (including a zeocin-resistance cassette; Invitrogen) containing a C-
terminal tandem affinity purification (TAP) tag consisting of two FLAG and two 
StrepII epitopes (Gloeckner et al., 2007), generating plasmid C4-TAP (Table 2.1 for 
primer sequences).  
 
2.5.2. Construction of C4-TAP inducible cell line 
 
The C4-TAP plasmid was transfected into HEK293T-Rex cells (Invitrogen) using the 
calcium phosphate transfection method (section 2.2.4.). Once confluent, these cells 
were serially diluted and transferred to new dishes with medium containing zeocin 
(100 µg/ml). After 2 weeks of selection, clonal zeocin-resistant cells derived from 
isolated parental cells were picked and amplified. Clonal C4-TAP cell lines were 
tested for inducible C4 expression by growing in the presence or absence of 2 µg/ml 
doxycycline for 24 h, followed by analysis of cell extracts by immunoblotting.    
 
2.5.3. TAP assay 
 
Twenty T175 flasks of the C4-TAP inducible cell line were grown to 80 % 
confluency and doxycycline was added to a final concentration of 2 µg/ml to ten 
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flasks overnight; the other ten flasks were left untreated. Alternatively, twenty T175 
flasks of HEK293T cells were grown to 80 % confluency and then ten flasks were 
infected with vC4-TAP at 2 p.f.u/cell overnight; the other ten flasks were infected 
with a control TAP-tagged virus. The next morning cells were detached into PBS and 
were collected by centrifugation at 1000 x g for 10 min at 4 °C.  Cell pellets were 
washed twice with PBS and then lysed with ice-cold TAP lysis buffer (0.5 % (v/v) 
NP-40 in PBS, pH 7.4) supplemented with protease and phosphatase inhibitors 
(Roche) for 20 min at 4 °C on a roller platform.  The resultant lysates were cleared of 
genomic DNA and lipid aggregates by centrifugation at 4000 x g for 20 min at 4 °C 
and then the supernatants were transferred to clean 50 ml tubes. 
 
All of the following procedures were performed at 4 °C.  A 150 µl aliquot of the 
cleared lysates (‘Input’) was removed and stored in NuPAGE LDS Sample Buffer (4 
x; Invitrogen) at -20 °C until SDS-PAGE.  The remaining lysates were incubated with 
100 µl Strep-Tactin Superflow beads (IBA) for 1 h with rotation.  After incubation, 
the beads were collected by centrifugation at 1000 x g for 5 min.  A 150 µl aliquot of 
the flow-through (‘Strep FT’) was removed and stored with sample buffer as before.  
The remainder of the supernatant was discarded and the pellet was washed three times 
with TAP wash buffer (0.1 % (v/v) NP-40 in PBS, pH 7.4) supplemented with 
protease and phosphatase inhibitors (Roche).  After the final wash, the supernatant 
was removed using a syringe and the proteins were eluted from the beads by 
incubation with Strep-Tag elution buffer (desthiobiotin; IBA) for 30 min.  The Strep-
Tactin Superflow beads were collected by centrifugation at 1000 x g for 5 min and the 
supernatant was transferred to a clean microcentrifuge tube; the beads (‘Strep beads’) 
were stored with sample buffer as before.  The supernatant was incubated with anti-
FLAG M2 agarose beads (Sigma) for 1 h with rotation and the beads were collected 
as before.  A 150 µl aliquot of the flow-through (‘FLAG FT’) was stored with sample 
buffer as before and the remainder of the supernatant was discarded.  The FLAG 
beads were washed four times with TAP wash buffer and the protein complexes were 
eluted by incubation with 125 µg FLAG-peptide (Sigma) in PBS for 30 min with 
rotation. The FLAG beads were collected by centrifugation as before and the 
supernatant was transferred to an Amicon Ultra-0.5 Membrane centrifugal filter 
(Millipore). The supernatant was centrifuged at 15,000 x g for 30 – 40 min, until the 
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eluted proteins (‘Final elution’) were concentrated into a final volume of 70 – 100 µl.  
The collected beads (‘FLAG beads’) were stored with sample buffer as before. The 
various protein fractions were heated at 100 °C for 5 min and then were separated by 
SDS-PAGE through a NuPAGE Novex Bis-Tris 4-12 % precast gel (Invitrogen).  
Proteins were visualised by silver staining (section 2.3.7.).   
 
2.5.4. Identification of proteins by mass spectrometry 
 
Silver-stained bands from tandem affinity purification were excised using a clean 
scalpel and placed in 100 µl molecular biology grade ddH2O (Sigma). Samples were 
analysed by liquid chromatography mass spectrometry (LC-MS/MS) at the 
Cambridge Centre for Proteomics (CPP; University of Cambridge). 
 
2.6. Luciferase reporter assays 
 
Luciferase reporter-gene assays were performed by seeding HEK293T cells at a 
density of 10,000 cells per well before transfection with PEI (section 2.2.3.). 
Transfection mixtures contained 10 ng GL3-Renilla control plasmid per well, 60 ng 
IFN", AP-1, or NF-#B firefly reporter plasmid per well (gifts from A. Bowie, Trinity 
College Dublin, Ireland, and G. Sen, Lerner Research Institute, Cleveland, OH, USA) 
and 70 ng expression vector or pcDNA4.0/TO empty vector control per well. After 24 
h incubation, transfected cells were stimulated with 40 ng IL-1" or TNF$ (Peprotech) 
for 8 h or transfected with 800 ng poly(dA:dT) or poly(I:C) (Sigma) for 24 h. The 
cells were harvested in Passive Lysis Buffer (Promega), fluorescence intensities were 
measured using a FLUOstar Omega instrument and then these data were analysed 
with MARS data analysis software (BMG Labtech). For data analysis, firefly 
luciferase activity values were normalized against Renilla luciferase activity values. 
Experiments were performed in biological triplicate and repeated a minimum of three 
times. Data are expressed as means ±SD. 
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2.7. Construction of recombinant VACVs 
 
2.7.1. Plasmid construction 
 
For construction of the C4 deletion virus (v%C4), 300 bp of each C4L flanking region 
were amplified by PCR from VACV-WR genomic DNA, joined by overlapping PCR 
and cloned into a selection plasmid encoding Ecogpt (Boyle & Coupar, 1988) fused to 
EGFP, generating Z11%C4. A revertant virus (vC4-Rev) in which the C4L gene was 
to be reinserted back into the VACV genome at its natural position was constructed 
by amplifying the complete C4L locus (i.e. the flanks plus C4L) from WR genomic 
DNA and then cloning this fragment into the selection plasmid, generating 
Z11C4Rev. For construction of the TAP-tagged C4 revertant virus (vC4-TAPRev), 
C4L and the left flanking region were cloned upstream of the TAP tag into the 
pcDNA4.0/TO vector using restriction enzymes EcoRI and NotI. The C4L right 
flanking region was then cloned downstream of the TAP tag using restriction 
enzymes SacII and XbaI. The complete C4L locus and TAP tag was subsequently 
subcloned into the pUC13 mammalian expression vector modified to contain the 
Ecogpt and EGFP genes (Maluquer de Motes et al., 2011) using restriction enzymes 
EcoRI and XbaI, generating the plasmid pUC13-C4TAPRev.  
 
The fidelity of all plasmids constructed using PCR was confirmed by sequencing. 
 
 2.7.2. Transient dominant selection 
 
Recombinant VACVs were constructed using the transient dominant selection method 
(Falkner & Moss, 1990). The C4 deletion virus, v%C4, was constructed by infecting 
CV-1 cells with a third-passage VACV strain Western Reserve (WR) parental isolate 
at 0.01 plaque forming units (p.f.u.) per cell for 1.5 h in infection medium (DMEM + 
2.5 % (v/v) FBS + 50 µg/ml PS). The infected cells were then transfected with 5 µg of 
plasmid Z11%C4 using FuGENE-6 transfection reagent (section 2.2.3.) and harvested 
48 h later. The resultant virus progeny were used to infect RK-13 cells in the presence 
of mycophenolic acid (25 µg/ml; MPA), hypoxanthine (15 µg/ml; HX) and xanthine 
(250 µg/ml; X). Viruses that had integrated plasmid Z11%C4 into their genomic DNA 
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appeared as green plaques and were purified by three rounds of plaque purification in 
the presence of MPA drug selection in BSC-1 cells. These intermediate viruses were 
resolved by three rounds of plaque purification without MPA drug selection in BSC-1 
cells and the genotype of resolved viruses was analysed by locus-specific PCR 
(section 2.7.3.). A plaque-purified wild-type virus (vC4) and C4L deletion mutant 
virus (v%C4) were identified and amplified to obtain working stocks (section 2.7.4.). 
 
For construction of the revertant (vC4-Rev) and TAP-tagged revertant (vC4-TAPRev) 
viruses, CV-1 cells were infected with v%C4 and then transfected with plasmids 
Z11C4Rev or pUC13-C4TAPRev, respectively. For construction of the C16L and 
C4L double deletion virus (v%C16,%C4), CV-1 cells were infected with v%C16 
(constructed previously by Fahy et al., (2008)) and then transfected with plasmid 
Z11%C4.  
 
 2.7.3. Screening of viruses using locus-specific PCR 
 
To confirm the genotype of intermediate and resolved viruses, locus-specific PCR 
was used. Confluent BSC-1 cells in a 96-well plate were infected with 50 µl (10 % 
(v/v) of a plaque homogenate in infection medium for 48 h. The infection medium 
was then aspirated and the cells were washed gently twice with PBS. After the 
removal of PBS, 50 µl of proteinase K lysis solution (6 µg proteinase K (Sigma) + 5 
µl 10 x GoTaq Flexi PCR buffer (Promega) + 45 µl ddH2O) was added and the cells 
were freeze-thawed twice. The cells were then scraped to form a homogenate and 
then the contents were transferred to a 0.2 ml PCR tube. Virus DNA was extracted by 
heating the homogenate at 56 °C for 20 min and then at 85 °C for 10 min.   
 
For locus-specific PCR, the following components were mixed together: 2 µl of the 
proteinase K-treated lysate, 10 x Taq PCR buffer (Promega), 2 mM MgCl2, dNTPs 
(0.2 mM each), 0.2 µM sense primer, 0.2 µM antisense primer and 1 U GoTaq 
polymerase (Promega), made up to a total volume of 50 µl with ddH2O. PCR was 
then performed (section 2.1.1.) and the PCR products were analysed by agarose gel 
electrophoresis (section 2.1.2.). 
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 2.7.4. Amplification of virus stocks 
 
For the preparation of a crude virus master stock, a 25 cm2 flask of RK-13 cells was 
infected with 50 µl 10 % (v/v) of a plaque homogenate in infection medium for 48 h. 
The cells were scraped into their growth medium, collected by centrifugation at 500 x 
g for 5 min at 4 °C and re-suspended in 1 ml infection medium. For preparation of a 
crude virus working stock, five 175 cm2 flasks of RK-13 cells were infected with at 
0.1 p.f.u. per cell for 48 h. The cells were scraped into their growth medium, collected 
by centrifugation at 500 x g for 5 min at 4 °C and re-suspended in 5 ml infection 
medium. Virus stocks were stored at -80 °C. 
 
 2.7.5. Virus titration 
 
Recombinant VACVs were titrated by plaque assay, in duplicate, on confluent 
monolayers of BSC-1 cells grown in 6-well plates. A ten-fold serial dilution of the 
virus was made using infection medium and used to infect cells for 1.5 h at 37 °C 
with gentle rocking every 15 min. Medium was then aspirated and was replaced with 
2 ml overlay medium (50 % MEM (supplemented with 5 % (v/v) FBS + 100 µg/ml 
PS) and 50 % carboxy methyl cellulose solution (3 %; CMC). The cells were 
incubated for 48 – 72 h to allow plaque formation, then the overlay medium was 
aspirated and the cells were washed once with PBS. The cells were then stained for 1 
h with crystal violet solution (0.1 % (v/v) crystal violet (Sigma), 15 % ethanol (v/v)), 
washed with water and the number of plaques was counted.  
 
2.7.6. Partial purification of virus through a sucrose cushion 
 
Before recombinant viruses were used in vivo, they were first partially purified by 
sedimentation twice through a 36 % sucrose cushion. Ten 175 cm2 flasks of RK13 
cells were infected per virus at 0.1 p.f.u. per cell for 72 h. The cells were then scraped 
into the growth medium and were collected by centrifugation at 500 x g for 5 min at 4 
°C. The cells were resuspended in 10 mM Tris, pH 9.0 (1 ml per flask), incubated for 
10 min and then disrupted by dounce homogenisation. Intact nuclei were collected by 
centrifugation at 250 x g for 5 min and then the cytoplasmic extract was transferred to 
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a clean tube on ice. The pellet was resuspended again, disrupted by dounce 
homogenisation as before. The cytoplasmic extracts were combined, sonicated at 100 
W for 10 s and then were layered onto a 36 % (w/v) sucrose cushion. The samples 
were centrifuged at 32,500 x g for 80 min at 4 °C and the resultant virus pellet was 
resuspended in 1 ml 10 mM Tris, pH 9.0 by sonication as before. The sonicated virus 
suspension was then layered on to a fresh 36 % (w/v) sucrose cushion and centrifuged 
as before. The supernatant was aspirated and the virus pellet was washed by 
resuspension in 10 mM Tris, pH 9.0. The virus suspension was centrifuged at 26,000 
x g for 50 min at 4 °C and the purified virus pellet was finally resuspended in 1 ml 10 
mM Tris, pH 9.0 and stored at -80 °C. 
 
 2.8. Analysis of recombinant VACVs 
 
 2.8.1. General virus infection protocol 
 
Cells were washed once with PBS prior to infection. Virus tubes were freeze-thawed 
three times and sonicated at 100 W for 20 s in order to break-up cell clumps and 
separate virus particles. The appropriate volume of virus to infect cells with an MOI 
of 1 (or lower/higher depending on the purpose of the experiment) was then diluted 
with infection medium and added to the cells so as to minimally cover their surfaces 
(typcially, 0.5 ml per well of a 6-well plate). The cells were incubated with the 
infection medium for 1.5 h at 37 °C with gentle rocking every 15 min to prevent the 
cells drying out. After this time, the infection medium containing unbound virus was 
aspirated and replaced with either 1 % (w/v) low melting temperature agarose 
(Agarose type VII, Sigma) in DMEM with 2.5 % (v/v) FBS, a semi-solid overlay 
containing 1.5 % (w/v) carboxymethylcellulose (CMC) in DMEM with 2.5 % (v/v) 
FBS or only liquid DMEM with 2.5 % (v/v) FBS and the cells were returned to the 
incubator. Agarose/CMC overlays were used for plaque assays; liquid growth 
medium was used for general virus infection.   
 
 2.8.2. Purification of virus through a sucrose density gradient 
 
To obtain VACV genomic DNA of sufficient purity to perform genomic digests, IMV 
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cores purified through a sucrose cushion were purified further by sedimentation 
through a 24-40 % (w/v) sucrose gradient. Sucrose gradients were prepared a day in 
advance by layering 5.8 ml bands of 40, 36, 32, 28 and 24 % (w/v) sucrose in 10 mM 
Tris, pH 9.0 and storing at 4 °C overnight. The partially purified virus (section 2.7.6.) 
was then layered onto the sucrose gradient and centrifuged at 26,000 x g for 50 min at 
4 °C. After centrifugation, the virus visible as a white band was carefully transferred 
into a clean tube and made up to a total volume of 36 ml with 10 mM Tris, pH 9.0. 
The virus was collected by centrifugation at 32,900 x g for 80 min at 4 °C and then 
the washed virus pellet was resuspended in 0.5 ml 50 mM Tris, pH 7.8. 
 
To extract VACV genomic DNA, the purified virus was incubated with a proteinase 
K-containing buffer (4000 U proteinase K, 0.5 % (w/v) SDS, 6 % (w/v) sucrose and 
50 mM Tris, pH 7.8) and incubated at 37 °C for 6 h. VACV genomic DNA was then 
extracted with phenol-chloroform (section 2.1.11) and recovered by ethanol 
precipitation (section 2.1.12.).   
 
 2.8.3. Cellular fractionation 
 
HeLa cells were grown on 14 cm2 dishes and infected with recombinant viruses at 10 
p.f.u. per cell for the indicated times. The cells were washed twice with ice-cold LS 
buffer (0.5 mM MgCl2, 0.5 mM DTT and 20 mM HEPES, pH7.8) and then incubated 
with 5 ml LS buffer on ice for 20 min. The cells were scraped into LS buffer and were 
disrupted by dounce homogenisation on ice using 20 strokes of a loose fitting 
homogeniser. The disrupted lysates were transferred to clean 15 ml tubes and were 
centrifuged at 600 x g for 2 min at 4 °C to pellet nuclei. The supernatant (cytoplasmic 
fraction) was collected into a new tube and the nuclear pellet was washed five times 
with ice-cold PBS. Finally, the nuclei were resuspended in 100 µl nuclei resuspension 
buffer (0.5 mM MgCl2, 20 mM iodoactetamide, and 50 mM Tris, pH 8.0) 
supplemented with protease inhibitors (Roche) and sonciated at 100 W for 20 s. 
 
 2.8.4. Analysis of plaque size 
 
The diameters of 30 plaques per virus were measured using Axiovision 4.6 on a Zeiss 
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Axiovert 200 M microscope (Zeiss). 
 
 2.8.5. Analysis of virus growth kinetics 
 
Monolayers of BSC-1 cells were infected with either 10 or 0.01 p.f.u. per cell with 
recombinant viruses for measurement of single-step or multi-step growth kinetics, 
respectively. After 1.5 h of virus attachment and entry into cells, the infection 
medium was aspirated, the cells were washed twice with fresh medium to remove any 
unbound virus and then the flasks were returned to the incubator. At the indicated 
times post-infection, the medium was removed and the cells were collected by 
centrifugation at 500 x g for 10 min at 4 °C. The supernatant (containing extracellular 
virus) was collected and titrated immediately (section 2.7.5.). The cells still attached 
to the flask were scraped into 3 ml of fresh medium and added to the pellet from the 
first centrifugation step. The cells (containing intracellular virus) were collected by 
centrifugation as described above, resuspended into 500 µl infection medium and 
stored at -20 °C until titration.   
 
 2.9. Virulence assays 
 
 2.9.1. Intranasal model of infection 
 
Female BALB/c mice (6–8 weeks old) were anaesthetised and infected intranasally 
(i.n.) with 5 ! 103 p.f.u. of VACV partially purified from a sucrose cushion (section 
2.7.6.; Alcami & Smith, 1992). Mice were weighed daily before and after infection. 
Signs of illness were also assessed using the following scoring system:   
 
1 = Hair ruffling. 
2 = Back arching. 
3 = Reduced mobility. 
4 = Severe pneumonia. 
 
Animals that lost more than 30 % of their original body weight or had signs of illness 
scores higher than 3.0 were sacrificed. The titre of each inoculum was confirmed by 
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plaque assay (section 2.7.5.).  
 
 2.9.2. Extraction of cells from BAL fluid 
 
The bronchoalveolar lavage (BAL) fluid was harvested by flushing lungs with 1 ml of 
PBS containing 10 U/ml heparin per animal. The cells were collected by 
centrifugation at 500 x g for 5 min at 4 °C and then resuspended in 500 µl of ACK 
buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.4) and incubated 
for 3 min at room temperature to lyse erythrocytes. Ten ml of RPMI medium 
(containing 10 % FBS + 50 µg/ml PS; RPMI-10) was added and the cells were  
collected by centrifugation. Finally, the cells were resuspended in 300 µl of 
fluorescence-activated cell sorting (FACS) buffer (0.1 % (w/v) BSA, 0.1 % (w/v) 
NaN3 in PBS, pH 7.4) and enumerated by trypan blue exclusion.  
 
 2.9.3. Extraction of lung cells 
 
The lung tissue was cut into small pieces and incubated in 3 ml digestion buffer 
(RPMI-10 + 1 mg/ml collagenase + 30 µg/ml DNaseI) for 30 min at 37 °C with 
occasional agitation. The lung homogenate was filtered through a cell strainer and 250 
µl collected for virus titration (section 2.7.5.). The remainder of the lung homogenate 
was centrifuged at 500 x g for 5 min at 4 °C to collect the cells. The cells were then 
resuspended in ACK buffer and incubated at room temperature for 3 min. Nineteen 
ml of RPMI-10 buffer was added and the cells were collected as before by 
centrifugation. The cells were then resuspended in 5 ml 20 % Percoll (Sigma) in 
RPMI-10 and were centrifuged at 1000 x g for 20 min. Finally, the cells were 
resuspended in 1 ml FACS buffer and enumerated by trypan blue exclusion.  
 
 2.9.4. Extraction of spleen cells 
 
The spleen tissue was cut into small pieces, mixed with 5 ml RPMI-10 and then 
pressed through a cell strainer. The cell suspension was centrifuged at 500 x g for 5 
min at 4 °C to collect the cells. The cells were then resuspended in 4 ml ACK buffer 
and incubated at room temperature for 3 min. Sixteen ml of RPMI-10 was added to 
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the cell suspension and then the cells were collected as before. Finally, the cells were 
resuspended in 1 ml FACS buffer and enumerated by trypan blue exclusion. 
 
 2.9.5. Flow cytometry 
 
After extraction of cells (sections 2.9.2.-2.9.4.), 1 ! 106 cells were resuspended in 
FACS blocking buffer (10 % (v/v) rat serum (AbD Serotech) + 1:500 anti-CD16/32 
Fc gamma receptor (BD Biosciences) in FACS buffer) for 30 min at 4 °C. The FACS 
Abs were then prepared by diluting to the appropriate concentration with FACS 
blocking buffer (Table 2.4). The cells were collected by centrifugation at 500 x g for 5 
min at 4 °C and then were resuspended in FACS stain containing the appropriate Abs 
for 30 min at 4 °C in the dark. The cells were collected as before, washed with 500 µl 
PBS and then resuspended in 10 µl LIVE/DEAD! Fixable Aqua Dead Cell Stain 
(Invitrogen) and were incubated for 30 min at 4 °C in the dark. The cells were 
collected, washed as before and then were resuspended in 100 µl fixing solution (2 % 
(v/v) PFA in PBS, pH 7.4) for 30 min at room temperature in the dark. Finally, the 
cells were collected, washed as before and then resuspended in 1 ml FACS blocking 
buffer and stored at 4 °C until analysis. Stained cells were measured by flow 
cytometry on a BD FACS CantoII flow cytometer and these data were analysed using 
Summit software (Beckman Coulter). 
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Table 2.5. FACS antibodies used in this study 
Antibody Supplier Dilution 
CD3 APC-Cy7 BD Biosciences (560590) 1:50 
CD4 APC BD Biosciences (553051) 1:200 
CD8 FITC BD Biosciences (553031) 1:100 
CD69 PE BD Biosciences (553237) 1:100 
CD19 PE-Cy7 BD Biosciences (552854) 1:200 
F4/80 APC Serotec (MCA 497 APC) 1:50 
Ly6G PE BD Biosciences (551461) 1:100 
DX5 FITC BD Biosciences (553857) 1:100 
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 2.9.6. Intradermal model of infection 
 
Female C57BL/6 mice (6–8 weeks old) were anaesthetised and infected intradermally 
(i.d.) with 104 p.f.u. of VACV partially purified from a sucrose cushion in both ear 
pinna and the resultant lesion sizes were measured daily with a micrometer (Tscharke 
& Smith, 1999). The titre of each inoculum was confirmed by plaque assay (section 
2.7.5.).   
 
 2.9.7. Vaccination and challenge 
 
Female C57BL/6 mice (6–8 weeks old) were anaesthetised and infected i.d. with 104 
p.f.u. of VACV partially purified from a sucrose cushion in both ear pinna (section 
2.9.6.). Twenty eight days after infection, the animals were challenged i.n. with 5 ! 
106 p.f.u. of VACV-WR per animal (section 2.9.1.). Weight loss was measured daily 
and the titres of each inoculum were confirmed by plaque assay (section 2.7.5.).   
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Chapter Three 
Analysis of the VACV strain WR ORF 024 and its protein C4 
 
This chapter describes a bioinformatic analysis of the C4 protein and its promoter, the 
construction of VACVs that do or do not contain the C4L gene, and the expression of 
C4 in bacteria. 
 
3.1. Bioinformatic analysis of the C4 protein 
 
3.1.1. Comparative analysis 
 
The VACV strain WR ORF 024 (gene C4L in VACV strain Copenhagen) is 951 bp in 
length and located as a single copy towards the left end of the genome. C4L is 
predicted to encode a hitherto uncharacterised protein of 316 amino acids with a 
molecular mass of 37.2 kDa (referred to as protein C4 hereafter; GenBank accession 
no. YP_232906). C4 exhibits 43.7% amino acid (aa) identity to VACV strain WR 
protein C16 (gene C10L in VACV strain Copenhagen; GenBank accession no. 
YP_232892; Figure 3.1), a protein characterised by Fahy et al (2008) and shown to 
affect virus virulence and the host response to infection. Interestingly, conservation 
between C4 and C16 is highest in the C-terminal 100 amino acids, where there is 
56.0% aa identity. Conversely, the N-terminal 100 amino acids show only 34.0% aa 
identity, and most strikingly, C4 contains two 8–aa deletions (aa residues 1-8 and 89-
96 relative to the C16 protein sequence).     
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Figure 3.1. C16 and C4 are closely-related VACV proteins. Amino acid sequences 
were aligned using the ClustalW2 multiple sequence alignment tool. Asterisks (*), 
colon (:) and period (.) indicate conserved, highly similar and weakly similar residues, 
respectively. Yellow highlighted residues indicate the position of the IL-1Ra-like 
motif.  
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A comparison of the C4 aa sequence with that of known proteins using BLAST 
(Altschul et al., 1990) found no evidence of similar cellular proteins. However, a 
previous study by Kluczyk et al (2002) revealed that protein C16 contains a C-
terminal peptide (VTRFYF) that is highly similar to that found within the same 
location of the IL-1Ra (VKRFYF). The immunosuppressive activity of the IL-1Ra 
was mapped to this C-terminal motif and a 12 aa peptide from C16 containing this IL-
1Ra-like motif exhibited similar immunosuppressive properties (Kluczyk et al., 2002; 
Kluczyk et al., 2004). A highly similar IL-1Ra-like motif is also found within the C-
terminal region of C4 (VTKYYI).     
 
A bioinformatic analysis established that C4 is conserved (>99% aa identity) in 7 out 
of 15 VACV strains, including: WR, RPXV-Utrecht, Copenhagen and Lister (with its 
derivatives such as LC16m0). Sequence divergence between C4 orthologues encoded 
by these VACV strains is restricted to two single aa substitutions at positions 173 
(leucine or isoleucine) and 221 (alanine or threonine). All of the VACV strains in 
which C4 has been conserved also contain the C-terminal VTKYYI peptide. It is 
particularly interesting that C4 is not conserved in the remaining 8 sequenced VACV 
strains that are predominately exemplified by their high level of attenuation, including 
modified vaccinia Ankara (MVA).     
 
C4 shows a high level of conservation (94.9-100.0% aa identity) within the OPV 
genus, having orthologues in 6 out of 8 sequenced species, including VACV, cowpox 
virus (CPXV), camelpox virus (CMLV), taterapox virus (TATV), variola virus 
(VARV) and monkeypox virus (MPXV; Figure 3.2). Sequence divergence between 
C4 orthologues encoded by these OPV species is restricted to 30 evenly distributed 
single aa substitutions; the exceptions to this are CPXV and CMLV that also contain a 
single aa deletion at position 75 and 316, respectively. All of the OPV C4 othologues 
contain the C-terminal VTKYYI peptide (yellow highlighting). Moreover, C4 is more 
conserved in OPVs than C16 (Table 3.1). Notably, whilst both C4 and C16 are 
conserved in VACV, CPXV and VARV, they appear to have been selectively 
conserved in the other OPVs that lack one protein or the other.  
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Figure 3.2. C4 is highly conserved in the OPV genus. The amino acid sequences of 
C4 orthologues were aligned using the ClustalW2 multiple sequence alignment tool. 
Asterisks (*), colon (:) and period (.) indicate conserved, highly similar and weakly 
similar residues, respectively. Yellow highlighted residues indicate the position of the 
C4 IL-1Ra-like motif (VTKYYI). Red bars, predicted !-sheets; blue bars, predicted 
"-helices; green circles, predicted phosphorylation sites. 
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Table 3.1. Conservation of C4 and C16 orthologues within OPVs. 
 
OPV Orthologue % aa identity 
to VACV-WR C4 
Orthologue % aa identity 
to VACV-WR C16 
VACV-WR 100 100 
CPXV-GRI 99.0 98.9 
VARV-BEN68 96.5 97.9 
CMLV-CMS 96.8 Not conserved 
MPXV-COP58 94.9 Not conserved 
TATV-DAH68 97.2 Not conserved 
ECTV-MOS Not conserved 97.9 
HSPV-MNR76 Not conserved 97.0 
 
 
C4 shows limited conservation in a third group of distantly-related proteins (22.6-
31.2% aa identity) that are from poxviruses outside the OPV genus. These proteins 
are encoded by sheeppox virus (SPPV), lumpy skin disease virus (LSDV) and 
goatpox virus (GTPV; members of the genus Capripoxvirus), Yaba monkey tumour 
virus (YMTV) and tanapox virus (TANV; members of the genus Yatapoxvirus), 
canarypox virus (CNPV) and fowlpox virus (FWPV; members of the genus 
Avipoxvirus) and also by the unclassified mule deer poxvirus (DPV). These proteins 
exhibit sequence similarity to both C4 and C16 but do not contain the IL-1Ra-like 
motif near the C terminus. 
 
The phylogenetic relationship between these proteins is shown by a rooted tree based 
upon an alignment of their aa sequences (Figure 3.3). The Group I proteins contain 
C4 orthologues within VACV strains and other OPV species and have #94.9% aa 
identity to C4 from VACV strain WR. The Group II proteins contain C16 OPV 
orthologues and have 42.3-43.7% aa identity to C4. Lastly, Group III comprises 
distantly-related proteins from poxviruses outside the OPV genus and have 22.6-
31.2% aa identity to C4.  
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Figure 3.3. Phylogenetic relatedness of C4-like poxvirus proteins. The amino acid 
sequences of C4 orthologues were aligned using the ClustalW2 multiple sequence 
alignment tool and a rooted tree was obtained from this alignment using PHYLIP 
(Phylogeny Inference Package). The bootstrap values for 1000 replica samplings are 
indicated. Scale bar, 0.1 substitutions per site.  
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3.1.2. Analysis of the C4L promoter 
 
The C4L ORF and surrounding genomic regions were analysed to identify 
transcriptional regulatory sequences. Although an exact match to the critical region of 
the VACV early gene promoter could not be found, a highly similar A/T-rich 
sequence was identified (highlighted in green; Figure 3.4; Davison & Moss, 1989). 
Consistent with other VACV early genes, a 10-bp T-rich spacer region adjacent to the 
critical region (highlighted in red) and a 7-bp region from within which 
transcriptional initiation may occur (highlighted in yellow) were also identified. A 
VACV early termination signal was identified 25 to 31-bp downstream of the C4L 
stop codon (highlighted in turquoise; Yuen & Moss, 1987). Taken together, the 
presence of an early promoter and early termination motif indicates that C4 is likely 
to be transcribed early during VACV infection. 
 
 
 
Figure 3.4. C4 has a VACV early gene promoter sequence. The coding sequence 
of C4 is indicated by underlining. Positions of the A/T-rich critical region, T-rich 
spacer, and initiation region of the early promoter, and an early termination signal are 
indicated by green, red, yellow and turquoise highlighting, respectively.  
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3.1.3. Biochemical and structural predictions for C4  
 
Within C4 there is no recognised secretory signal peptide indicating that C4 is 
unlikely to be secreted from the cell (www.poxvirus.org). Furthermore, an inspection 
of C4 with PSORTb (Yu et al., 2010) revealed that there is no evidence of a nuclear 
localisation signal (NLS) or indeed any other signal that would localise C4 to a 
particular cellular compartment. The C4 aa sequence was analysed with the GREASE 
hydropathy profile prediction tool (Rice, 2000) and the hydrophobicity plot generated 
(Kyte & Doolittle, 1982) indicated that C4 lacked transmembrane domains and so was 
unlikely to be a membrane-integrated protein. Predictions of C4 secondary structure 
were made using the program PELE (Subramaniam, 1998), and a consensus 
alignment (Figure 3.2) suggested C4, like C16 (Fahy et al., 2008), is predominantly 
!-sheet in structure. In addition, an analysis of the C4 aa sequence with the 
PROSEARCH prediction tool (Kolakowski et al., 1992), revealed it contains 14 
potential phosphorylation sites (Figure 3.2). In the absence of a C4 three-dimensional 
structure, FUGUE (Shi et al., 2001) was utilised to conduct sequence-structure 
homology recognition analysis to compare the predicted C4 secondary and tertiary 
structures with proteins of known structure from the HOMSTRAD database (Table 
3.2; Mizuguchi et al., 1998). An analysis of the full-length C4 aa sequence using 
FUGUE did not return any positive matches; a similar analysis for C16 produced 
strong matches to two bacterial prolyl-4-hydroxylases. However, an analysis of the N-
terminal aa residues 1 to 158 and 1 to 166 of C4 and C16, respectively, revealed 
several strong matches (90-99% confidence) from the prolyl-4-hydroxlase family of 
proteins. A similar analysis of the C-terminal aa residues 159 to 316 and 167 to 331 of 
C4 and C16, respectively, revealed single matches (90% confidence) to the human 
protein death-associated protein 6 (DAXX) and the bacterial protein thermolysin, 
respectively.  
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Table 3.2. C4 is predicted to contain an N-terminal PHD2-like and a C-terminal 
death-associated protein 6 domain. 
 
 
 
The indicated amino acids from proteins C4 and C16 were analysed using the 
FUGUE structural prediction tool and matches from the HOMSTRAD database are 
displayed. A Z-score >8 is ‘certain’ (99% confidence); >6 is ‘very likely’ (95% 
confidence) and >4 is ‘likely’ (90% confidence). 
! *+#!
 
 3.2. The VACV strain WR C4 protein 
 
 3.2.1. Expression of C4 by transfection 
 
To study the C4 protein within cultured cells, the C4L gene was codon-optimised for 
expression within mammalian cells since virally-encoded C4 mRNA contains cryptic 
splice sites. During VACV infection, the splice sites are not significant since the 
transcription of the C4L gene takes place within the cytoplasm. However, during 
expression of C4 following plasmid transfection, the C4 mRNA is exposed to splicing 
machinery within the nucleus and therefore the protein produced is significantly 
reduced compared with virus infection (data not shown). The codon-optimised C4L 
gene was inserted into the mammalian expression vector pcDNA4.0/TO modified to 
contain either an N- or C-terminal tandem affinity purification (TAP) tag (section 
2.5.1.). To confirm that C4 was expressed within mammalian cells, HEK293T cells 
were transfected with plasmids encoding C4 and cell lysates were analysed by 
immunoblotting (Figure 3.5). Immunoblotting with an anti-FLAG antibody confirmed 
the expression of C4 as a 37-kDa polypeptide on a denaturing gel, consistent with its 
predicted size. Transfection of cells with C16 yielded a slightly larger protein of 
approximately 38-40 kDa, as observed by Fahy et al (2008). Moreover, to test 
whether or not the IL-1Ra-like motif conserved in C4 and C16 could influence the 
stability of these proteins, plasmids expressing C4 or C16 mutants lacking this motif 
were transfected into HEK293T cells. Although the C4 and C16 mutant proteins 
migrated as expected, their stability was markedly reduced compared to the wild-type 
forms of these proteins.    
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Figure 3.5. C4 is a 37-kDa protein. HEK293T cells were transfected with plasmids 
encoding TAP-tagged C4 and C16 for 24 h. The cells were washed with PBS, 
harvested and then protein lysates were resolved by SDS-PAGE and analysed by 
immunoblotting with antibodies against the indicated proteins. The positions of 
molecular mass markers are shown (kDa). 
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 3.2.2. C4 is both cytoplasmic and nuclear by transfection 
 
The subcellular localisations of C4 and C16 were analysed within mammalian cells 
by immunofluorescence. HeLa cells were transfected with C4 or C16 for 24 h, fixed, 
permeabilised and then stained with an anti-FLAG antibody (Figure 3.6). 
Transfection with C4 indicated that the localisation of this protein was influenced by 
the position of the TAP-tag and the presence (or absence thereof) the IL-1Ra-like 
motif. The C4 protein containing an N-terminal TAP-tag (C4-N’TAP) exhibited both 
a cytoplasmic and nuclear localisation; in particular, a clear co-localisation of C4 with 
DAPI-stained DNA was observed in the nucleus of transfected cells. In contrast, C4 
containing a C-terminal TAP-tag (C4-C’TAP) was largely cytoplasmic by 
transfection. Furthermore, an N-terminal TAP-tag truncation mutant of C4 lacking the 
C-terminal IL-1Ra-like motif (C4-$IL-1Ra) was largely cytoplasmic, although some 
nuclear localisation was also observed. Protein C16 exhibited a nucleocytoplasmic 
localisation, irrespective of the position of the TAP-tag and as noted previously (Fahy 
et al., 2008). It was also noteworthy that the distribution of cytoplasmic C4 and C16 
was diffuse, indicating that these proteins did not traffic to a specific organelle or 
region within the cytoplasm of transfected cells.  
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Figure 3.6. C4 is both cytoplasmic and nuclear. HeLa cells were transfected with 
plasmids encoding TAP-tagged C4 and C16 for the indicated times. Cells were 
washed with PBS, fixed, permeabilised and stained with anti-FLAG mAb. The 
localisation of C4/C16 (FLAG; red; middle panels), DNA stained with DAPI (blue; 
left panels) and phase-contrast/merged images (right panels) are shown. Bars, 20 µm. 
! *+'!
 
 3.2.3. Construction of C4 recombinant VACVs 
 
To examine the contribution of C4 to viral replication in cell culture and to assess its 
impact on virus virulence in vivo, two panels of recombinant VACVs were 
constructed. The first panel of recombinant VACVs (‘Panel 1’) were constructed to 
assess the effect of only deleting C4; a second panel of recombinant VACVs ‘Panel 2’ 
were constructed to assess whether or not there is a combined effect of deleting both 
C16 and C4 from the VACV genome.  
 
C4 recombinant VACVs were constructed using the transient dominant selection 
method (section 2.7.2.). Briefly, to construct a VACV lacking C4 (v$C4), CV-1 cells 
were infected with VACV strain WR and then transfected with the Z11$C4 plasmid 
(section 2.7.1.). A single homologous recombination event between one of the natural 
C4 flanks and its counterpart within the plasmid resulted in integration of the entire 
plasmid into the virus genome (Figure 3.7a). Only viruses containing this plasmid 
could replicate in the presence of mycophenolic acid (MPA; Boyle & Coupar, 1988). 
Once MPA drug selection was removed, a second homologous recombination event 
could occur to eject the selection plasmid, resolving intermediate viruses containing 
the plasmid to either the v$C4 (deletion) or vC4 (wild-type) genotype (Figure 3.7b). 
Construction of revertant (vC4-Rev) and TAP-tagged revertant (vC4-TAPRev) 
viruses were performed in a similar manner by transfecting v$C4-infected CV-1 cells 
with Z11C4Rev or pUC13-C4TAPRev, respectively (section 2.7.1.). Construction of 
Panel 2 viruses (v$C16,$C4 and v$C16-Rev) was carried out in the same manner but 
using v$C16 as the starting virus (Fahy et al., 2008). 
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Figure 3.7. Schematic representation of the recombination events during 
construction of v$C4 by transient dominant selection. CV-1 cells were infected 
with VACV strain WR and transfected afterwards with Z11$C4 containing the C4L 
flanking sequences and Ecogpt-EGFP selection markers. (a) A single homologous 
recombination event between either the left or right C4L flanking sequences results in 
integration of Z11$C4 into the virus genome. The virus intermediates containing 
direct repeat sequences are selected in the presence of MPA. (b) A second single 
homologous recombination event between one set of direct repeat sequences occurs 
upon MPA removal, resolving intermediate viruses to either a wild-type (vC4) or 
deletion C4 (v$C4) genotype. LF, left flank and RF, right flank.   
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 3.2.4. Recombinant VACV genome analysis 
 
The genotype of recombinant VACVs was investigated by analysis of the presence or 
absence of C4L. PCR primers were designed to amplify the C4L locus including 300 
bp flanks either side of the gene, yielding an expected PCR product size of 1,554 bp 
for the wild-type locus.  However, when the C4L gene is absent, the expected PCR 
product is 603 bp, and when the TAP-tag is present the amplicon is 1,674 bp (Figure 
3.8a).  Primers were also designed for amplification of gene C16L to confirm the 
presence of C16L in Panel 1 viruses and its absence in Panel 2 viruses. DNA 
extracted from all recombinant viruses was found to give PCR products of the 
expected sizes (Figure 3.8b) as were the plasmids used to generate those viruses 
(Figure 3.8c).  
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Figure 3.8. Locus-specific PCR confirmation of recombinant VACV genotypes. 
(a) Schematic representation of the VACV strain WR C4L locus. Expected PCR sizes 
are indicated (bp). (b) BSC-1 cells were infected with the indicated viruses for 24 h 
and then cells were scraped into the culture medium. Genomic DNA was extracted 
from virion cores by proteinase K digestion and this was used as a template for PCR 
with C4L flanking primers (top panels) and C16L primers (lower panels). (c) DNA 
from the plasmids utilised during recombinant VACV construction were used as 
templates for PCR with C4L flanking primers. PCR products were resolved by 
agarose gel electrophoresis. The positions of DNA size markers are shown (kb). 
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The genotypes of recombinant VACVs to be used in vivo were analysed further to 
identify any potential large-scale deletions that may have occurred during their 
generation. Genomic DNA isolated from purified virion cores was digested with the 
restriction endonucleases HindIII and XhoI and analysed by pulsed-field gel 
electrophoresis. As a result of gene C4L residing within the ‘C’ fragment (22.1 kb) 
following digestion of genomic DNA with HindIII, its deletion caused no discernable 
differences between the Panel 1 and Panel 2 viruses on a 0.7% agarose gel (Figure 
3.9a). Equally, the indistinguishable HindIII DNA banding profile for all of the other 
fragments demonstrated that no large-scale rearrangements or deletions had occurred 
within these genomic regions during virus construction. By contrast, digestion of 
genomic DNA with XhoI showed differences between the viruses because the gene 
C4L resides within the XhoI ‘G’ fragment, which is smaller (7.3 kb; Figure 3.9b). A 
clear reduction in size of the G fragment from approximately 7.3 (red box) to 6.3 
(green box) kb was observed between vC4 and v$C4 (Panel 1) and between v$C16 
and v$C16,$C4 (Panel 2). 
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Figure 3.9. Analysis of recombinant VACV genomes by HindIII and XhoI 
restriction endonuclease digestion. Genomic DNA was extracted from sucrose 
gradient purified virion cores by proteinase K digestion and 1 µg was digested with 
(a) HindIII and (b) XhoI. The DNA fragments produced were resolved on a 0.7% 
agarose gel by pulsed-field gel electrophoresis at 4 °C, stained with ethidium bromide 
and then visualised using a UV lamp. The positions of DNA size markers are shown 
(kb). The individual restriction fragments are indicated by letters on the right. 
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 3.2.5. Protein expression from recombinant VACVs 
 
To investigate expression of C4 or C16 from the recombinant VACVs, BSC-1 cells 
were infected overnight and then cell lysates analysed by immunoblotting (Figure 
3.10). Equal loading of all samples was confirmed by immunoblotting for "-tubulin. 
Similar levels of virus infection were confirmed by the detection of D8 (a late VACV 
structural protein) in all but mock-infected cells. Only vC4-TAP expressed the 37-
kDa C4-TAP protein, as determined by immunoblotting with an anti-FLAG antibody, 
as expected. Furthermore, immunoblotting with an anti-C16 polyclonal rabbit 
antiserum revealed that C16 was only expressed from Panel 1 viruses.  
 
 
 
Figure 3.10. Expression of C4 or C16 by recombinant VACVs. BSC-1 cells were 
infected with the indicated viruses at 2 p.f.u. per cell overnight. The cells were 
washed with PBS, harvested and then protein lysates resolved by SDS-PAGE and 
analysed by immunoblotting with antibodies against the indicated proteins. The 
positions of molecular mass markers are shown (kDa). 
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 3.2.6. C4 is expressed early after VACV infection 
 
An analysis of the C4L locus identified a putative VACV early gene promoter: to test 
the hypothesis that C4 is expressed early after VACV infection, BSC-1 cells were 
infected at 10 p.f.u. per cell in the presence or absence of cytosine arabinoside 
(AraC), an inhibitor of VACV DNA replication and therefore of late gene expression, 
and extracts of cells were analysed by immunoblotting at different times p.i. (Figure 
3.11). Like protein C16 (Fahy et al., 2008), C4 was detected from 2 h p.i. and in the 
presence of AraC, indicating that C4 is expressed early after infection. In contrast, D8 
was only expressed from 4 h p.i. and in the absence of AraC, as predicted for this 
VACV late protein (Niles & Seto, 1988). Equal loading of protein lysates was 
confirmed by equivalent yields of "-tubulin.   
 
 
 
Figure 3.11. C4 is expressed early after VACV infection. BSC-1 cells were 
infected with vC4-TAP at 10 p.f.u. per cell in the presence or absence of 40 µg/ml 
AraC. At the indicated times p.i., the cells were washed with PBS and lysed. Protein 
lysates resolved by SDS-PAGE were analysed by immunoblotting with antibodies 
against the indicated proteins. The positions of molecular mass markers are shown 
(kDa).       
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3.2.7. C4 is both cytoplasmic and nuclear during VACV infection 
 
The subcellular localisation of C4 in the context of VACV infection was investigated 
by infecting HeLa cells with vC4-TAP and then examining fixed cells by 
immunofluorescence at different times p.i. Consistent with immunoblotting data, C4 
was detected from 2 h p.i. within the cytoplasm of infected cells (Figure 3.12). 
Notably, C4 became increasingly nuclear at later time-points. By 6 h p.i. C4 was 
detected within both the cytoplasm and nucleus but by 24 h p.i. was predominantly 
nuclear. An additional indication of the relative proportion of cytoplasmic and nuclear 
C4 and C16 over the course of infection was provided by biochemical fractionation of 
vC4-TAP-infected HeLa cells (Figure 3.13a). Successful separation of cytoplasmic 
and nuclear compartments was confirmed by the presence of "-tubulin and lamin A/C 
in only the cytoplasmic and nuclear fractions, respectively. C4 and C16 expression 
were detected with an anti-FLAG antibody and C16 antiserum. A quantitative 
comparison of C4 and C16 protein expression over time by immunoblotting and 
LICOR analysis (Figure 3.13) corroborated data obtained by immunofluorescence 
(Figure 3.12). The migration of C4 (Figure 3.13b) and C16 (Figure 3.13c) into the 
nuclear compartment coincided with a decrease in their cytoplasmic abundances and, 
in the case of C4, was almost exclusively nuclear by 24 h p.i. (Figure 3.13b). 
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Figure 3.12. Immunofluorescence showing C4 is cytoplasmic and nuclear during 
VACV infection. HeLa cells were infected with vC4-TAP at 0.5 p.f.u. per cell for the 
indicated times. Cells were washed with PBS, fixed, permeabilised and stained with 
anti-FLAG mAb. The localisation of C4/FLAG (red; middle panels), DNA stained 
with DAPI (blue; left panels) and phase-contrast/merged images (right panels) are 
shown. Bars, 20 µm (0-6 h); 10 µm (24 h). 
 
! **'!
 
 
Figure 3.13. C4 accumulates in the nucleus during VACV infection. (a) BSC-1 
cells were infected at 10 p.f.u. per cell with vC4-TAP for the indicated times, 
harvested and fractionated into cytoplasmic and nuclear fractions. Protein lysates 
were resolved by SDS-PAGE and analysed by immunoblotting with antibodies 
against the indicated proteins. The positions of molecular mass markers are shown 
(kDa). (b) Li-COR quantification of FLAG (C4). (c) Li-COR quantification of C16. 
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3.3. Recombinant C4 protein production in bacteria 
 
3.3.1. C4 is insoluble when purified under standard conditions 
 
With the aim of obtaining a C4 antibody as well as the crystal structure of C4, efforts 
were made to purify 6x His-tagged C4 protein from the BL21(DE3)-R3/Rosetta strain 
of Escherichia coli (Rosetta E. coli). As a starting point to testing whether or not it 
would be feasible to purify C4, Rosetta E. coli were transformed with plasmids for the 
expression of 6x His-tagged C4 (section 2.4.1.). An isolated colony of freshly-
transformed Rosetta E. coli was picked and inoculated into 4 ml of TB to create a 
starter culture that was grown overnight at 37 °C. The next morning, the starter 
culture was used to inoculate 50 ml cultures of TB and once the bacteria had reached 
logarithmic growth, 0.1 mM IPTG was added to induce the expression of C4. After 4 
h induction, the bacteria were harvested and lysed into soluble and insoluble fractions 
(section 2.4.3.). Under the two temperature conditions tested, the solubility of C4 was 
very poor and did not show substantial variation independent of the plasmid used for 
transformation or position of the 6x His-tag. Bacteria transformed with C4 containing 
an N-terminal 6x His-tag expressed C4 almost entirely within inclusion bodies, 
irrespective of the plasmid used (Figure 3.14a and b). Analysis of C4 expressed with a 
C-terminal 6x His-tag produced similar results (Figure 3.14c and d). Overall C4 
solubility was very poor regardless of the IPTG concentration used for induction (data 
not shown). 
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Figure 3.14. Recombinant C4 expressed by bacteria is insoluble. The BL21(DE3)-
R3/Rosetta strain of E. coli was transformed with plasmids encoding C4 tagged with a 
6x His-tag at the (a – b) N terminus or (c – d) C terminus. An isolated colony of 
bacteria was used to inoculate a starter culture of TB overnight. The next day, 50 ml 
of TB was inoculated with the starter culture and bacteria grown until an OD600 0.6. 
The incubator temperature was maintained (37 °C) or reduced to 18 °C and then C4 
expression induced with the addition of 0.1 mM IPTG for 4 h. The soluble and 
insoluble fractions were harvested, resolved by SDS-PAGE and then either stained 
with Coomassie or immunoblotted with an anti-His6 antibody. The positions of 
molecular mass markers are shown (kDa).   
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 3.3.2. C4 is solubilised with sarkosyl 
 
As a substitute to non-ionic detergents such as Triton X-100, sarkosyl is often utilised 
to assist in solubilising proteins that form inclusion bodies or are highly hydrophobic 
(e.g. membrane proteins; Tao et al., 2010). A starter culture of Rosetta E. coli 
transformed with pET28a-C4CHis was used to inoculate 250 ml of TB and this was 
induced with 0.1 mM of IPTG once the bacteria entered logarithmic growth. Bacteria 
were grown overnight at 18 °C, harvested and lysed in a phosphate buffer containing 
different concentrations of sarkosyl (Figure 3.15a). A protein migrating with a 
molecular mass just below 37 kDa was seen by Coomassie staining, and 
immunoblotting with an anti-His antibody confirmed this as C4. Notably, as the 
concentration of sarkosyl in the lysis buffer was increased, the ratio of soluble 
(supernatant) to insoluble (pellet) C4 increased, such that with 10% sarkosyl, C4 was 
found almost exclusively within the soluble fraction. Therefore, 10% sarkosyl was 
used for the subsequent optimisation of C4 purification conditions.       
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Figure 3.15. Recombinant C4 can be solubilised with sarkosyl. (a) The BL21(DE3)-
R3/Rosetta strain of E. coli was transformed with pET28a-C4CHis and an isolated colony of 
bacteria used to inoculate a starter culture of TB overnight. The next day, 250 ml of TB was 
inoculated with the starter culture and the bacteria grown until an OD600 0.6. The incubator 
temperature was reduced to 18 °C and then C4 expression was induced by the addition of 0.1 
mM IPTG for 12 h. The soluble and insoluble fractions were harvested in a lysis buffer 
containing the indicated concentration of sarkosyl, resolved by SDS-PAGE and then either 
stained with Coomassie or immunblotted with an anti-His antibody. (b – c) Aliquots (0.5 ml) 
of C4 solubilised with 10% sarkosyl were diluted to the indicated final concentrations of 
sarkosyl, with or without the addition of 20 mM CHAPS, and soluble C4 was purified by 
IMAC using a His-Trap column. Protein fractions were analysed as for (a). W, wash; E, 
elution fraction (0.5 ml). (d) A 1 L culture of bacteria was grown as in (a) and C4 solubilised 
with 10% sarkosyl. The soluble fraction was then diluted to contain 1% sarkosyl with 20 mM 
CHAPS and recombinant C4 was purified by IMAC as in (b – c). Protein fractions were 
analysed as for (a). The positions of molecular mass markers are shown (kDa). 
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Prior to attempting the large-scale purification of C4 by IMAC, it was necessary to 
establish whether the 6x His-tag would bind to the His-Trap affinity resin in the 
presence of sarkosyl. One of the main complicating factors of using sarkosyl for the 
purification of highly insoluble proteins is the ability of the 6x His-tag to chelate Ni2+ 
ions in the presence of this detergent (Lilie et al., 1998). To overcome the problem 
associated with high concentrations of sarkosyl, solubilised C4 was diluted with 
phosphate buffer either without any added detergent or supplemented with 20 mM 
CHAPS. A previous study by Tao et al (2010) demonstrated the improved binding 
properties of sarkosyl-solubilised proteins to affinity resins in the presence of 
CHAPS. The diluted protein lysates were then loaded on to a His-Trap column to test 
the ability of C4 to bind to the affinity resin (Figure 3.15b and c). In each case tested, 
the solubility of C4 was largely maintained, however a final sarkosyl concentration of 
1% with the addition of 20 mM CHAPS (Figure 3.15b) did appear to result in slightly 
more binding to the His-Trap column than 0.5% and 0.1% sarkosyl (Figure 3.15c). 
These results confirmed that C4 could be purified by IMAC in the presence of 1% 
sarkosyl.  
 
Following optimisation of the conditions required for solubilisation and purification 
of C4, these conditions were tested with a large-scale bacterial culture. A1 L culture 
of induced Rosetta E. coli was harvested, lysed and the soluble fraction containing 1% 
sarkosyl and 20 mM CHAPS was loaded on to a His-Trap column. Coomassie 
staining showed that a distinct band matching the expected size of C4 was present 
within the soluble fraction following lysis and that it bound to, and was eluted from, 
the His-Trap column (Figure 3.15d). Taken together, these data showed that the native 
purification conditions optimised for C4 on a small-scale could be scaled-up for larger 
culture sizes. Future efforts will be directed towards purifying C4 protein for 
antiserum production and structural studies.  
 
 3.4. Summary  
 
A bioinformatics analysis revealed that protein C4 is well-conserved within the OPV 
genus and exhibits 43.7% amino acid identity to the VACV virulence factor, C16. In 
addition, C4 and C16 both contain an IL-1Ra-like motif at the C terminus. Although 
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no cellular orthologues could be found for C4, the N and C termini were predicted to 
fold into PHD2-like and DAXX-like domains, respectively. Immunofluorescence and 
cell fractionation confirmed that C4 is expressed from 2 h p.i. and exhibits both a 
cytoplasmic and nuclear localisation. A panel of recombinant VACVs was 
constructed to investigate the contribution of C4 to viral replication and virulence in 
vivo and their genomic integrity was established by locus-specific PCR and genomic 
digestion. Finally, an optimised protocol for the native purification of soluble C4 was 
developed and its applicability for use with large bacterial cultures demonstrated.  
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Chapter Four 
Characterisation of C4 as a modulator of innate immune signalling 
 
Given that C4 exhibits strong conservation amongst the OPV genus, is expressed 
early after infection and shares 43.7% aa identity with VACV virulence factor C16 
(Fahy et al., 2008), it was hypothesised that C4 may be a modulator of innate 
immunity. In this chapter, the effects of C4 on innate immune signalling pathways 
were investigated. Moreover, the effects of C16 and the icIL-1Ra on innate immune 
signalling, and the effect of removing the IL-1Ra-like motif from C4 and C16, were 
examined. Finally, the effect of C4 on cytoplasmic DNA sensing within murine 
embryonic fibroblasts (MEFs) and the identification of binding-partners using tandem 
affinity purification are described.        
 
4.1. TAP-tagged proteins show equivalent levels of expression 
 
Following transfection into HEK293T cells, the expression levels of C4, C16 and the 
icIL-1Ra were similar to each other and to the control proteins C6, B14 and GFP 
(Figure 4.1). This indicated that any effects of these individual proteins on innate 
immune signalling were unlikely to be due to differences in protein expression.  
 
 
Figure 4.1. TAP-tagged proteins have equivalent levels of expression. HEK293T 
cells were transfected using PEI with plasmids encoding C-terminally TAP-tagged 
proteins for 24 h. The cells were washed with PBS, harvested (with protease 
inhibitors) and then protein lysates were resolved by SDS-PAGE and analysed by 
immunoblotting with antibodies against the indicated proteins. The positions of 
molecular mass markers are shown (kDa). 
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4.2. C4 is an inhibitor of IFN!  promoter activity  
 
Given the importance of IFN! to the response against viral infection, the ability of C4 
to inhibit IFN! promoter activity was investigated. HEK293T cells were co-
transfected with reporter plasmids encoding firefly luciferase under control of the 
IFN! promoter and renilla luciferase under control of the thymidine kinase promoter, 
as well as expression plasmids encoding TAP-tagged proteins. Twenty four h after 
transfection, these cells were either mock-stimulated or stimulated by transfection of 
800 ng per well of dsRNA mimic [poly (I:C)] or dsDNA mimic [poly (dA:dT)] for a 
further 24 h. Within the cytoplasm of HEK293T cells, dsRNA is detected by RIG-I 
(Ablasser et al., 2009; Chiu et al., 2009) and MDA-5 (Andrejeva et al., 2004) 
resulting in signal transduction through the canonical and non-canonical IKK 
pathways, ultimately leading to the activation of NF-%B and IRF3 and the production 
of IFN! (Yoneyama et al., 2004; Sasai et al., 2006). Stimulation of HEK293T cells 
with poly (I:C) resulted in a 10-fold induction of IFN! promoter activity and this was 
inhibited in a statistically significant manner by C4 but not GFP (Figure 4.2a). 
Inhibition of IFN! promoter activity was also provided by VACV proteins B14 and 
C6, known inhibitors of NF-%B and IRF3 signalling, respectively (Chen et al., 2008; 
Unterholzner et al., 2011).   
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Figure 4.2. C4 inhibits IFN!  promoter activity. HEK293T cells were transfected 
with a firefly luciferase reporter plasmid under the control of an IFN!-dependent 
promoter, a renilla luciferase transfection control and a C4, B14, C6 or GFP 
expression plasmid or EV. Cells were transfected 24 h later with (a) poly (I:C) or (b) 
poly (dA:dT) at 800 ng per well for 24 h and then harvested. Firefly luciferase activity 
was normalised to renilla luciferase activity. Data are from one experiment 
representative of at least three, each performed in triplicate and presented as means 
±SD. *P<0.05; **P<0.005, compared with EV and GFP. 
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To test whether or not inhibition of IFN! promoter activity by C4 was restricted to the 
sensing of foreign RNA, the pathway was also stimulated with the dsDNA analogue 
poly (dA:dT). In the cytoplasm of HEK293T cells, poly (dA:dT) is transcribed by 
RNA pol III into RNA substrates for RIG-I (Chiu et al., 2009). Stimulation of 
HEK293T cells with poly (dA:dT) resulted in a 25-fold induction of IFN! promoter 
activity and, again, this was inhibited in a statistically significant manner by C4 but 
not GFP (Figure 4.2b). As before, VACV proteins B14 and C6 could inhibit IFN! 
promoter activity in response to dsDNA, as expected. In conclusion, these data 
demonstrated C4 can inhibit IFN! promoter activation downstream of the 
cytoplasmic RNA sensors RIG-I and MDA-5 in response to dsRNA and dsDNA.  
 
4.3. C4 does not inhibit IRF3 promoter activity 
 
The promoter of the IFN! gene is known to contain binding sites for three 
transcription factors: IRF3, NF-%B and AP-1, whose activities are regulated by 
different signalling pathways (Agalioti et al., 2000; Hiscott, 2007; Thanos & 
Maniatis, 1995). Therefore, to identify the specific pathway targeted by C4, it was 
necessary to isolate the promoter for each transcription factor in turn and test whether 
or not C4 could inhibit its activation. To this end, a firefly luciferase reporter plasmid 
containing an ISG56.1 promoter was used to assess the effect of C4 on IRF3 
signalling. The promoter from the ISG56.1 gene was used because ISG56.1 is a 
specific transcriptional target of the IRF3 transcription factor (Grandvaux et al., 
2002). Stimulation of HEK293T cells with poly (I:C) (Figure 4.3a) or poly (dA:dT) 
(Figure 4.3b) resulted in a 14- and 8- fold activation of ISG56.1 promoter activity, 
respectively, and this was unaffected by the presence of C4 or B14. Protein C6, 
however, could inhibit these stimuli since it binds the TBK-1 adaptor proteins, 
preventing the activation of IRF3 (Unterholzner et al., 2011).   
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Figure 4.3. C4 does not inhibit IRF3 promoter activity. HEK293T cells were 
transfected with a firefly luciferase reporter plasmid under the control of an ISG56.1-
dependent promoter, a renilla luciferase transfection control and a C4, B14 or C6 
expression plasmid or EV. Cells were transfected 24 h later with (a) poly (I:C) or (b) 
poly (dA:dT) at 800 ng per well for 24 h and then harvested. Firefly luciferase activity 
was normalised to renilla luciferase activity. Data are from one experiment 
representative of at least three, each performed in triplicate and presented as means 
±SD. **P<0.005; ***P<0.0005, compared with EV. 
 
! *#)!
 
4.4. C4 is an inhibitor of NF-%B signalling 
 
  4.4.1. C4 inhibits IL-1!  and TNF"  induced NF-%B activation 
 
Since C4 inhibited IFN! promoter activation in an IRF3-independent manner, the 
effect of C4 on NF-%B signalling was investigated next. Twenty four h after 
transfection, cells were either mock-stimulated or stimulated with IL-1! or TNF" for 
8 h. Stimulation of HEK293T cells with IL-1! resulted in a 70-fold activation of the 
NF-%B promoter and this was inhibited in a statistically significant manner by C4 
(Figure 4.4a). Inhibition was also observed in the presence of B14 but not C6, as 
expected. Similarly, stimulation of HEK293T cells with TNF" resulted in an 18-fold 
activation of the NF-%B promoter, and this was inhibited in a statistically significant 
manner by both C4 and B14, but not C6 (Figure 4.4b). 
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Figure 4.4. C4 inhibits NF-%B promoter activity. HEK293T cells were transfected 
with a firefly luciferase reporter plasmid under the control of an NF-%B-dependent 
promoter, a renilla luciferase transfection control and a C4, B14 or C6 expression 
plasmid or EV. Cells were stimulated directly with (a) IL-1! or (b) TNF" at 40 ng/ml 
for 8 h and then harvested. Firefly luciferase activity was normalised to renilla 
luciferase activity. Data are from one experiment representative of at least three, each 
performed in triplicate and presented as means ±SD. **P<0.005, compared with EV. 
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In addition, the effect of C4 on NF-%B signalling at the mRNA level was investigated 
by measuring the steady-state mRNA levels of NF-%B-responsive genes in HeLa 
cells. HeLa cells were transfected in triplicate with expression plasmids encoding C4, 
B14, C6 or EV and 24 later cells were either mock-stimulated or stimulated with IL-
1! for 4 h. RNA was then extracted and used to generate cDNA libraries for qRT-
PCR analysis of IFNB1 and the NF-%B-specific gene NFKB1A (Sun et al., 1993). 
Stimulation of HeLa cells with IL-1! resulted in a 32- and 70- fold increase in IFNB1 
(Figure 4.5a) and NFKB1A mRNA (Figure 4.5b), respectively, and this was reduced 
by approximately 75% in each case by C4 and B14 but not C6.  
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Figure 4.5. C4 inhibits NF-%B-dependent gene expression. HeLa cells were 
transfected in triplicate with C4, B14, C6 or EV expression plasmid. After 24 h the 
cells were stimulated directly with 40 ng/ml IL-1! for 4 h. Following stimulation, 
cellular RNA was extracted to generate cDNA libraries and this was used for qRT-
PCR analysis in duplicate using primers specific for human (a) IFNB1 and (b) 
NFKB1A. Data are represented as mean ±SD relative to stimulated EV. ***P<0.0005, 
compared with EV. 
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The effect of C4 on IL-6 mRNA and protein expression was also examined. HeLa 
cells were transfected as before and then stimulated with IL-1! for 6 h. The 
supernatants were then analysed for IL-6 by ELISA and the RNA was extracted from 
the cells for qRT-PCR analysis of IL6 mRNA. Stimulation of cells with IL-1! 
resulted in a 36-fold increase in IL6 mRNA levels and this was significantly reduced 
by C4 and B14, but not C6 (Figure 4.6a). There was also a 5-fold increase in the 
secretion of IL-6 into the supernatant and this was reduced by 10% in the presence of 
C4 and B14 but was unaffected by C6 (Figure 4.6b). Taken together, these data 
demonstrated that C4 inhibits NF-%B-induced gene expression. 
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Figure 4.6. C4 inhibits NF-%B-dependent gene expression and protein 
production. HeLa cells were transfected in triplicate with C4, B14, C6 or EV 
expression plasmid. After 24 h the cells were stimulated directly with 40 ng/ml IL-1! 
for 6 h. (a) Cellular RNA was extracted to generate cDNA libraries and this was used 
for qRT-PCR analysis in duplicate using primers specific for human IL6. Data are 
represented as mean ±SD relative to stimulated EV and C6. (b) The culture 
supernatant was analysed for human IL-6 in duplicate by ELISA. Data are represented 
as mean ±SD. ***P<0.0005, compared with EV. 
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4.4.2. C4 inhibits NF-%B signalling at, or downstream of, the IKK 
complex 
 
To dissect the mechanism of C4-mediated NF-%B signalling inhibition, luciferase 
reporter gene assays were performed in which NF-%B activation was achieved by 
over-expressing individual components known to have a role in the signalling 
cascade. For this purpose, the key adaptor proteins TRAF2, which acts downstream of 
the TNF receptor, and TRAF6, which acts downstream of the IL-1 receptor, were 
over-expressed in HEK293T cells containing NF-%B and renilla reporters and 
expression plasmids for C4, B14, C6 or EV. Over-expression of TRAF2 or TRAF6 
both stimulated NF-%B expression and both pathways were inhibited by C4 and B14, 
but not C6 or EV (Figure 4.7a and b). This suggested that C4 was acting at, or 
downstream of, the position where the TNF and IL-1 receptor signalling pathways 
converge. Over-expression of the IKK! subunit also activated the pathway (Figure 
4.7c) and as before, C4 and B14 inhibited this activation. This confirmed that C4 was 
acting at, or downstream of, the IKK complex.  
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Figure 4.7. C4 inhibits NF-%B activation at, or downstream of, the IKK complex. 
HEK293T cells were transfected with a firefly luciferase reporter plasmid under the 
control of an NF-%B-dependent promoter and (a) TRAF2, (b) TRAF6 or (c) IKK! 
expression plasmids. Cells were co-transfected with a renilla luciferase control and a 
C4, B14 or C6 expression plasmid or EV for 24 h. Firefly luciferase activity was 
normalised to renilla luciferase activity. Data are from one experiment representative 
of at least three, each performed in triplicate and presented as mean ±SD. *P<0.05; 
**P<0.005, compared with EV. 
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During canonical NF-%B signalling, activation of the IKK complex results in the 
phosphorylation of I%B" (p-I%B"; Beg et al., 1993). Once phosphorylated, p-I%B" 
undergoes ubiquitination and proteasomal degradation by the 26S proteasome, thus 
releasing NF-%B dimers that translocate to the nucleus and induce the transcription of 
NF-%B-responsive genes (Mercurio et al., 1997). To test if C4 may prevent the 
phosphorylation of I%B", thereby inhibiting the activation of NF-%B, immunoblotting 
was used to examine I%B" levels (Figure 4.8a). Equal loading of all samples and 
equivalent expression levels of C4, B14 and C6 were confirmed by immunoblotting 
for "-tubulin (Figure 4.8d) and FLAG (Figure 4.8e), respectively. In non-stimulated 
cells there were no differences in the levels of p-I%B" in the presence of any VACV 
protein (Figure 4.8b). However, after 20 min of IL-1! stimulation, there was a large 
increase in the level of p-I%B" in the presence of C6 and in cells transfected with EV, 
indicating that transfection with these plasmids had no effect on the phosphorylation 
of I%B". Concomitant with an increase of p-I%B", there was also a large decrease in 
the total level of I%B" (Figure 4.8c), demonstrating that C6 was not preventing the 
degradation of I%B" once it had been phosphorylated. Taken together, this showed 
that C6 did not affect the cytokine-induced activation of NF-%B, as expected 
(Unterholzner et al., 2011). In contrast, there were no increases in the level of p-I%B" 
after 20 min of IL-1! stimulation in the presence of C4 and B14, indicating that these 
proteins were inhibiting the phosphorylation of I%B" (Figure 4.8b). The total levels of 
I%B" within these cells were also significantly higher than in cells transfected with 
C6 or EV (Figure 4.8c), demonstrating that I%B" degradation was reduced due to the 
inhibition of its phosphorylation by C4 and B14. Taken together, this showed that C4 
and B14 (Chen et al., 2008), as expected, prevented the phosphorylation of I%B" and 
that this resulted in the inhibition of NF-%B activation observed by luciferase reporter 
gene assay. 
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Figure 4.8. C4 prevents I%B"  phosphorylation. HeLa cells were transfected in 
triplicate with C4, B14, C6 or EV. After 24 h the cells were stimulated directly with 
40 ng/ml IL-1! for 0, 20 or 50 min, then washed with PBS and harvested. (a) Protein 
lysates were resolved by SDS-PAGE and analysed by immunoblotting with 
antibodies against the indicated proteins. The positions of molecular mass markers are 
shown (kDa). (b – e) Li-COR quantification of protein levels. *P<0.05; **P<0.005, 
compared with EV. 
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To test whether or not viruses lacking C4 were impaired in the ability to prevent the 
phosphorylation of I%B", HeLa cells were infected for 4 h with v$C4 or wild-type 
viruses and then stimulated with IL-1! for 0, 20 or 50 min and whole cell lysates were 
prepared. Equal loading of all samples was confirmed by immunoblotting for "-
tubulin (Figure 4.9a and d). In addition, protein C16 was present in the extracts of 
cells infected with each virus, indicating that VACV early gene expression had 
already occurred prior to IL-1! stimulation (Figure 4.9e). In non-stimulated cells, 
there were no differences in the levels of p-I%B" (Figure 4.9b) or total I%B" (Figure 
4.9c) after infection with any virus. However, after stimulation of v$C4-infected cells 
with IL-1! for 20 min, there was a significantly higher level of p-I%B" compared to 
that in wild-type infected cells (Figure 4.9b). Furthermore, in the absence of C4 the 
levels of total I%B" were also markedly reduced following IL-1! stimulation 
compared to wild-type infected cells (Figure 4.9c). Taken together, these data 
suggested the loss of C4 enhanced the cytokine-induced phosphorylation of I%B" and 
that this was responsible for the increased degradation of I%B" during VACV 
infection. 
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Figure 4.9. Deletion of C4 from VACV enhances I%B"  phosphorylation. HeLa 
cells were infected in triplicate with control viruses (vC4 and vC4-Rev) or v$C4. 
After 4 h the cells were stimulated directly with 40 ng/ml IL-1! for 0, 20 or 50 min, 
then washed with PBS and harvested. (a) Protein lysates were resolved by SDS-
PAGE and analysed by immunoblotting with antibodies against the indicated proteins. 
The positions of molecular mass markers are shown (kDa). (b – e) Li-COR 
quantification of protein levels. **P<0.005, compared with control viruses (vC4 and 
vC4-Rev). 
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The effect of C4 on the translocation of p65 into the nucleus of cells was investigated 
by immunofluorescence. HeLa cells were transfected with EV or C4 for 24 h and then 
either mock-stimulated or stimulated with IL-1! for 20 min (Figure 4.10a). In 
unstimulated cells, p65 was cytoplasmic regardless of the presence of EV or C4. 
However, following stimulation of cells with IL-1!, p65 translocated to the nucleus in 
EV-transfected cells. In contrast, this was inhibited in the presence of C4 (Figure 
4.10a). A quantification of nuclear p65 under these different conditions is shown in 
Figure 4.10b. Interestingly, p65 nuclear translocation was slightly less efficient in 
neighbouring non-transfected cells (note the mixed population of transfected and non-
transfected cells), suggesting that C4 may have bystander effects which influence the 
ability of these cells to respond to IL-1!.  
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Figure 4.10. C4 blocks p65 translocation. (a) Immunofluorescence. HEK293T cells 
were transfected with a C4 expression plasmid or EV. After 24 h, cells were mock-
stimulated or stimulated with 20 ng/ml IL-1! for 20 min. Cells were washed with 
PBS, fixed and stained with anti-FLAG (red) and anti-p65 (green) mAbs. DNA 
stained with DAPI (blue; left panels) and phase-contrast/merged images (right panels) 
are shown. Bar, 20 µm. (b). Scoring: 90 cells per condition were quantified for 
nuclear translocation of p65. ***P<0.0005, compared with EV. 
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4.4.3. C4 interacts with IKK!  and NEMO 
 
Functional data presented in this chapter have demonstrated that C4 inhibits NF-%B 
signalling between the IKK complex and the phosphorylation of I%B". In the 
canonical model of NF-%B activation, phosphorylation of I%B" serine residues 32 and 
36 by the catalytic subunits of the IKK complex (mainly IKK!) are responsible for its 
polyubiquitination and subsequent degradation by the 26S proteosome (Li et al, 
1999). To examine if C4 interacts with IKK!, HeLa cells were co-transfected with 
plasmids encoding HA-tagged IKK! and C-terminally TAP-tagged VACV proteins 
and IKK! was precipitated with an anti-HA mAb (Figure 4.11a). Immunoblotting 
indicated that C4 and B14 were co-precipitated with IKK! whereas C6 was not. B14 
is known to bind IKK! (Chen et al., 2008) and C6 served as a negative control. The 
IKK complex is composed of IKK", IKK!, and IKK& (also known as NEMO) and so 
an interaction with any one component of this complex might Co-IP other 
components. Therefore the interaction of C4 with NEMO was also investigated. HA-
tagged NEMO was transfected into cells co-transfected with TAP-tagged C4, C6 or 
B14, and NEMO was immunoprecipitated with an anti-HA mAb (Figure 4.11b). 
Immunoblotting confirmed that C4 and B14 were also co-precipitated with NEMO, 
whereas C6 was not, as expected. It was notable that NEMO pulled down more C4 
than B14 (Figure 4.11b), whereas the interaction of these proteins with IKK! seemed 
more equivalent (Figure 4.11a). This would be consistent with (but does not prove) a 
direct interaction of C4 with NEMO, rather than with IKK!. Protein B14, on the other 
hand, needs IKK! for interaction with the IKK complex (Chen et al., 2008). 
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Figure 4.11. C4 co-immunoprecipitates with IKK!  and NEMO. HEK293T cells 
were co-transfected with plasmids encoding (a) HA-tagged IKK! or (b) HA-tagged 
NEMO, and the indicated C-terminally TAP-tagged proteins for 24 h. The cells were 
washed with PBS, harvested in IP lysis buffer and then pre-cleared lysates were 
incubated with anti-HA or isotype control antibodies (Iso) coupled to protein G 
sepharose beads for 1 h. Whole cell protein lysates (‘Input’) and precipitated protein 
complexes (IP) were then separated by SDS-PAGE and analysed by immunoblotting 
with antibodies against the indicated proteins. Asterisks indicate the positions of IgG 
light chains. The positions of molecular mass markers are shown (kDa). 
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A recent study by Schröfelbauer et al (2012) demonstrated that as well as being 
essential for IKK! activation, NEMO also has an important role as a specificity factor 
by targeting IKK! to I%B". A conserved region within the I%B proteins was 
identified, termed the I%B signalling responsive domain (ISRD), and within this 
region two aspartic acid residues were found to be necessary for binding to NEMO. 
The authors therefore proposed a model whereby NEMO simultaneously interacts 
with IKK! through its N-terminal helical domain (HLX1) and with I%B" through its 
C-terminal zinc finger (ZF) domain (Figure 4.12a). In this way, NEMO may act as a 
scaffold on which I%B substrates are directed towards the IKK! catalytic site. 
 
An analysis of the C4 protein identified a sequence within the C-terminal domain that 
closely resembles the ISRD domain of I%B proteins, and this may assist in explaining 
how C4 interacts with NEMO (Figure 4.12b). By competitively binding to NEMO via 
an ISRD-like domain, it is possible that C4 is preventing the association of NEMO 
with I%B", thus inhibiting the I%B" phosphorylation step necessary for NF-%B 
activation. C4 might also function as a pseudosubstrate for IKK! and it is notable that 
C4 migrates as two bands both in the context of over-expression and virus infection in 
the presence of phosphatase inhibitors. If C4 binds NEMO directly, it suggests that 
the C4-IKK! interaction is indirect. A similar analysis of C16 showed a more 
distantly related ISRD like domain, and while the arginine and aspartic acid residues 
are conserved, the serine and threonines downstream are not. An ISRD-like domain 
within icIL-1Ra was not evident. Further investigation is needed to determine whether 
C16 can also interact with NEMO or the IKK complex and whether the ISRD domain 
of C4 is needed for this interaction. 
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Figure 4.12. The C4-NEMO protein interaction may be mediated by an ISRD-
like domain. (a) NEMO is a specificity factor that targets IKK! to I%B" 
(Schröfelbauer et al, 2012). A stable ternary complex is formed whereby the N-
terminal region of NEMO, containing a helical domain (HLX1), binds to IKK! and 
the C-terminal region of NEMO, containing a zinc-finger (ZF) domain, binds to 
I%B". A conserved region in I%B proteins, termed the I%B signalling responsive 
domain (ISRD), is implicated in the binding to the ZF domain of NEMO. Mutation of 
negatively charged residues D27 and D28 results in significantly reduced binding to 
NEMO and phosphorylation by IKK!. (b) Identification of the closest matches to an 
ISRD-like domain in C4 and C16. Green residues, positively-charged; blue residues, 
negatively-charged; red residues, phospho-acceptor. 
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4.5. C16 and the icIL-1Ra are inhibitors of NF-%B signalling  
 
Given that C4 displays 43.7% amino acid identity to C16 and that both intracellular 
proteins contained an IL-1Ra-like motif at their C-termini, the effects of C16 and the 
icIL-1Ra on NF-%B signalling were investigated. Stimulation of HEK293T cells with 
IL-1! resulted in a 50-fold activation of the NF-%B promoter and this was inhibited in 
a statistically significant manner by C16, the icIL-1Ra and B14 but was unaffected by 
the presence of C6 (Figure 4.13a). To identify the positions within the NF-%B 
signalling pathway at which C16 and the icIL-1Ra were acting, TRAF2, TRAF6 and 
IKK! were over-expressed. Over-expression of TRAF2 (Figure 4.13b), TRAF6 
(Figure 4.13c) and IKK! (Figure 4.13d) resulted in a 62-, 210- and 8- fold activation 
of the NF-%B promoter, respectively, and this was inhibited in each case by C16 and 
B14, but not C6, as expected. The icIL-1Ra could only inhibit NF-%B promoter 
activity following over-expression of TRAF6; however it should also be noted that 
there was a modest, albeit statistically insignificant, inhibition following the over-
expression of TRAF2. Taken together, these data demonstrate that like protein C4, 
C16 was acting at, or downstream of, the IKK complex; the icIL-1Ra by contrast may 
be specific to inhibiting IL-1!-induced NF-%B activation. 
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Figure 4.13. C16 and the icIL-1Ra inhibit NF-%B promoter activation. HEK293T 
cells were transfected with a firefly luciferase reporter plasmid under the control of an 
NF-%B-dependent promoter. Stimulation of cells was achieved with (a) 40 ng/ml IL-
1! for 8 h or by co-transfecting cells with (b) TRAF2, (c) TRAF6 or (d) IKK! 
expression plasmids. Cells were also co-transfected with a renilla luciferase control 
and a C16, icIL-1Ra, B14 or C6 expression plasmid or EV for 24 h. Firefly luciferase 
activity was normalised to renilla luciferase activity. Data are from one experiment 
representative of at least three, each performed in triplicate and presented as mean 
±SD. *P<0.05; **P<0.005; ***P<0.0005 compared with EV. 
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4.6. NF-%B inhibition is attenuated by C4 and C16 mutants that are 
less stable 
 
To determine whether or not the C-terminal IL-1Ra-like motif was responsible for 
mediating the inhibitory effects of C4 and C16 on NF-%B signalling, HEK293T cells 
were co-transfected with the NF-%B reporter and expression plasmids encoding C4, 
C16, and truncation mutants thereof lacking the IL-1Ra-like motif or EV. Activation 
of NF-%B was achieved with TRAF2 (Figure 4.14a) and TRAF6 (Figure 4.14b) over-
expression and resulted in 28- and 43- fold activation of the NF-%B promoter, 
respectively. NF-%B promoter activity was inhibited in a statistically significant 
manner by C4 and C16, irrespective of the presence of the IL-1Ra-like motif. 
Nevertheless, it was noteworthy that truncation mutants lacking the IL-1Ra-like motif 
showed a slightly poorer inhibitory effect and this may be explained by the reduced 
stability of these proteins within cells (section 3.2.1.).  
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Figure 4.14. NF-%B signalling inhibition is attenuated by C4 and C16 mutants 
that are less stable. HEK293T cells were transfected with a firefly luciferase reporter 
plasmid under the control of an NF-%B-dependent promoter and (a) TRAF2 or (b) 
TRAF6 expression plasmids. Cells were co-transfected with a renilla luciferase 
control and a C4, C4$IL-1Ra, C16 or C16$IL-1Ra expression plasmid or EV for 24 
h. Firefly luciferase activity was normalized to renilla luciferase activity. Data are 
from one experiment representative of at least three, each performed in triplicate and 
presented as mean ±SD. **P<0.005, compared with EV. 
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4.7. C4 is an inhibitor of cytoplasmic DNA sensing in MEFs 
 
Recently, the trimeric DNA sensor, DNA-PK, comprised of Ku70, Ku80 and DNA-
PKcs has been shown by our laboratory to induce the expression of type I IFN, 
CXCL10 and IL-6 within MEFs and this is dependant upon STING, TBK1 and IRF3 
(Ferguson et al, 2012). Moreover, C16 was shown to inhibit the binding of the Ku 
heterodimer to DNA, thereby preventing the DNA-mediated induction of CXCL10 
and IL-6 in MEFs (Peters et al, manuscript in preparation) and this led to the proposal 
that DNA-PK is capable of detecting poxvirus DNA and activating IRF3-dependent 
innate immunity. To test whether or not C4 also inhibits DNA sensing in MEFs, 
Ku80+/+ cells were co-transfected with expression plasmids encoding TAP-tagged 
proteins and concatamerised DNA for 24 h and then CXCL10 production was 
measured by ELISA (Figure 4.15a). Following stimulation of cells by co-transfection 
of plasmid and linear DNA, there was a robust induction of CXCL10 and this was 
inhibited in a statistically significant manner by C4 and C16 but not by GFP or EV. 
To determine whether the inhibition was dependant on Ku, CXCL10 production was 
measured by repeating the experiment with Ku80-/- MEFs (Figure 4.15b). This time 
although CXCL10 production was induced in response to transfected DNA, the 
concentrations were significantly lower compared to those by wild-type MEFs (note 
the different scales on the y-axis), supporting the hypothesis that Ku is a DNA sensor. 
! *&*!
 
 
 
 
Figure 4.15. C4 inhibits DNA sensing in MEFs. (a) Ku80+/+ (Trp53-/- Xrcc5+/+) and 
(b) Ku80-/- (Trp53-/-Xrcc5-/-) MEFs were co-transfected in triplicate with 200 ng/ml of 
a C4, C16 or GFP expression plasmid or EV with 5 mg/ml concatamerised DNA for 
24 h. The culture supernatant was then analysed for murine CXCL10 in duplicate by 
ELISA. Data are represented as mean ±SD. **P<0.005; ***P<0.0005, compared with 
EV and GFP. (c) DNA concatamers were analysed by gel electrophoresis, stained 
with ethidium bromide and visualised using a UV lamp. The positions of DNA size 
markers are shown (kb). (d) Disruption of the C4 and C16 ORF ablates inhibition of 
DNA sensing. Ku80+/+ (Trp53-/- Xrcc5+/+) MEFs were transfected in triplicate with 
200 ng/ml of MluI- or XcmI-, or MluI- or BspMI- linearised C4 and C16 expression 
plasmids, respectively, for 24 h. The culture supernatant was then analysed for murine 
CXCL10 in duplicate by ELISA. Data are represented as mean ±SD. ***P<0.0005, 
compared with XcmI- and BspMI- digested C4 and C16, respectively. 
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Since it was possible that there could be inconsistencies caused by co-transfecting 
circular and concatamerised DNA (Figure 4.15c), an alternative method for testing 
DNA sensing was used. Plasmids encoding C4 and C16 were linearised in two 
different ways: either to retain the promoter and ORF intact, or to cut the ORF 
thereby preventing protein expression. This allowed the delivery vehicle to serve also 
as the DNA stimulus, and in addition, ensured each cell contained the C4 or C16 
plasmid. Cells stimulated with plasmids cut to prevent C4 and C16 expression (i.e. 
those linearised with XcmI and BspMI, respectively) gave a robust production of 
CXCL10, indicating that the DNA-sensing pathway had been activated (Figure 
4.15d). In contrast, the production of CXCL10 was significantly reduced by cells in 
which C4 or C16 was present (i.e. those linearised with MluI), indicating that the 
DNA-sensing pathway had been inhibited. Taken together, these data suggest C4 is an 
inhibitor of DNA sensing in MEFs and that this inhibition may be Ku-dependant. 
 
4.8. The identification of C4 binding-partners 
 
Data presented in section 4.7. demonstrated that C4, like protein C16, inhibits 
signalling deriving from the recognition of foreign DNA by DNA-PK. Previously in 
our laboratory, an inducible cell line expressing TAP-tagged C16 was used to identify 
protein binding-partners by tandem affinity purification (Nicholas Peters, manuscript 
in preparation). Using this unbiased proteomics-based approach, C16 was found to 
interact with Ku70 and Ku80 and this was subsequently confirmed in the context of 
virus infection. In order to determine whether or not C4 also interacted with the Ku 
heterodimer (and if there were other novel binding-partners), tandem affinity 
purification was performed firstly using an inducible C4-TAP cell line and then using 
the TAP virus (vC4-TAP). 
 
4.8.1 Construction of an inducible cell line expressing TAP-tagged C4 
 
To construct an inducible C4-TAP cell line, the C4-C’TAP plasmid containing two 
tandem copies of the Strep-tag II and one FLAG-tag (Figure 4.16a; Gloeckner et al., 
2007) and a zeocin-resistance cassette, was transfected into HEK293T-REx cells and 
stable clones were selected in the presence of zeocin. Drug-resistant cell lines were 
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selected, amplified and screened for C4 expression after induction with doxycycline 
(Figure 4.16b). Clone 2 was chosen for amplification and tandem affinity purification 
because it inducibly expressed C4 at reasonable levels and with no evidence of leaky 
expression. 
 
 
Figure 4.16. Construction of the C4-C’TAP inducible cell line. (a) Schematic of 
the TAP-tag used during tandem affinity purification. (b) Clonal cell lines were tested 
for C4 expression by incubating in the presence or absence of 2 µg/ml doxycyline for 
24 h. Cell lysates were analysed by immunoblotting with antibodies against the 
indicated proteins. The positions of molecular mass markers are shown (kDa). 
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4.8.2. Identification of C4 binding-partners by tandem affinity 
purification 
 
To identify C4-binding partners, the C4-expressing cell line was used for tandem 
affinity purification and purified proteins were analysed by silver staining (Figure 
4.17a) and immunoblotting (Figure 4.17b). Induction of C4 expression was confirmed 
by the presence of a silver-stained band at approximately 37 kDa (dashed arrow, 
Figure 4.17a) and this protein was also detected with an anti-FLAG antibody (Figure 
4.17b). In addition to C4, six other proteins were identified (solid arrows, Figure 
4.17a) that were markedly more abundant than from uninduced cells. The silver-
stained proteins at approximately 70 and 80 kDa were of particular interest since it 
was already known than C16 interacts with Ku70 (70 kDa) and Ku80 (80 kDa) 
(Peters et al, manuscript in preparation). Immunoblotting of affinity-purified proteins 
with antibodies specific to these proteins confirmed that both Ku70 and Ku80 co-
purified with C4 from induced cells. In contrast, only small amounts of these proteins 
co-purified from uninduced cells and this might have been because of a small amount 
of leaky C4 expression that was not seen with the smaller amounts of material 
analysed in the previous pilot study (Figure 4.16b). The third component of the 
heterotrimeric DNA-PK complex is the catalytic subunit (DNA-PKcs), which has a 
molecular mass of 460 kDa (Collis et al., 2005). Notably, a large molecular mass 
protein also co-precipitated with C4 (red arrow, Figure 4.17a), however 
immunoblotting indicated this was not DNA-PKcs (Figure 4.17b).  
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Figure 4.17. Tandem affinity purification using the inducible C4 cell line. (a) 
Twenty T175 flasks of the C4-C’TAP inducible cell line were grown to 70 – 80% 
confluency and half were induced with 2 µg/ml doxycyline overnight. Protein lysates 
from induced and uninduced cells were then subjected to tandem affinity purification. 
Proteins were separated by SDS-PAGE and visualised by silver staining. (b) Protein 
samples prior to tandem affinity purification (‘Input’) and affinity-purified proteins 
(‘Final elution’) were analysed by immunoblotting with antibodies against the 
indicated proteins. The positions of molecular mass markers are shown (kDa). 
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A potential drawback to the use of an inducible cell line for the identification of viral 
binding-partners is that the protein of interest is expressed in the absence of other 
viral proteins that may be required for virus-host protein interactions to occur. In 
addition, potential virus-virus protein interactions would be missed. To address these 
concerns, tandem affinity purification was performed from vC4-TAP- and vC6-TAP- 
infected cells. Silver-stained bands of approximately 37 and 20 kDa were precipitated 
(dashed arrows, Figure 4.18a) and these were confirmed as C4 and C6, respectively, 
by immunoblotting with an anti-FLAG antibody (Figure 4.18b). Notably, the six 
additional affinity-purified proteins observed using the inducible C4 cell line were 
also co-precipitated with C4 in the context of VACV infection (solid arrows, Figure 
4.18a). This suggested that C4 does not have viral binding-partners. Immunoblotting 
of affinity-purified proteins with antibodies specific for Ku70 and Ku80 confirmed 
these proteins co-precipitated with C4 during VACV infection, but not with C6, as 
expected (Figure 4.18b). Since C16 binds the Ku heterodimer, affinity-purified 
proteins were also immunoblotted with a C16 antiserum to determine if C4 and C16 
interacted during VACV infection or if Ku could bind to C4 and C16 simultaneously. 
Under the conditions tested, C4 and C16 were not found to interact during infection 
(Figure 4.18b).  
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Figure 4.18. Tandem affinity purification of C4 using a TAP-tagged virus. (a) 
Twenty T175 flasks of HEK293T cells were grown to 80% confluency and 10 were 
infected overnight with 2 p.f.u. per cell of vC4-TAP and the other 10 with vC6-TAP. 
Protein lysates were then subjected to tandem affinity purification, separated by SDS-
PAGE and visualised by silver staining. (b) Protein samples prior to tandem affinity 
purification (‘Input’) and affinity-purified proteins (‘Final elution’) were analysed by 
immunoblotting with antibodies against the indicated proteins. The positions of 
molecular mass markers are shown (kDa). 
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Finally, a high molecular mass protein was identified by silver staining (red arrow, 
Figure 4.18a) and this only co-precipitated with C4. This protein was not recognised 
by an anti-DNA-PKcs antibody (Figure 4.18b). LC-MS/MS mass spectrometry 
analysis revealed that this band contained three unique proteins specific to C4 
precipitation that matched the approximate size of the band sent for analysis. In order 
of peptide abundance, these were filamin B, filamin A and myospryn (also known as 
cardiomyopathy-associated 5; CMYA5; Table 4.1). A total ion score >35 indicates 
identity or extensive homology (P<0.05) to the protein hit. Filamin B, the strongest 
hit, has a molecular mass of 278.9 kDa and is a ubiquitously expressed cytoplasmic 
protein with an essential role in the re-organization of the cellular cytoskeleton in 
response to extracellular receptor engagement (Stossel et al., 2001; van der Flier & 
Sonnenberg, 2001). Interestingly, filamin B is increasingly being described as an 
immunological scaffolding protein for the induction of interferon signalling (Jeon et 
al., 2008;  Jeon et al., 2009). Filamin A, the second strongest hit, is structurally 
related to filamin B (70% aa identity) and performs similar functions (Nakamura et 
al., 2007; Van der Flier & Sonnenberg, 2001). Myospryn is a 450.8-kDa protein 
implicated in the pathogenesis of Duchenne muscular dystrophy (Reynolds et al., 
2008). Whilst relatively little is known about myospryn, it belongs to the tripartite 
motif (TRIM) superfamily of proteins, is expressed in cardiac and skeletal muscle 
(Benson et al., 2004), exhibits a cytoplasmic (Durham et al., 2006) and perinuclear 
(Kouloumenta et al., 2007) subcellular localisation and interacts with another skeletal 
muscle protein, dysbindin (Benson et al., 2004). 
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Table 4.1. Mass spectrometry. 
 
Total Ion Score Identification Molecular 
Mass (kDa) 
5525 Filamin B 278.9 
 
390 Filamin A 248.1 
 
37 Myospryn 450.8 
 
 
The silver-stained uppermost band from vC4-TAP tandem affinity purification (red 
arrow, Figure 4.18a) was sent along with a negative control band from the adjacent 
lane for analysis at the Cambridge Centre for Proteomics. Protein hits represent 
unique proteins found only within the C4 band. A total ion score >35 indicates 
identity or extensive homology (P<0.05) to the protein hit.   
  
 
The identities of the other three proteins that co-precipitated with C4, which had 
approximate molecular masses of 60, 100 and 150 kDa (question marks, Figure 4.19), 
are unknown at this time since they did not react with any of the antibodies used for 
immunoblotting and have not yet been sent for mass spectrometry analysis. These 
data indicate that both over-expressed C4 (Figure 4.17) and C4 expressed at natural 
levels during VACV infection (Figure 4.18), can interact with endogenous Ku70 and 
Ku80, two components of the cytoplasmic DNA sensor, DNA-PK. Furthermore, mass 
spectrometry analysis identified filamin B, filamin A and myospryn as unique C4 
binding-partners (P<0.05) during VACV infection. Collectively, this suggests that C4 
may have multiple functions during VACV infection. This is reflected in the ability of 
C4 to perform at least three different functions: preventing NF-%B activation (Chapter 
4), inhibiting DNA sensing (Chapter 4) and contributing to HIF-1"-induced gene 
expression (Chapter 5).  
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Figure 4.19. Identification of potential C4 binding-partners. Affinity-purified 
proteins from vC4-TAP-infected HEK293T cells were identified by either 
immunoblotting with the indicated antibodies (black arrows) or mass spectrometry 
(red arrow). The positions of molecular mass markers are shown (kDa). 
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4.8.3. Confirmation of the C4-Ku interaction 
 
Protein-protein interactions identified by tandem affinity purification need 
confirmation by an alternative method. To confirm the interaction of C4 with Ku70, 
HEK293T cells were infected overnight with vC4-TAP or vC6-TAP and then protein 
complexes were precipitated from lysates with either Ku70 or isotype control 
antibodies (Figure 4.20a). Immunoblotting confirmed C4 was precipitated with Ku70 
during VACV infection and that this interaction was specific because C6 did not 
interact with Ku70 under the same conditions. Furthermore, the fact that C4 was not 
precipitated with an isotype control antibody confirmed that C4 was not simply 
binding in an unspecific manner to the protein G sepharose beads. The interaction of 
C4 with Ku80 in the context of VACV infection was also confirmed by a co-
immunoprecipitation (co-IP) using an anti-Ku80 antibody (Figure 4.20b).  
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Figure 4.20. Confirmation of the C4 interaction with Ku70 and Ku80. HEK293T 
cells were infected overnight with 2 p.f.u. per cell of vC4-TAP or vC6-TAP and then 
harvested in IP lysis buffer. Pre-cleared lysates were then incubated with (a) anti-
Ku70, (b) anti-Ku80 or isotype control antibodies (Iso) coupled to protein G 
sepharose beads for 1 h. Whole cell protein lysates (‘Input’) and precipitated protein 
complexes (IP) were then separated by SDS-PAGE and analysed by immunoblotting 
with antibodies against the indicated proteins. Asterisks indicate the positions of IgG 
light chains. The positions of molecular mass markers are shown (kDa). 
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4.9. Summary 
 
C4 inhibited the activation of NF-%B in response to IL-1! and TNF" and this 
inhibition was shown to be mediated at, or downstream of, the IKK complex. This 
was confirmed by immunofluorescence that showed the translocation of p65 into the 
nucleus was prevented by C4 in response to IL-1R engagement. Mechanistically, the 
inhibition of NF-%B activation by C4 was attributed to prevention of the cytokine-
induced phosphorylation of I%B" in transfected and VACV-infected cells. Consistent 
with this mechanism of action, C4 was found to interact with the canonical IKK 
proteins NEMO and IKK!. The identification of an ISRD-like domain within C4 
suggests the possible formation of a protein complex involving the simultaneous 
binding of C4 to NEMO and IKK!, which may also contain IKK". VACV protein 
C16 and the icIL-1Ra were also shown to inhibit NF-%B activation. Although deletion 
of the IL-1Ra-like motifs from C4 and C16 did not ablate the inhibitory function of 
these proteins, it did slightly reduce their ability to inhibit NF-%B signalling relative 
to the wild-type forms. Similar to C16, protein C4 was also shown to inhibit the 
sensing of DNA in MEFs and that this inhibition may be Ku-dependant. Using the 
unbiased approach of tandem affinity purification, a recombinant virus expressing 
TAP-tagged C4 was found to interact with Ku (Ku70 and Ku80), filamin B, filamin A 
and myospryn during infection. Finally, the C4-Ku interaction was confirmed by 
reciprocal co-IP using VACV-infected cells.  
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Chapter Five 
VACV and hypoxia-inducible factor-1"  stabilisation 
 
The N termini of both C16 and C4 were predicted to fold into a PHD2-like domain 
using the sequence-structure homology prediction tool FUGUE. Since PHD2 
functions in the hypoxic response, the effects of C16 and C4 on hypoxia inducible 
factor (HIF)-1" protein stabilisation and hypoxia-responsive gene expression were 
investigated.  
 
5.1. C16 and C4 do not contain the PHD2 active site 
 
Under hypoxic conditions, HIF-1" translocates to the nucleus and following 
dimerisation with HIF-1!, binds to hypoxia-response elements (HREs) within the 
promoters of hypoxia-responsive genes and induces their transcription (Crews, 1998). 
Under conditions of normal oxygen concentration, termed normoxia, HIF-1" is 
constitutively degraded (t1/2 ~ 5 min) with the consequence that the hypoxic 
transcriptional program is not active (Salceda & Caro, 1997). The degradation of HIF-
1" takes place after the hydroxylation of proline residues P402 and P564 within both 
of its oxygen-dependent degradation domains (ODDs) by prolyl hydroxylase domain-
containing enzymes (PHDs), primarily PHD2 (Bruick & McKnight, 2001). PHDs 
belong to the 2-oxoglutarate (2-OG)-dependent dioxygenase family of proteins that 
have an absolute requirement for molecular oxygen for their catalytic activities 
(Epstein et al., 2001). Once hydroxylated, HIF-1" is bound by the von Hippel-Lindau 
(VHL) E3 ubiquitin ligase complex and degraded in a 26S proteasome-dependent 
manner (Salceda & Caro, 1997). The structure of the C-terminal catalytic region of 
PHD2 (PHD2cat) in complex with Fe(II) was described by McDonough et al (2006). 
The PHD2cat structure contains four "-helices and ten !-strands, with the latter eight 
(!3-10) contributing to a double-stranded !-helix (DSBH) fold that is conserved 
within the 2-oxoglutarate (2OG) oxygenase family of proteins (Clifton et al., 2006). 
The PHD2 active site contains an Fe(II) coordinating triad consisting of the iron-
binding motif ‘H-X-D/E … H’ (where X is any amino acid residue) that is conserved 
within all members of the 2OG oxygenase protein family. Alignments of the N-
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terminal halves of C16 and C4 with PHD2cat were made using FUGUE (section 3.1.3; 
Shi et al., 2001) and the data evaluated with JOY (Mizuguchi et al., 1998b), a protein 
sequence-structure analysis tool. Protein C16 exhibited a close fit to PHD2cat as 
expected from the high Z-score derived from FUGUE, and this was exemplified by 
the high degree of secondary structure conservation (Figure 5.1a). However, whilst 
the DSBH fold was partially intact, the Fe(II) coordinating triad of the active site was 
not present. Specifically, both histidine residues of the ‘H-X-D/E … H’ iron-binding 
motif (His-313 and His-374) were absent. In addition, a large section of the N-
terminal "-helice ("1) and the second !-strand (!2) were missing. A similar analysis 
of C4 revealed that it has markedly less similarity to PHD2cat than C16, reflected in its 
lower Z-score (Figure 5.1b). In particular, although C4 contained parts of all the 
constituent !-strands of the DSBH fold, the predicted secondary structure indicated 
that large sections of the intervening flexible loops were missing. Furthermore, like 
C16, the active site of PHD2 was absent from C4. Taken together, the fact that C16 
and C4 both lacked the PHD active site rendered it highly unlikely that these proteins 
facilitated the hydroxylation and thereby the subsequent degradation of HIF-1".  
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Figure. 5.1. Structural alignments of C16 and C4 with PHD2. The predicted 
structure of (a) C16 (aa 1 ' 166) and (b) C4 (aa 1 ' 158) were compared to the known 
structure of PHD2cat (aa 181 ' 426; PDB, 2g19) using the protein sequence-structure 
representation and analysis tool, JOY (Miziguchi et al, 1998). The consensus protein 
structure is shown beneath amino acid sequences. Red arrow, PHD2 catalytic residue; 
pink bar, alpha-helix; blue bar, beta-strand; open bar, missing region of alpha-
helix/beta-strand; dashed line, missing region of flexible loop. 
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5.2. C16 stabilises HIF-1"  following plasmid transfection 
 
The effect of C16 and C4 on HIF-1" stabilisation was investigated by 
immunoblotting following transfection of HeLa cells with plasmids encoding C-
terminally TAP-tagged versions of these viral proteins (Figure 5.2). Equal loading of 
all samples and confirmation of TAP-tagged protein expression were confirmed by 
immunoblotting for "-tubulin and FLAG, respectively. Following transfection, HIF-
1" was detected as a band of approximately 110 kDa in the presence of C16 but not 
C4 or C6, indicating that only C16 can stabilise HIF-1". As a positive control for 
HIF-1" stabilisation, some cells were treated with dimethyloxallyl glycine (DMOG) 
for 6 h before harvesting. DMOG is a cell permeable pan-PHD inhibitor and thus 
HIF-1" is constitutively stabilised in its presence (Sears et al., 2008). VACV protein 
C6 was included as a negative control since this protein does not have a known role 
within the hypoxic signalling pathway (Unterholzner et al., 2011). The observation 
that HIF-1" is not stabilised after plasmid transfection of C4 indicates either that C4 
does not contribute to HIF-1" stabilisation, that the stabilisation of HIF-1" by C4 
cannot be detected under the conditions tested or that C4 only contributes to HIF-1" 
stabilisation in the context of infection.  
 
 
Figure 5.2. C16 stabilises HIF-1"  following plasmid transfection. HEK293T cells 
were transfected with plasmids encoding TAP-tagged C16, C4 or C6 for 24 h, or 
treated for 6 h with DMOG. The cells were washed with PBS, harvested and then 
protein lysates were resolved by SDS-PAGE and analysed by immunoblotting with 
antibodies against the indicated proteins. The positions of molecular mass markers are 
shown (kDa). 
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5.3. C16 and C4 both contribute to HIF-1"  stabilisation and nuclear 
translocation during VACV infection 
 
To investigate if VACV infection promotes the stabilisation of HIF-1", HeLa cells 
were infected with the indicated viruses at 10 p.f.u. per cell for 6 h and then studied 
by immunofluorescence using an anti-HIF-1" monoclonal antibody (mAb). HeLa 
cells infected with wild-type VACV showed increased levels and nuclear 
translocation of HIF-1", although the level of HIF-1" was less than that in DMOG-
treated cells (Figure 5.3a). The contribution of C4 and C16 to VACV-induced HIF-1" 
stabilisation and nuclear translocation was investigated by infecting cells with v$C4 
or v$C16. Following v$C4 infection there was visibly less stabilisation of HIF-1" 
compared to that in wild-type infected cells. In the absence of C16, there was almost 
no detectable stabilisation of HIF-1" and there was little difference compared to 
mock-infected cells. v$C16,$C4-infected cells were similar to those after v$C16 
infection and were indistinguishable to the mock-infected group. To assess the 
relative stabilisation of HIF-1" by infection with the different viruses, the integrated 
signal intensities of 30 cell nuclei per condition were calculated using ImageJ 
(Abràmoff, 2004) and normalised to mock-infected cells (Figure 5.3b). Taken 
together, this data suggested four important conclusions. Firstly, HIF-1" is stabilised 
and undergoes nuclear translocation during VACV infection. Secondly, both C16 and 
C4 contribute to this process in the context of infection because deletion of either 
protein alone reduces HIF-1" stabilisation. Thirdly, C16 and C4 are the only VACV 
proteins that regulate this process since in their absence there is no HIF-1" 
stabilisation. Finally, C16 contributes more to HIF-1" stabilisation that C4 during 
infection. 
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Figure 5.3. HIF-1"  is stabilised and translocates to the nucleus during VACV 
infection. (a) Immunofluorescence. HeLa cells were infected with the indicated 
viruses at 10 p.f.u. per cell for the 6 h. Cells were washed with PBS, fixed, 
permeabilised and stained with an anti-HIF-1" mAb. The localisation of HIF-1" (red; 
left panels), phase-contrast (middle panels) and phase-contrast/merged images (right 
panels) are shown. (b) Scoring. Thirty cells per condition were quantified for HIF-1" 
nuclear translocation. Data shown are from one experiment representative of three. 
DMOG, dimethyloxallyl glycine. ***P<0.0005, compared with mock or between 
indicated groups. 
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To establish how quickly HIF-1" is stabilised during VACV infection, MEFs were 
infected with the indicated viruses and cell lysates were analysed by immunoblotting 
(Figure 5.4). Equal loading of all samples was confirmed by immunoblotting for "-
tubulin and similar levels of virus infection were confirmed by the detection of similar 
levels of D8 in the infected cells. The expression of C4 was detected from vC4-TAP-
infected cells as a 37-kDa protein from 2 h p.i. (Figure 5.4a). As seen by 
immunofluorescence, HIF-1" was stabilised after WT (vC16) VACV infection and 
these blotting data showed that this occurred maximally between 2 and 4 h p.i., 
indicating that this is an early event (Figure 5.4b). This was consistent with the 
temporal expression kinetics of C4 and C16 (Figures 5.4a and b; Fahy et al., 2008). 
No stabilisation of HIF-1" was seen after infection by v$C16,$C4, confirming C4 
and C16 are the only VACV proteins required for this process (Figure 5.4e). The 
relative contributions of C4 and C16 were assessed by analysis of HIF-1" levels in 
cells infected with viruses lacking each protein separately. In the presence of C16 
(v$C4 infection) HIF-1" stabilisation occurred, albeit to levels less than seen after 
WT virus infection (Figure 5.4c). In the presence of C4 (v$C16 infection) there was 
only slightly more HIF-1" than in mock-infected cells (Figure 5.4d). Collectively, 
these data indicate that C16 is more important for HIF-1" stabilisation than C4, but 
C4 does have a role in this process. 
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Figure 5.4. C4 and C16 contribute to HIF-1"  stabilisation. MEFs were infected 
with (a) vC4-TAP, (b) vC16, (c) v$C4, (d) v$C16 or (e) v$C16,$C4 at 10 p.f.u. per 
cell for at the indicated times. Protein lysates were prepared, resolved by SDS-PAGE 
and analysed by immunoblotting with antibodies against the indicated proteins. The 
positions of molecular mass markers are shown (kDa). This work was performed with 
Dr. Michela Mazzon. 
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5.4. Viruses lacking C16 and C4 show impaired HIF-1"-induced gene 
expression 
 
During hypoxia, a transcriptional programme is elicited by HIF-1" that includes the 
induction of tissue-specific genes involved in the adaptation to low oxygen 
conditions. Amongst the more than 100 hypoxia-responsive genes so far 
characterised, subsets for erythropoiesis, angiogensis, glucose metabolism, cell 
proliferation and apoptosis have been identified (Lee et al., 2004). Although HIF-1" 
is stabilised and undergoes nuclear translocation during VACV infection, it was 
unclear whether this resulted in the induction of hypoxic gene expression, since it is 
known that VACV infection shuts off host gene expression (Rice & Roberts, 1983;  
Buller & Palumbo, 1991). To test this, MEFs were infected with recombinant VACVs 
for 6 h and the levels of glucose transporter 1 (GLUT-1), pyruvate dehydrogenase 
lipoamide kinase isozyme 1 (PDK-1), vascular endothelial growth factor A (VEGF-
A), BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNip3) and VACV 
E9L (DNA polymerase) mRNA were assessed by qRT-PCR. Similar levels of virus 
infection were confirmed by the detection of equivalent levels of E9L (Figure 5.5a). 
Infection of cells with wild-type VACV (vC16 and vC16-Rev) resulted in a 
statistically significant increase of GLUT-1 mRNA compared to cells infected with 
v$C16 (Figure 5.5b). The lowest yields of GLUT-1 mRNA levels were seen in 
v$C16,$C4-infected cells and these were significantly different from v$C16-infected 
cells, indicating that both C16 and C4 contributed to the induction of GLUT-1 during 
VACV infection. A similar trend was observed for the mRNA levels of PDK-1 
(Figure 5.5c) and VEGF-A (Figure 5.5d). The mRNA levels of BNip3 were also 
decreased in v$C16-infected cells, albeit the difference was not statistically 
significant (Figure 5.5e). Despite this, cells infected with v$C16,$C4 showed 
decreased levels of BNip3 mRNA compared to wild-type infections and this was 
statistically significant. Taken together, these data indicated that HIF-1" is stabilised 
and activated by VACV infection and that this induces the transcription of hypoxia-
responsive genes. Furthermore, both C16 and C4 are required for maximal induction 
of these genes.  
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Figure 5.5. Recombinant viruses lacking C16 and C4 induce less hypoxic gene 
expression. MEFs were infected with the indicated viruses at 10 p.f.u./cell for 6 h. 
Cellular RNA was extracted to generate cDNA libraries and this was used for qRT-
PCR analysis in duplicate using primers specific for (a) E9L, (b) GLUT-1, (c) PDK-1, 
(d) VEGF-A and (e) BNip3. Data are represented as mean ±SD, N=3. *P<0.05; 
**P<0.005; ***P<0.0005. This work was performed with Dr. Michela Mazzon. 
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5.5. C4 does not interact with PHD2 
 
Proteins C16 and C4 lack the Fe(II) coordinating triad of the PHD2 active site 
(section 5.1.), and function to stabilise HIF-1". This might be mediated by either 
inhibiting PHD2 hydroxylase activity or stabilising HIF-1" after it is hydroxylated. 
Recently, C16 was shown in our laboratory to interact with PHD2 (Nicholas Peters, 
manuscript in preparation) and by collaborators to antagonise PHD2 hydroxylase 
activity (Dr. Christoph Loenarz, manuscript in preparation). To test if C4 also 
interacts with PHD2, HEK293T cells were transfected with plasmids encoding C-
terminally TAP-tagged C4, C6, C16 or B14 for 24 h and then incubated in the 
presence or absence of DMOG for 6 h. Protein complexes were affinity-purified from 
lysates using Strep-Tactin beads and analysed by immunoblotting (Figure 5.6). As 
expected, C16 strongly interacted with PHD2 in both the presence and absence of 
DMOG. In contrast, PHD2 was not affinity-purified by C4, C6 or B14. Furthermore, 
C4 did not interact with HIF-1" and this was not affected by the pan-inhibition of 
PHD activity using DMOG. Taken together, no evidence could be found that C4 
interacts with PHD2 or HIF-1" in HEK293T cells.   
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Figure 5.6. C4 does not co-immunoprecipitate with PHD2 or HIF-1" . HEK293T 
cells were transfected with plasmids encoding the indicated C-terminally TAP-tagged 
proteins for 24 h and then incubated in the presence or absence of 1 mM DMOG for a 
further 6 h. The cells were washed with PBS, harvested in IP lysis buffer and then 
pre-cleared lysates were incubated with Strep-Tactin beads for 1 h. Whole cell protein 
lysates (‘Input’) and affinity-purified protein complexes were then separated by SDS-
PAGE and analysed by immunoblotting with antibodies against the indicated proteins. 
The positions of molecular mass markers are shown (kDa). 
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5.6. Summary 
 
A bioinformatics analysis indicated that whilst the N terminal halves of C16 and C4 
were likely to fold into a PHD2-like domain, both proteins lacked the enzyme’s active 
site. Transfection of plasmids encoding C16 and C4 showed that only C16 was 
capable of stabilising HIF-1" under the conditions tested. However, in the context of 
VACV infection, both proteins contribute to HIF-1" stabilisation and nuclear 
translocation. Protein C16 is the more potent in this regard because viruses lacking it 
are more impaired at performing this function. HIF-1" stabilisation during VACV 
infection is associated with an induction of hypoxia-responsive gene expression and 
this is significantly impaired in the absence of both C16 and C4. Whilst C4 
contributes to the induction of hypoxic signalling, it did not interact with PHD2 or 
HIF-1" under the conditions tested. 
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Chapter Six 
C4 is a VACV virulence factor 
 
Since C4 had been shown to down-regulate the innate immune response by inhibiting 
NF-%B signalling and DNA sensing (Chapter 4), it was hypothesised that C4 may 
affect virus virulence. In this chapter, the contribution of C4 to virus growth in vitro 
and to virus virulence in vivo was assessed. Where an attenuation of virus virulence 
was found, flow cytometry was utilised to inspect and quantify the differences in 
immune cell recruitment. Finally, the effect of removing both C16 and C4 from 
VACV on virus virulence was examined.  
 
6.1. C4 does not contribute to VACV spread or replication in cell 
culture 
 
The fact that not all strains of VACV contain gene C4L indicate that it is not 
necessary for viral replication in cell culture and this was confirmed for VACV strain 
WR by the isolation of the C4 deletion mutant, v$C4 (section 3.2.3.). To ascertain 
whether or not deletion of C4 had an effect on viral spread, the size of plaques formed 
by v$C4 on monolayers of BSC-1 and RK13 cells was compared with those of 
control viruses (Figure 6.1a). The plaques formed by v$C4 were found to be slightly 
smaller than those formed by control viruses in both cell types tested, although this 
difference was not statistically significant.  
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Figure 6.1. C4 is non-essential for virus replication and spread in cell culture. (a) 
Plaque size. Monolayers of BSC-1 or RK13 cells were infected with the indicated 
viruses for 72 h. The sizes of 30 plaques were measured for each virus. Data are 
expressed as the mean ± SD plaque diameter (µm). For single (b, c) and multi-step (d, 
e) growth curves, BSC-1 cells were infected at 10 or 0.01 p.f.u. per cell, respectively, 
and intracellular (b and d) and extracellular (c and e) virus were collected at the 
indicated times and titrated by plaque assay in BSC-1 cells. Data are presented as the 
mean ± SD log10 (p.f.u.). 
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Next, the effect of C4 on virus replication in BSC-1 cells was examined after 
infection at 10 p.f.u./cell. Virus present in the intra- and extracellular fractions were 
titrated by plaque assay in BSC-1 cells. The production of both intracellular 
(predominately IMV; Figure 6.1b) and extracellular (predominately EEV; Figure 
6.1c) virus was found to be equivalent between v$C4 and control viruses. Since 
smaller differences in viral replication are more easily differentiated during multi-step 
growth kinetics as the virus spreads from cell-to-cell, BSC-1 cells were examined 
after infection at 0.01 p.f.u./cell and virus production was quantified as before. Again, 
the production of both IMV (Figure 6.1d) and EEV (Figure 6.1e) were 
indistinguishable between the different viruses. Taken together, these data 
demonstrate that C4 is non-essential for virus replication. 
 
6.2. C4 affects virus virulence in the intranasal model of infection 
 
There have been many instances of poxvirus proteins (e.g. N1, Bartlett et al., 2002; 
B14, Chen et al., 2006; C6, Unterholzner et al., 2011) that have had no effect on virus 
replication in vitro but have significantly contributed to the outcome of virus infection 
in vivo. To test if C4 contributed to virus virulence, the virulence of v$C4 was tested 
in the murine intranasal (i.n.) model of VACV infection. The i.n. model results in a 
systemic VACV infection because virus produced from replication in the respiratory 
tract spreads to other organs such as the spleen, liver and brain (Williamson et al., 
1990). VACV virulence is measured over time as a function of animal weight loss and 
signs of illness (Alcami et al., 1992). Mice infected with v$C4 lost less weight 
(Figure 6.2a), showed fewer signs of illness (Figure 6.2.b) and recovered earlier 
compared to control infections (Figure 6.2a). Mice infected with vC4 or vC4-Rev had 
indistinguishable outcomes indicating that attenuation of v$C4 was directly 
attributable to the loss of C4. Taken together, these data demonstrate viruses lacking 
C4 are attenuated in the murine i.n. model of infection and therefore that C4 is a 
virulence factor.  
 
The virus titres in infected lungs were also measured (Figure 6.2c). At day 2 p.i. all 
viruses had replicated to equivalent levels, indicating that, as in vitro, the loss of C4 
does not impair virus replication in vivo. However, by days 5 and 8 p.i. v$C4-infected 
! *)+!
mice had lower virus titres than controls, which were statistically significant, 
suggesting more rapid clearance of virus in the absence of C4.  
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Figure 6.2. C4 is a virulence factor. BALB/c mice (n=5) were infected intranasally 
with 5 x 103 p.f.u. per mouse of the indicated viruses and their weights and signs of 
illness were measured daily. (a) Weights. Data (means ± SEM) are expressed as a 
percentage of the mean weight of the same group of animals on day 0. (b) Signs of 
illness. The mean ± SEM score of each group of animals is shown. The horizontal 
bars indicate days on which the weight loss or signs of illness induced by v$C4 were 
statistically different (P<0.05) from both vC4 and vC4-Rev. (c) Lung virus titres. 
BALB/c mice (n=5) were infected intranasally with the indicated viruses and five 
mice per group were sacrificed at the indicated days p.i. and their lungs harvested. 
Lung virus titres were established by plaque assay in BSC-1 cells. Data are presented 
as the mean viral titre ± SEM. 
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6.3. C4 affects recruitment of immune cells 
 
To address the basis for the attenuation of virus virulence in the absence of C4, cells 
were isolated from bronchoalveolar lavage (BAL) fluid, lungs and spleens of infected 
mice and their phenotypes inspected by flow cytometry. The total infiltration of cells 
into the BAL fluid was enumerated by trypan blue exclusion and this revealed an 
increased number of cells in v$C4-infected mice as early as day 2 p.i. (Figure 6.3a). 
By day 8 p.i., there were fewer cells in the BAL fluid of these mice compared to those 
infected by control viruses. Therefore, the recruitment of cells into the BAL fluid 
showed both quantitative and kinetic differences following infection with v$C4. 
Notably, by day 8 p.i. the number of cells in the BAL fluid of mice infected with 
control viruses was equivalent to that at day 5, whereas in v$C4-infected animals the 
cell number had already declined from that at day 5 p.i., indicating recovery from 
infection.  
 
Next, an analysis of the number of macrophages and neutrophils within the BAL fluid 
of mice was performed by flow cytometry. By day 2 p.i., there were increased 
numbers of macrophages (Figure 6.3b) and neutrophils (Figure 6.3c) in mice infected 
with v$C4 compared to control viruses, thus the early difference in BAL fluid cell 
numbers is in part attributable to the infiltration of these innate immune cell types. 
There were still increased numbers of these cell types by day 5 p.i. but by day 8 their 
levels had decreased indicating that the inflammatory response in these mice had 
begun to subside. In contrast, the numbers of macrophages and neutrophils steadily 
increased in mice infected with control viruses throughout the same period, indicating 
an ongoing inflammatory response and slower clearance of the infection. 
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Figure 6.3. Absence of C4 leads to an increased recruitment of innate immune 
cells into the BAL fluid. BALB/c mice were infected intranasally with 5 x 103 p.f.u. 
per mouse of the indicated viruses and at the indicated times p.i., groups (n=5) were 
sacrificed and cells were extracted from BAL fluid. (a) Total number of viable cells in 
BAL fluid. (b, c) Flow cytometry. BAL cells were stained for (b) macrophages and 
(c) neutrophils using anti- F4/80 and Ly6G antibodies, respectively. Data are 
presented as mean ± SEM cell counts. *P<0.05 and ***P<0.0005 for v$C4, 
compared with both vC4 and vC4-Rev.  
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To investigate whether or not the absence of C4 also affected the infiltration of innate 
immune cells into the lungs, cells were extracted from lung homogenates and cells 
were stained for the presence of macrophage (F4/80), neutrophil (Ly6G) or NK cell 
markers (DX5). As seen in BAL fluid, there was as increase in the number of 
macrophages (Figure 6.4a) and neutrophils (Figure 6.4b) in the lungs of v$C4-
infected mice compared to control infections as early as day 2 p.i. By day 8 p.i. this 
trend had reversed such that the numbers of these cell types had decreased in v$C4-
infected mice, whereas for control infections these numbers were unchanged from day 
5 p.i. Furthermore, an analysis of the NK cell population revealed that there were also 
more NK cells in the lungs of v$C4-infected mice at day 2 p.i. compared to control 
infections, although the numbers of these cells were found to be equivalent at later 
time-points (Figure 6.4c). 
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Figure 6.4. Absence of C4 leads to an increased recruitment of innate immune 
cells into the lungs. BALB/c mice were infected intranasally with 5 x 103 p.f.u. per 
mouse of the indicated viruses and at the indicated times p.i., groups (n=5) were 
sacrificed. Lung cells were stained for (a) macrophages, (b) neutrophils and (c) NK 
cells using anti- F4/80, Ly6G and DX5 antibodies, respectively. Data are presented as 
mean ± SEM cell counts. *P<0.05 for v$C4, compared with both vC4 and vC4-Rev.  
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Cells isolated from lung homogenates were also stained for lymphocyte markers to 
assess the development of the adaptive immune response to VACV infection. To 
analyse the T cell population, CD3+ cells were gated and the surface expression of 
CD4 and CD8 were examined to differentiate between CD4+ and CD8+ T cell subsets. 
Moreover, to inspect the activation state of T cells, the surface expression of CD69 
was also quantified (Yamashita et al., 1993). Although there were no statistically 
significant differences in the total numbers of CD4+ (Figure 6.5a) and CD8+ (Figure 
6.5c) T cells, measurement of their activation status indicated that more of these cell 
types displayed an activated phenotype (CD69+) by day 5 p.i. in the lungs of v$C4-
infected mice compared to control infections (Figure 6.5b and d). Finally, lung cells 
were also stained for CD19, a pan-B cell surface marker (Tedder & Isaacs, 1989), but 
no significant difference in the number of these cells was observed between any of the 
virus infections (Figure 6.5e).  
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Figure 6.5. Absence of C4 leads to the increased activation of T cells in the lungs. 
BALB/c mice were infected intranasally with 5 x 103 p.f.u. per mouse of the indicated 
viruses and at the indicated times p.i., groups (n=5) were sacrificed. Lung cells were 
stained for (a) CD4+, (b) activated CD4+, (c) CD8+ and (d) activated CD8+ T cells and 
(e) B cells. Data are presented as mean ± SEM cell counts. *P<0.05 for v$C4, 
compared with both vC4 and vC4-Rev. 
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The populations of immune cells in the spleens of infected mice were also 
investigated. The numbers of macrophages in the spleen increased steadily until day 5 
p.i., however by day 8, there were fewer of these cells in the spleens of mice infected 
with v$C4 compared to control viruses and this was statistically significant (Figure 
6.6a). There were no statistically significant differences in the numbers of neutophils 
(Figure 6.6b) and NK cells (Figure 6.6c).  
 
 
 
Figure 6.6. C4 affects the recruitment of macrophages into the spleen. BALB/c 
mice were infected intranasally with 5 x 103 p.f.u. per mouse of the indicated viruses 
and at the indicated times p.i., groups (n=5) were sacrificed. Lung cells were stained 
for (a) macrophages, (b) neutrophils and (c) NK cells using anti- F4/80, Ly6G and 
DX5 antibodies, respectively. Data are presented as mean ± SEM cell counts. 
*P<0.05 for v$C4, compared with both vC4 and vC4-Rev.   
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Next, spleen homogenates were analysed for the presence of lymphoid cells. The 
numbers of CD4+ T cells (Figure 6.7a) and those that were activated (Figure 6.7b) 
increased for the duration of the experiment, however there were no differences 
between virus infections. Likewise, the numbers of CD8+ (Figure 6.7c), activated 
CD8+ T cells (Figure 6.7d) and B cells (Figure 6.7e) increased with time p.i. but there 
were no significant differences between virus infections.   
 
Taken together, these data demonstrate that there are increased numbers of innate 
immune cells and activated T cells in the lungs of mice infected with viruses lacking 
C4. The more rapid recruitment of these cells correlated with a more rapid clearance 
of virus from v$C4-infected mice, showing that C4 is both an immunomodulator and 
a virulence factor. 
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Figure 6.7. C4 has no affect on the activation status of T cells in the spleen. 
BALB/c mice were infected intranasally with 5 x 103 p.f.u. per mouse of the indicated 
viruses and at the indicated times p.i., groups (n=5) were sacrificed. Lung cells were 
stained for (a) CD4+, (b) activated CD4+, (c) CD8+ and (d) activated CD8+ T cells and 
(e) B cells. Data are presented as mean ± SEM cell counts.  
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6.4. C4 does not affect virus virulence in the intradermal model of 
infection 
 
The murine intradermal (i.d.) model of VACV infection is a localised ear infection 
with very little, if any, spread to other tissues (Tscharke & Smith, 1999). Virus 
virulence is assessed by measuring the size of the resultant skin lesion over time. The 
deletion of C4 had no effect on virus virulence in this model as the size of skin lesion 
induced was not statistically different from those caused by control viruses (Figure 
6.8a). To investigate the effectiveness of v$C4 as a vaccine, these mice were then 
challenged i.n. 28 days p.i. with a lethal dose (5 !106 p.f.u. per mouse) of VACV 
strain WR. Since the challenge dose was 100 LD50 for BALB/c mice of the same age, 
the mice began to lose weight more rapidly than during a primary VACV infection 
(Figure 6.8b). Maximal weight loss was reached by days 2 and 3 p.i. and mice 
recovered to their original starting weights by day 6 p.i. However, there were no 
differences between animals immunised with the different viruses. Taken together, 
these data demonstrated that the deletion of C4 had no effect on virus virulence in the 
i.d. model of infection and that v$C4 did not alter the protection against lethal 
challenge compared to control viruses.    
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Figure 6.8. C4 does not affect virus virulence in the intradermal model of 
infection. Groups of C57BL/6 mice (n=5) were infected i.d. with 104 p.f.u. in both 
ears of the indicated viruses. (a) Lesion sizes were measured daily with a micrometer. 
Data are presented as mean lesion size ± SEM. (b) Challenge. Twenty eight days 
post-i.d. infection with the indicated viruses, animals were infected i.n with 5 x 106 
p.f.u. of VACV strain WR per mouse and their weights recorded daily. Data are 
presented as a percentage of the mean weight ± SEM of the same group of animals on 
day 0. 
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6.5. Deletion of C16 and C4 leads to a synergistic attenuation of virus 
virulence 
 
Whilst protein C16 was shown to be non-essential for virus replication, it does 
influence virus spread in cell culture as seen by a significantly reduced plaque size 
(Fahy et al., 2008). The consequence of removing both C16L and C4L on these 
parameters was examined. Recombinant viruses lacking both genes were constructed 
starting with v$C16 as parental virus (section 3.2.3.). Plaques formed by 
v$C16,$C4L were significantly smaller than those formed by viruses lacking only 
C16 in both BSC-1 and RK13 cells (Figure 6.9a). Next, the consequence of removing 
both C16L and C4L on virus replication in BSC-1 cells was examined after infection 
at 10 p.f.u./cell. The production of both IMV (Figure 6.9b) and EEV (Figure 6.9c) by 
v$C16,$C4 and v$C16 were found to be equivalent, indicating that C16 and C4 are 
non-essential for virus replication. Similar results were obtained for the production of 
IMV (Figure 6.9d) and EEV (Figure 6.9e) after infection at 0.01 p.f.u./cell. Since the 
reduction in plaque size was not due to reduced production of infectious virus, this 
suggests it might be due to the effect of C4 and C16 on antiviral innate immune 
responses (e.g. by inhibiting IFN production) or some aspect of virus spread not 
examined here.   
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Figure 6.9. Absence of both C16 and C4 leads to a synergistic decrease in plaque 
size in vitro. (a) Plaque size. Monolayers of BSC-1 or RK13 cells were infected with 
the indicated viruses for 72 h. The sizes of 30 plaques were measured for each virus. 
Data are expressed as the mean ± SD plaque diameter (µm). For single (b, c) and 
multi-step (d, e) growth curves, BSC-1 cells were infected at 10 or 0.01 p.f.u. per cell, 
respectively, and intracellular (b and d) and extracellular (c and e) virus were 
collected at the indicated times and titrated by plaque assay in BSC-1 cells. Data are 
presented as the mean ± SD log10 (p.f.u.). ***P<0.0005 for v$C16,$C4 compared 
with both v$C16 and v$C16-Rev.     
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Like C4, viruses lacking C16 are attenuated in the murine i.n., but not the i.d., model 
of VACV infection (Fahy et al., 2008). The consequence of removing both genes on 
virus virulence in the i.n. model of infection was investigated. Mice were infected 
with 1 ! 105 p.f.u. and weight loss and signs of illness were measured. The onset of 
weight loss began after day 3 p.i., irrespective of the virus used for infection, however 
mice infected with v$C16,$C4 lost less weight (Figure 6.10a), showed fewer signs of 
illness (Figure 6.10b) and recovered earlier compared to mice infected with viruses 
lacking only C16 (v$C16 and v$C16-Rev), which were equivalent. Next, the 
virulence of the double deletion mutant was examined in the i.d. model (Figure 
6.10c). Skin lesions caused by v$C16,$C4 were smaller and healed sooner than those 
caused by viruses lacking only C16. This was interesting because loss of either C4 
(Figure 6.8a) or C16 (Fahy et al., 2008) in isolation does not influence virus virulence 
in this model. Lastly, challenge of these mice 28 days p.i. with a lethal dose of VACV 
showed that there were no significant differences in the level of protection afforded 
by vaccination with v$C16,$C4 compared to v$C16 (Figure 6.10d). 
 
Taken together, these data demonstrate that the loss of both C16 and C4 leads to a 
synergistic reduction of plaque size in cell culture and the attenuation of viruses in the 
i.n. and i.d. models of infection.   
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Figure 6.10. Absence of both C16 and C4 leads to a synergistic attenuation of 
virus virulence in the intranasal and intradermal models of infection. (a, b) 
Intranasal infection. BALB/c mice (n=5) were infected intranasally with 1 x 105 p.f.u. 
per mouse of the indicated viruses and their weights and signs of illness were 
measured daily. (a) Weights. Data (means ± SEM) are expressed as a percentage of 
the mean weight of the same group of animals on day 0. (b) Signs of illness. The 
mean ± SEM score of each group of animals is shown. The horizontal bars indicate 
days on which the weight loss or signs of illness induced by v$C16,$C4 was 
statistically different (P<0.05) from both v$C16 and v$C16-Rev. (c) Intradermal 
infection. C57BL/6 mice (n=5) were infected i.d. with 104 p.f.u. in both ears of the 
indicated viruses. (a) Lesion sizes were measured daily with a micrometer. Data are 
presented as mean lesion size ± SEM. (d) Challenge. Twenty eight days p.i., animals 
were infected i.n with 5 x 106 p.f.u. of VACV strain WR per mouse and their weights 
were recorded daily. Data are presented as a percentage of the mean weight ± SEM of 
the same group of animals on day 0. 
 
! *"(!
 
6.6. Summary 
 
The deletion of C4 had no significant effect on virus growth in vitro but viruses 
lacking C4 were attenuated in the murine i.n. model of infection, indicating that C4 is 
a virulence factor. The early infiltration kinetics of innate immune cells correlated 
with more rapid clearance of virus from v$C4-infected mice, showing that C4 is both 
an immunomodulator and a virulence factor. Like C16, C4 does not affect virus 
virulence in the i.d. model of infection or afford better protection against a subsequent 
lethal VACV challenge. In contrast, loss of both C16 and C4 led to a synergistic 
attenuation of viruses in both the i.n. and i.d. models of infection.     
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7.0. Discussion 
 
Although gene C4L is conserved among several OPV species and is closely related to 
C16, a virulence factor (Fahy et al., 2008), the C4 protein was uncharacterised prior 
to this study.  
 
7.1. Basic characterisation of C4 
 
The C4L gene is present towards the left end of the VACV genome in a region 
encoding many immunomodulatory proteins. For example, the genes two ORFs 
upstream and downstream of C4L (C2L and C6L) encode a secreted complement 
binding protein (Kotwal & Moss, 1988) and an intracellular inhibitor of IRF3 
activation (Unterholzner et al., 2011), respectively. Protein C4 is conserved in six out 
of eight OPV species, suggesting an important function, and notably is conserved in 
those OPV species that do not encode C16. Whilst C4 and C16 have partially 
overlapping functions, they are functionally non-redundant because deletion of either 
one leads to an attenuation of virus virulence in vivo (this study and Fahy et al, 2009).  
 
Although C4 and C16 exhibit 43.7% aa sequence identity, it is their C-terminal 100 
amino acids that share the greatest degree of conservation (56% aa identity) and 
wherein both proteins contain an IL-1Ra-like motif. Ectopic expression of C4 and 
C16 truncation mutants lacking the IL-1Ra-like motif were significantly less stable 
than their wild-type counterparts, suggesting an important function for this motif in 
maintaining the structural integrity of these proteins. Consistent with this proposal, 
the structure of the human icIL-1Ra (Stockman et al., 1994) shows that this motif is 
required for the formation of its C-terminal beta-strand (aa residues 147 to 151). 
Taken together, the IL-1Ra-like motif may be crucial for maintaining the correct 
folding of these proteins.  
 
Protein C4 is detected from 2 h p.i. and in the presence of AraC, an inhibitor of DNA 
replication, indicating that it is a VACV early gene. The expression of C4 parallels 
that of C16, which is also made early during infection (Fahy et al., 2008) and is 
consistent with the identification of an early promoter and a genome-wide 
transcriptional analysis that detected C4 mRNA from 0.5 h p.i. (Assarsson et al., 
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2008). The early expression of C4 is consistent with its function described as an 
inhibitor of the host innate immune response. Other VACV inhibitors of the innate 
immune response such as B14 (Chen et al., 2006), C6 (Unterholzner et al., 2011), E3 
(Yuwen et al., 1993) and N1 (Bartlett et al., 2002), are also notable for their early 
expression kinetics. One exception to this principle is B15, an IL-1!-binding protein 
that is expressed late during infection and which controls the body temperature of 
infected animals (Smith & Chan, 1991; Alcami & Smith, 1992; Alcami & Smith, 
1996).  
 
Despite the absence of a predicted NLS, C4 exhibited both a cytoplasmic and nuclear 
localisation in the context of VACV infection. This suggests either that C4 interacts 
with a cellular protein to mediate the nuclear translocation of this protein, or that it 
passively diffuses between both cellular compartments (possible for proteins ( 50 
kDa; Macara, 2001). However, the strong nuclear localisation of C4 late during 
infection is inconsistent with passive diffusion. Whilst the nuclear localisation of C4 
is interesting given that VACV replicates within the cytoplasm, it is not without 
president as other immunomodulatory proteins such as E3 (Yuwen et al., 1993), C16 
(Fahy et al., 2008) and C6 (Unterholzner et al., 2011) also exhibit a 
nucleocytoplasmic distribution during the virus life cycle.  
 
Recombinant C4 was expressed and purified from E. coli and thus an antiserum to C4 
should be generated in the future. In parallel with this, it will also be important to 
attempt the co-purification and structural determination of C4 in complex with its 
different binding partners (discussed later) identified in this study. Detailed 
information derived from such C4 co-structures will permit the mapping of these 
various interactions to specific regions of the C4 protein. This information will enable 
the construction of mutant viruses that cannot perform one function or the other (e.g. 
inhibition of NF-%B activation or DNA sensing) and to assess their relative 
contributions to virus virulence in vivo.  
! #++!
 
7.2. C4 is an inhibitor of NF-%B activation 
 
Functional screens established that C4 inhibits activation of the IFN! promoter 
following poly (dA:dT) and poly (I:C) stimulation, and that this is attributable to the 
inhibition of NF-%B activation. Given the importance of the transcription factor NF-
%B for the expression of proinflammatory cytokines and the induction of type I IFN, 
many viruses encode proteins that inhibit NF-%B activation. VACV is no exception 
and encodes many proteins that target this pathway, including A46 (Bowie et al., 
2000; Stack et al., 2005), A52 (Bowie et al., 2000; Harte et al., 2003), N1 (DiPerna et 
al., 2004), B14 (Chen et al., 2006; 2008), M2 (Gedey et al., 2006), K1 (Shisler & Jin, 
2004), K7 (Schröder et al., 2008), E3 (Myskiw et al., 2009; Valentine & Smith, 2010) 
and A49 (Maluquer de Motes et al., manuscript submitted). Therefore, the discovery 
that C4 and C16 also inhibit NF-%B activation means that the list of intracellular 
VACV-encoded inhibitors of NF-%B activation extends to eleven proteins.  
 
Protein C4 inhibited NF-%B activation following stimulation by IL-1! and TNF", 
thus implying that C4 was likely to act at, or downstream of, where these signalling 
pathways converge. Consistent with this hypothesis, C4 was shown to co-precipitate 
with the canonical IKK proteins, NEMO and IKK!, indicating that it may interfere 
with the catalytic properties of the IKK complex. In agreement with this proposal, the 
phosphorylation of I%B" was reduced in the presence of C4. These findings suggest 
that C4 may be functioning in a similar way to B14, which binds to and prevents the 
activation of IKK! and thereby prevents the phosphorylation of I%B" (Chen et al., 
2008; Graham et al., 2008). In the future, it will be necessary to confirm that C4 
prevents I%B" phosphorylation with a complementary approach. For example, it will 
be informative to test IKK activity in the presence of C4 using an in vitro kinase 
assay. Such an approach demonstrated that a synthetic I%B" peptide was inefficiently 
phosphorylated using immunoprecipitated IKK complexes from cells expressing B14 
(Chen et al., 2008). 
 
It was noteworthy that the efficiency of IL-1!-induced p65 nuclear translocation was 
slightly reduced in neighbouring non-transfected cells, suggesting C4 may have 
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bystander effects which influence the ability of these cells to respond to IL-1!. One 
way of testing this would be to collect the supernatant from C4-expressing cells and 
to add it to a new dish of non-transfected cells: if IL-1!-induced p65 nuclear 
translocation is still reduced compared to an untreated control dish of cells (i.e. 
stimulated with IL-1! but containing normal culture medium instead of C4 
supernatant), this indicates that C4 is promoting the release of molecules that are 
inducing a quasi-anergic state within neighbouring cells.    
 
The fact that ectopic expression of C4 inhibited NF-%B activation demonstrated that 
C4 does not require other VACV proteins to perform this function. This observation 
is consistent with the finding that C4 only appears to have cellular, rather than a 
combination of both cellular and viral, binding-partners. Whilst ectopically expressed 
C4 can co-precipitate with NEMO and IKK!, it will be necessary to establish if C4 
can also do so in the context of VACV infection at endogenous levels of these 
proteins.  
 
The co-precipitation of C4 with both NEMO and IKK! suggests the formation of a 
stable complex between these proteins, which might also contain IKK". Clues as to 
how such a protein complex could be formed have been provided by a model recently 
presented by Schröfelbauer et al (2012). By adaptation of this model, it is feasible that 
C4 is competitively binding to NEMO using an ISRD-like domain in order to prevent 
formation of the IKK!-NEMO-I%B" complex necessary for the phosphorylation of 
I%B" (Mercurio et al., 1997). The ISRD-like domain of C4 contains serine and 
threonine residues at equivalent positions to serine residues 32 and 36 of I%B", 
respectively, and this raises the possibility that C4 also serves as a pseudosubstrate for 
IKK!. Consistent with this proposal, ectopically- and virally-expressed C4 migrates 
as two bands during SDS-PAGE and the larger protein could represent a 
phosphorylated C4 isoform.  
 
Given the similar function and position at which C4 and B14 act and the fact that C4 
represents the eleventh intracellular VACV protein to inhibit NF-%B signalling, it is 
surprising that the loss of C4 causes an attenuated virus phenotype in vivo. In the 
absence of B14, attenuation of virus virulence is evident in the i.d. model but not the 
! #+#!
i.n. model of infection (Chen et al., 2006), whereas with C4, the opposite is observed. 
However, in all cases where the loss of an individual NF-%B inhibitor has been 
studied in vivo – A46 (Stack et al., 2005), A52 (Harte et al., 2003), B14 (Chen et al., 
2006), N1 (Bartlett et al., 2002), C16 (Fahy et al., 2008) and C4 – there is also an 
attenuated phenotype, despite the presence of other inhibitors. These observations 
indicate that these proteins are non-redundant, which might be explained in different 
ways. First, the proteins may have multiple functions, as has been demonstrated for 
N1, which is an inhibitor of NF-%B activation and apoptosis (DiPerna et al., 2004; 
Cooray et al., 2007; Maluquer de Motes et al., 2011). Protein C4 also has multiple 
functions since in addition to inhibiting NF-%B activation, it also inhibits DNA 
sensing and contributes to the induction of hypoxic signalling. Second, the position in 
the NF-%B activation pathway at which an inhibitor functions could affect outcome. 
For instance, if an inhibitor blocked only IL-1! or only TNF"-induced NF-%B 
activation, the influence in vivo could be different from that of an inhibitor that acts 
on both of these pathways. Furthermore, crosstalk between NF-%B and other 
signalling pathways could also allow an inhibitor to influence outcomes in vivo 
differently depending on where it acts. It is noteworthy that because C4 and B14 
(Chen et al., 2008) function at a position downstream of signalling from the IL-1, 
TNF and TLR receptors, they are in an optimal position to block NF-%B activation by 
a variety of stimuli. In this regard, C4 and B14 differ from A46 (Stack et al., 2005) 
and A52 (Harte et al., 2003) that only inhibit IL-1 but not TNF-induced signalling.  
 
Another important discovery is the finding that C16 and the icIL-1Ra also inhibit NF-
%B signalling. Whilst C16 inhibits NF-%B signalling at, or downstream of IKK!, 
preliminary data suggest that inhibition by the icIL-1Ra may be specific to the IL-1R 
arm of NF-%B signalling. The next step in the functional characterisation of these 
molecules will be to confirm NF-%B signalling inhibition using complementary 
assays, such as qRT-PCR, and to determine if they interact with proteins within the 
NF-%B signalling pathway. In the case of C16, since it contains a more distantly 
related ISRD-like domain than C4, this may suggest it is unlikely to interact with the 
IKK complex via NEMO, but this has still to be tested. Interestingly, C16 interacted 
with K1 in a yeast-two hybrid screen (McCraith et al., 2000), a protein that effects 
both host range and the activation of NF-%B by preventing the degradation of I%B" 
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(Shisler & Jin, 2004). In addition, gel filtration of protein complexes from VACV-
infected cells demonstrate that C16 elutes with I%B" (Aodhnait Fahy, unpublished 
results), suggesting that they may interact directly or indirectly (e.g. via K1) and this 
could explain why C4 and C16 appear to block NF-%B activation at a similar position 
in the pathway. In contrast to C4 and C16, the icIL-1Ra does not contain an ISRD-
like domain and this fits with data that suggests it inhibits NF-%B signalling upstream 
of the IKK complex. The function of the icIL-1Ra remains unclear in the published 
literature (Arend & Guthridge, 2000) but its production appears to be induced 
following IL-1R engagement, suggesting that it may operate as part of a negative-
feedback loop to prevent the overproduction of IL-1 (Garat, 2003).  
 
7.3. C4 is an inhibitor of cytoplasmic DNA sensing in MEFs  
 
Using tandem affinity purification, it was established that C16 interacts with the Ku 
heterodimer (Nicholas Peters, unpublished data), an essential component of DNA-PK 
which is involved in the non-homologous end joining (NHEJ) DNA repair pathway 
and V(D)J recombination (Gottlieb & Jackson, 1993;  Kanaar et al., 1998). Why C16, 
a VACV protein, would interact with a protein complex principally characterised as a 
nuclear, double-stranded break (DSB) DNA repair protein was unknown initially. 
However, the observation that DNA-PK co-localised with transfected DNA and viral 
factories within VACV-infected cells suggested that it might be a cytoplasmic DNA 
sensor. In agreement with this hypothesis, it was shown that DNA-PK is responsible 
for DNA-specific innate immune responses in MEFs and that this is dependent on 
IRF3 (Ferguson et al., 2012).   
 
Tandem affinity purification has also shown that the Ku heterodimer precipitates with 
C4 in the context of both ectopic expression and virus infection. Confirmation of the 
Ku-C4 interaction was confirmed by co-IP using endogenous Ku70 and Ku80 from 
VACV-infected lysates. Similar to C16, C4 inhibits DNA sensing in MEFs, as 
measured by the production of CXCL10. The loss of Ku80, which leads to the 
instability and degradation of the Ku70 subunit (Wu & Lieber, 1996; Singleton et al., 
1997), severely abrogated CXCL10 production indicating that DNA-PK is required 
for DNA sensing. Taken together, this suggests that C16 and C4 have evolved as 
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inhibitors of DNA-PK in order to prevent the detection of VACV DNA by the innate 
immune system.  
 
The mechanism behind the inhibition of DNA sensing by C16 has been characterised 
by Nicholas Peters (unpublished data). In this model, C16 prevents the recognition of 
cytoplasmic DNA by binding to the Ku heterodimer and this prohibits the subsequent 
recruitment of DNA-PKcs necessary for IRF3 activation. Give that Ku also binds to 
C4, this suggests a similar mechanism of action for this protein, but this needs testing.  
 
Neither C16 (Nicholas Peters, unpublished data) nor C4 interact with DNA-PKcs 
during VACV infection or following over-expression but this can be explained by the 
DNA-binding properties of Ku. Following the binding of Ku to DNA, conformational 
changes occur within the Ku heterodimer and it is these changes that facilitate the 
recruitment of DNA-PKcs to DNA via the C-terminal of Ku80 (Lehman et al., 2008; 
Gell & Jackson, 1999). Therefore, by preventing the recognition of cytoplasmic DNA 
by Ku, C16 and C4 automatically prevent the subsequent Ku-mediated recruitment of 
DNA-PKcs that is necessary for IRF3 activation. In other words, an interaction 
between C16/C4 and DNA-PKcs is not required for the inhibition of DNA sensing if 
Ku is prevented from binding cytoplasmic DNA.  
 
The fact that the DNA-PK trimer is constitutively expressed to high levels in MEFs 
(Amatya et al., 2012) is consistent with its role as an innate PRR for ectopic DNA. 
This may be particularly important for the primary detection of and innate immune 
response to dsDNA viruses, such as VACV, which are likely to initially infect 
epithelial cells and fibroblasts in vivo. In this regard, DNA-PK is different from some 
other putative cytoplasmic DNA sensors, such as DAI, which do not exhibit a basal 
rate of expression but rather are induced by IFN (Takaoka et al., 2007).  
 
7.4. VACV and hypoxia 
 
Structural predictions suggest that the N-terminal halves of C16 and C4 are likely to 
fold into a PHD2-like domain, however both lack the enzyme’s catalytic residues. 
Recombinant C16 purified from E. coli has been shown to antagonise the prolyl 
hydroxylase activity of PHD2, leading to the stabilisation of HIF-1" (Christoph 
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Loenarz, University of Oxford, unpublished data). Since C16 is known to interact 
with PHD2 (Nicholas Peters, unpublished data), this implies that C16 binding is either 
changing the conformation of the PHD2 active site or is sterically hindering the 
association of PHD2 with HIF-1". In the future it will be informative to test whether 
recombinant C4 also antagonises PHD2 prolyl hydroxylase activity.  
 
HIF-1" stabilisation by VACV occurs early after infection and this matches the early 
expression profiles of both C16 (Fahy et al., 2008) and C4. Moreover, stabilisation of 
HIF-1" is solely dependent upon C16 and C4 because viruses lacking only these two 
proteins fail to stabilise HIF-1". Nonetheless, C16 is the principal protein responsible 
for this process because, in its absence, HIF-1" stabilisation by VACV is reduced by 
approximately 90%. The transactivational capacity of HIF-1" during infection also 
remains intact, as demonstrated by the relative upregulation of hypoxia-inducible 
genes such as VEGF-A and GLUT-1 in wild-type VACV-infected cells. This indicates 
that HIF-1" is activating the normal hypoxic signalling program during VACV 
infection.  
 
Whilst the mechanism behind the stabilisation of HIF-1" by C16 has now been 
largely elucidated, that of C4 remains to be solved. C4 from transfected and infected 
HEK293T cells did not interact with PHD2 or HIF-1", suggesting that it may instead 
alter the stability or function of these proteins indirectly. For example, it is possible 
that C4 interferes with the ubiquitination or SUMOylation of the VHL protein that are 
required for VHL’s stability and activity (Cai & Robertson, 2010). A yeast two-
hybrid study by Tsuchiya et al (1996) identified filamin A as a binding partner of the 
VHL protein and since filamin A is also a binding-partner of C4, it is feasible that C4 
is indirectly interacting with the VHL protein via filamin A and thereby influencing 
its post-translational modification. A similar function is mediated by the cellular 
hypoxia-inducible orphan receptor Nur77, which stabilises HIF-1" by binding to the 
VHL protein and preventing its E3 ubiquitin ligase activity (Kim et al., 2008). 
 
Also of interest is the recent finding that filamin A is a novel HIF-1"-interacting 
protein that facilitates HIF-1" nuclear translocation and transactivation (Zheng, 
2009), raising the prospect that C4 may interact with HIF-1" indirectly through 
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filamin A. Although C4 was not found to interact with HIF-1" in this study, one 
explanation for this could be that the filamin A-HIF-1" protein interaction is only 
formed within certain cell types. Only HEK293T cells were used for the identification 
of C4 binding-partners in this study; in contrast, COS-1 and A7 cell lines were used 
by Zheng (2009). If C4 augments the nuclear translocation and transactivation of HIF-
1" via filamin A, this would explain why transfection of C4 into cells does not 
promote HIF-1" stability. In addition, it may also explain why VACV encodes two 
proteins to induce hypoxic signalling: one protein (C16) may serve to stabilise HIF-
1" through the inhibition of PHD2 prolyl hydroxylase activity and the second protein 
(C4) may serve to facilitate HIF-1" translocation and transactivation. 
 
The stabilisation of HIF-1" by VACV represents a novel discovery in VACV 
biology, however the reason why this may be advantageous for VACV is currently 
unknown. In the case of viruses with known oncogenic potential, such as HBV and 
HCV, the stabilisation of HIF-1" has been associated with neovascularisation and 
tumour growth, and therefore this helps to explain why infection with these viruses 
can result in cancer (Nasimuzzaman et al., 2007). Although VACV is not an 
oncogenic virus, it is interesting that following the intravenous inoculation of tumour-
bearing animals with VACV, the largest viral burden is located in the tumours (Zeh & 
Bartlett, 2002). One suggestion for this peculiar tropism is that the large virion size of 
VACV preferentially uses leaky vasculature, typically associated with tumours, to 
enter other tissues (McCart et al., 2001; Zeh & Bartlett, 2002). By extension of this 
theory, it feasible that the release of VEGF from infected cells may facilitate the 
spread of VACV to other tissues and organs.  
 
Whilst there is a growing body of literature examining the relationship between 
hypoxic signalling and the immune response to infection, no clear consensus has been 
reached and both pro- and anti-inflammatory effects have been reported. For instance, 
hypoxic signalling has been reported to increase the survival and proinflammatory 
function of myeloid cells (Walmsley et al., 2005; Bosco et al., 2012; Cramer et al., 
2003) and to enhance phagocytosis in macrophages (Anand et al., 2007). The intimate 
link between increased inflammatory responses and hypoxic signalling in these cells 
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may be reflected by suggestions that NF-%B signalling can potentiate HIF-1" 
expression and vice versa (Görlach & Bonello, 2008; Rius et al., 2009).  
 
In contrast, a recent study by Rosenberger et al (2009) demonstrated that the gene 
encoding Netrin-1 is upregulated following HIF-1" stabilisation in mucosal epithelial 
cells and that this prevents neutrophil trans-migration. The production of 
erythropoietin (EPO), which is upregulated during hypoxic signalling, has also been 
reported to have a negative effect on the microbicidal activity of macrophages by 
disrupting NF-%B signalling (Nairz et al., 2011). Many immunosuppressive effects of 
HIF-1" stabilisation have also been linked to the mal-development and dysregulation 
of adaptive immune cells. For instance, HIF-1" has been shown to dysregulate Ca2+ 
signalling upon TCR engagement in thymocytes, thus preventing their development 
into mature T cells (Neumann et al., 2005). In addition, the production of 
proinflammatory cytokines is markedly attenuated by the expression of HIF-1" in 
activated CD4+ and CD8+ T cells (Lukashev et al., 2012). Similarly, HIF-" can also 
drive CD4+ T cells down the Th2 differentiation pathway, reducing the production 
IFN& (Ben-Shoshan et al., 2009). Collectively, these reports indicate that HIF-1" 
stabilisation can, under certain circumstances, be linked to anti-inflammatory effects. 
 
An alternative possibility is that VACV is stabilising HIF-1" in order to benefit from 
the changes in cellular metabolism caused by induction of the hypoxic transcriptional 
program. The expression of growth factors and glucose transporters, such as VEGF 
and GLUT-1, are associated with cell survival and thus it follows that these 
conditions may be highly favourable to virus production (Byrne et al., 2005; Heilig et 
al., 2003). Consistent with this hypothesis, data presented in this thesis indicate there 
are increased levels of GLUT-1 mRNA in cells infected with wild-type VACV. A 
recent study by Ripoli et al (2010) showed that cell lines expressing HCV proteins 
resulted in the stabilisation of HIF-1" and this was associated with an 80% increase in 
ATP levels. Finally, it is possible that VACV is targeting PHD2 and/or stabilising 
HIF-1" for some other, as yet undefined, function. As well as the prolyl 
hydroxylation of HIF-1", PHDs have additional targets and thus hypoxic signalling 
may be a side-effect of the subversion of PHD2 by VACV for a different function 
(Kaelin & Ratcliffe, 2008).  
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HIF-1" stabilisation by VACV is  novel and is worthy of further investigation. Future 
work will be aimed at addressing why VACV is actively stabilising HIF-1". Not only 
will this improve our understanding of HIF-1" and VACV pathogenesis, but it may 
also have translational consequences. For example, structural knowledge of the C16-
PHD2 interaction could be used for the design of small molecule inhibitors to treat 
diseases in which hypoxia is involved.  
 
7.5. C4 is a virulence factor and an immunomodulator 
 
The fact that not all VACV strains contain gene C4L indicate that it is non-essential 
for virus replication and this was confirmed for VACV strain WR by the isolation of a 
C4 deletion mutant, v$C4. Furthermore, v$C4 replicated to similar titres in single- 
and multi-step growth curves. Instead of affecting virus replication, C4 is an inhibitor 
of NF-%B activation and of DNA sensing.  
 
Viruses lacking C4 are attenuated in the murine i.n. model but not the i.d. model of 
infection, and this is characterised by significantly reduced virus-induced weight loss, 
less severe signs of illness and lower virus lung titres. Measurement of virus titres in 
lungs at day 2 p.i. showed that all viruses had replicated to equivalent levels but by 
days 5 and 8 p.i. the virus titres were significantly lower in v$C4-infected mice, 
indicating more rapid clearance of virus in the absence of C4. An investigation of the 
attenuated virus phenotype by flow cytometry showed there was an increased 
recruitment of innate immune cells, including macrophages, neutrophils and NK cells, 
by day 2 p.i. into the BAL fluid and lungs of mice in the absence of C4. The numbers 
of these cells then decreased in the absence of C4, whilst they continued to increase in 
mice infected with control viruses, showing that the recruitment of innate immune 
cells show both quantitative and kinetic differences. There are also increased numbers 
of activated CD4+ and CD8+ T cells in the lungs of mice in the absence of C4, 
indicating that both the innate and adaptive immune responses are weakened by C4. 
Collectively, these data demonstrate that C4 is both a virulence factor and an 
immunomodulator in vivo. 
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The infiltration of leukocytes to sites of infection is dependent upon the production of 
proinflammatory mediators, suggesting that C4 is hampering development of the host 
immune response by acting to inhibit their production. Since C4 is an inhibitor of NF-
%B activation, the production of proinflammatory cytokines, chemokines and type I 
IFNs, such as IL-12, CCL3, CXCL5 and IFN!, are likely to be lowered during 
infection. Furthermore, C4 inhibits the DNA-mediated induction of CXCL10 in 
MEFs. Given the chemoattractive properties of CXCL10 and the fact that fibroblasts 
and epithelial cells are the first cell types to be infected by VACV in vivo, this is 
consistent with the observation that i.n. infection with v$C4 results in an increased 
recruitment of leukocytes to sites of infection. In the future, ELISA can be used to 
measure the abundance of these cytokines using homogenates of VACV-infected 
tissues.   
 
Due to the relatively low number of cells contained in the BAL fluid of mice, it was 
only possible to measure the abundance of macrophages and neutrophils. In the future 
it will also be interesting to quantify other innate immune cells, such as DCs, which 
are vital for activating the adaptive immune response (reviewed in (Banchereau et al., 
2000)). This seems particularly pertinent due to the fact that C4 is diminishing the 
strength not just of the innate, but also of the adaptive immune response. 
 
Whilst viruses lacking C4 are attenuated in the i.n. model of infection, it has not been 
proven that this is caused by the immunomodulatory functions of C4, such as the 
inhibition of NF-%B activation. Ascertaining the contribution of each C4 function to 
virus attenuation will be challenging. One way to assist with this would be to infect 
different knockout strains of mice that lack expression of the various C4 binding-
partners identified in this study. Alternatively, mutant viruses may be constructed that 
cannot perform one function or the other. This strategy has been particularly effective 
in deducing that the anti-NF-%B signalling function of N1 is more important to virus 
virulence than its anti-apoptotic activity (Maluquer de Motes et al., 2011).     
 
Deletion of both C16 and C4 leads to a synergistic attenuation of virus virulence not 
just in the i.n. model, but also in the i.d. model of infection. This is interesting given 
that the loss of either protein alone is not sufficient to cause virus attenuation in the 
! #*+!
i.d. model of infection. Mechanistically, a propensity for an immunomodulator to 
show a phenotype in only one in vivo model has been attributed to its mechanism of 
action and the different inflammatory responses elicited by infection via either route 
(Tscharke et al., 2002; Reading & Smith, 2003). One explanation for the greater 
attenuation of VACV virulence following the deletion of C16 and C4 is that these 
proteins operate in a co-operative manner to perform an important function(s) during 
the virus life cycle that cannot be sufficiently performed by any other VACV-encoded 
proteins. In this study and from the work of Dr. Nicholas Peters, it has been shown 
that C16 and C4 have roles in inhibiting NF-%B activation and DNA sensing and in 
inducing hypoxic signalling. Although VACV encodes many inhibitors of the NF-%B 
and IRF3 signalling pathways (Introduction), only C16 and C4 are involved in the 
induction of hypoxic signalling, suggesting that loss of the latter function might 
contribute to the attenuation of v$C16,$C4. Whilst this is an interesting hypothesis, 
the only way of testing this in the future will be to construct recombinant viruses 
expressing mutant versions of C16 and C4 that lack the ability to induce hypoxic 
signalling but retain their other functionalities.    
 
7.6. Concluding remarks 
 
In this study, a functional characterisation of VACV protein C4 has been described. 
Data presented have demonstrated that C4 is a novel inhibitor of NF-%B activation 
and, mechanistically, this is due to the inhibition of I%B" phosphorylation. Consistent 
with this mode and site of action, C4 co-precipitated with NEMO and IKK!. Protein 
C4 also inhibits the DNA-mediated induction of CXCL10 in MEFs. Like VACV 
protein C16, C4 likely inhibits cytoplasmic DNA sensing by binding to the Ku 
heterodimer and diminishing the recruitment of DNA-PK to DNA. A third function of 
C4 is to facilitate the induction of hypoxic signalling during VACV infection in a co-
operative manner with C16. Viruses lacking C4 are attenuated in the i.n. model of 
infection and are associated with an increased recruitment of immune cells to sites of 
infection, indicating that C4 is both a virulence factor and an immunomodulator. 
Taken together, this study provides a fascinating example of the functional plasticity 
inherent in some viral proteins and has improved our understanding of VACV 
pathogenesis and the host immune response to infection.   
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